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ABSTRACT
The 3.5-kb RNA of equine infectious anemia virus (EIAV) is show n here
to encode the SI, S2 and envelope proteins in vitro. SI is expressed from this
RNA despite the lack of an AUG codon. Deletion m utants of a cDNA derived
from the 3.5-kb RNA were used to determ ine that sequences w ithin the first 14
codons of ORF SI are required for SI expression in vitro and trans-activation in
vivo. Amino-terminal sequence analysis of the in vitro synthesized SI protein is

consistent with initiation at a CUG codon.
The translation properties of the 3.5-kb RNA have been exam ined in
w heat germ extracts. The cap-dependence of the three cistrons was examined
by addition of m 7GpppG cap analog to the wheat germ extract translation
mixtures. The results indicated a near proportionate reduction in the
expression of each of the cistrons suggesting that their translation is dependent
on cap binding followed by ribosome scanning. The relative efficiencies of
expression of the three cistrons were examined in translation reactions where
the concentrations of m agnesium (Mg++) and potassium (K+) ions were varied.
Increasing the level of M g++ appeared to favor translation of the SI protein,
whereas increasing the K+ concentration resulted in significantly reduced
translation of SI w ith concomitant enhanced translation from the downstream
cistrons.
The in vitro synthesized S2 protein was immunoprecipitated w ith sera
obtained from EIAV-infected horses dem onstrating that this protein is
expressed in vivo. A 20-kd protein produced in vitro and in vivo from a Rev (S3)
cDNA w as im m unoprecipitated with a monoclonal antibody directed against
an epitope of the gp90 envelope protein. This finding indicates that env gene
sequences provide a translational initiation codon for Rev protein expression.
The Rev protein could be detected in EIAV-infected cells w ithin 20 hours after

infection and appeared to reach a maximal level of expression between 2 and 5
days post-infection.

CHAPTER 1
LITERATURE REVIEW
Retroviruses
Retroviruses have been intensely studied for decades due to their
ability to transduce cellular proto-oncogenes and cause neoplastic cell
grow th or cancer. M ore recently, interest in retroviral vectors for the
b u d d in g field of gene therapy has provided additional insight into the
replication and expression m echanisms of these viruses. In the last decade
the investigation of retroviruses has taken on a new sense of urgency with
the identification of hum an im m unodeficiency virus (HIV) as the causative
agent of acquired im m une deficiency syndrom e (AIDS). The vast am ount of
inform ation gathered regarding HIV-1 in a relatively short period of time is
unprecedented in science. Yet, like cancer, not enough inform ation has
been gathered to effectively treat this disease. The virus studied in this
dissertation, equine infectious anem ia virus (EIAV), is related to HIV-1 and
consequently shares some com m on features. In this review some
characteristics common to all retroviruses will first be described , then the
HIV literature relevant to the studies perform ed herein will be presented,
followed by a review of the relevant EIAV literature.
Retrovirus Taxonomy
The retroviruses are so nam ed because they reverse the norm al flow
of genetic inform ation by m aking double-stranded DNA from their genomic
RNA. The retrovirus fam ily contains three subfamilies: the oncovirinae,
lentivirinae, and spum avirinae. The sub-fam ily oncovirinae contains a
large num ber of endogenous and exogenous avian and m am m alian RNA
tum or viruses (oncoviruses). The genomes of the vast majority of these
viruses include only the three essential retroviral genes (gag, pol and env)
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that encode the virion structural proteins and the viral enzymes. Notable
exceptions to this are the replication com petent cellular oncogenecontaining viruses , such as Rous sarcoma virus (RSV). In addition, the
hum an T cell leukem ia viruses (HTLV-I, -II) and bovine leukem ia virus
(BLV) encode at least two essential trans-acting proteins functionally
hom ologous to the HIV-1 Tat and Rev proteins (see The HIV-1 Tat Protein
and The HIV-1 Rev Protein).
The retroviruses of the sub-fam ily lentivirinae, the lentiviruses,
result in slow persistent degenerative diseases in their respective host
organism s, hence the prefix lenti- derived from the Latin w ord m eaning
slow. M embers of this family include the prim ate im m unodeficiency
viruses (SIV, HIV-1, and HIV-2), feline im m unodeficiency virus, the
recently reported canine im m unodeficiency virus (Perk et ah, 1992) and a
num ber of ungulate viruses (equine infectious anem ia virus, bovine
im m unodeficiency-like virus, visna-m aedi virus, and caprine arthritisenteritis virus). All m em bers of this family encode functional equivalents
of the HIV-1 Tat transcriptional trans-activator and Rev regulator of
expression of virion proteins. A dditional proteins that contribute to the
specific pathogenicities of these viruses are also common.
The subfam ily spum avirinae contains a num ber of viruses found in a
w ide variety of m am m als, including hum ans, that cause no know n disease
(Weiss, 1988). These viruses are nam ed for their ability to induce
m ultinucleated syncytia w ith num erous vacuoles producing a foamy
cytopathic effect in culture, hence the prefix spum a- derived from the Latin
w ord m eaning foam. Like the lentiviruses, the prototypic spum avirus,
hum an foam y virus (HFV), encodes a transcriptional frans-activator as well
as three other proteins w ith undeterm ined functions.

W ith the increasing availability of nucleotide sequence data for
retroviruses, it has been suggested that this traditional division of
retroviruses based on pathogenicity should be replaced by a taxonomic
schem e based on genetic similarities (Cullen, 1991). In such a scheme, the
retroviruses w ould be divided into two basic groups, the sim ple and the
complex retroviruses. The sim ple retroviruses w ould include the m ajority
of the oncoviruses, b u t w ould exclude the HTLVs and BLV. The simple
retrovirus genom es contain only the obligatory gag, pol and env genes and
perhaps an oncogene. These viruses exhibit a simple splicing pattern in
w hich the gag and pol genes are expressed from unspliced genom ic RNA,
and the env gene and oncogene, if present, are expressed from a single
spliced RNA. The complex retroviruses w ould include the rem ainder of
the retroviruses, including the lentiviruses, the spum aviruses, the
oncoviruses HTLV-I, -II and BLV. These viruses express a num ber of
regulatory and auxiliary proteins from a variable num ber of alternatively
spliced transcripts. In addition, these viruses exhibit a tem poral regulation
of gene expression im parted by the action of the Rev-like protein, w here
regulatory proteins are expressed early in infection from small m ultiplyspliced transcripts and the virion proteins are expressed late infection from
the unspliced and singly-spliced RNAs.
Retrovirus Virion Structure
Retroviruses are enveloped positive strand RNA viruses. The RNA
is said to be of positive sense, since it is capable of being directly translated to
produce virion proteins. The genomic RNA resem bles norm al cellular
RNAs, in that it is capped at its 5'-end w ith the standard cellular cap
structure, 5'm 7GpppG5', and polyadenylated at its 3'-end. The retroviral
genom e is diploid, in that each virion particle contains two copies of the
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genom ic RNA th at are non-covalently linked near their 5'-term ini (Fig. 1A).
The RNA exists in a ribonucleoprotein complex w ith a large num ber of
copies of a basic nucleocapsid (NC) protein, and is also associated with
several copies (5-10) of the reverse transcriptase (RT) enzym e (Fig. IB). A
specific cellular tRNA molecule is base paired to the RNA near its 5' end.
This tRNA functions as the prim er for the reverse transcription reaction.
The ribonucleoprotein complex is encapsidated into a core that is m ade up
of predom inantly the major capsid (CA) protein. The core is surrounded by
a m atrix (MA) protein. The m atrix protein is believed to form a monolayer
directly beneath the phospholipid envelope. Retroviruses acquire this
envelope from the cellular plasm a m em brane as they bud from the surface
of an infected cell. The envelope bears two glycoproteins, the
transm em brane protein (TM) and the surface protein (SU). The SU protein
is highly glycosylated and the TM protein is only sparsely glycosylated.
These two proteins exist in the virion in a one-to-one ratio w ith the
transm em brane protein anchoring the surface protein to the virion.
The Retroviral Life Cycle
U pon infection, virion particles attach through their surface
glycoproteins to cellular receptors of the target cells. After binding to the
receptor a hydrophobic portion of the transm em brane protein is believed to
m ediate fusion of the viral envelope w ith the cell plasm a m em brane
releasing the viral core into the cytoplasm. Once the capsid is released into
the cytoplasm, the process of reverse transcription of the viral genomic
RNA into double-stranded DNA by the virion associated reverse
transcriptase occurs. The intracellular capsid appears to be much less tightly
associated than the virion capsid thereby allowing small molecules required
for reverse transcription such as deoxynucleotide triphosphates (dNTPs), to

Envelope

RNA Genome
Receptor-binding

Integrase
Transmembrane

RT

Reverse Transcriptase

Matrix
Capsid
Nucleoprotein

Figure 1. Genome and virion structure of a typical retrovirus. (A dapted
from Coffin, 1991).

freely enter this structure. A consequence of the reverse transcription
reaction is th at the resulting DNA is flanked by direct repeats com prised of
sequences derived from both the 5'- and 3'- ends of the genomic RNA.
These repeats m ay be from 200-800 bp in length and are know n as the long
term inal repeats (LTRs). Once the synthesis of the double-stranded DNA
copy of the genom ic RNA, know n as a provirus, is com pleted the capsid
structure is translocated to the cell nucleus by an as yet undeterm ined
m echanism. A t this point the proviral DNA, while still associated w ith the
capsid structure, becomes random ly integrated into the host cell
chrom osom e through a reaction catalyzed by the virion-associated integrase
protein.
Once integrated, the proviral DNA is transcribed by RNA polym erase
II of the host cell. The prim ary RNA transcript m ay be packaged as genomic
RNA into progeny virions, directly transported to the cytoplasm for
translation or spliced to provide mRNAs encoding the env protein or in the
case of m ore complex retroviruses a num ber of other protein products. The
prim ary transcript is translated to produce the products of the gag and pol
genes. The gag products are the internal viral structural proteins (CA, MA,
and NC) and the pol products are the virion-associated enzym es (RT, IN,
PR). Both the Gag and Pol proteins are translated as polyproteins that m ust
be post-translationally cleaved. The Gag and Pol precursors are directed to
the inner surface of the cellular plasm a m em brane at regions w here a high
density of the enu-encoded glycoproteins stud the outer surface of the
m em brane. M ost retroviruses do not form defined intracellular viral
particles, rather the first detectable virions are seen as egressing buds from
the infected cell plasm a m em brane. It appears that the core is not

completely form ed at the tim e of egress, as freshly budded particles are not
electron dense b u t become so soon after their release from the cell.
R etroviral G ene Expression
In this section, general principles of retroviruses gene expression will
be described w ith em phasis on lentiviral gene expression. The expression
strategies of the complex retrovirus HIV-1 will be used as a model to
describe the regulation of gene expression in lentiviruses, how ever some
strategies utilized by all retroviruses are also discussed. Although the
complex retroviruses are unique in their use of virally-encoded trans-acting
factors to regulate gene expression, all retroviruses m ust encode m ultiple
proteins from the gag and pol genes by translation of the full length
genomic RNA. Also, all retroviruses m ust use some type of strategy to
regulate the levels of spliced (env) and unspliced (gag/pol) RNA. A lthough
the complex retroviruses contain additional genes, the overall genome
structure and LTR structure is similar in all retroviruses.
The Structure of the HIV-1 Proviral G enom e
The HIV-1 proviral genom e is 9.7-kb in length and contains long
term inal repeats of approxim ately 650-bp each (Fig. 2). There is some
sequence variability betw een individual HIV-1 isolates, particularly in the
LTRs and the env gene. For convenience the genom ic organization of one
of the earliest published sequences, HIV-1/SF-2 (Sanchez-Pescador et al.,
1985; GenBank accession K02007), is described here. The LTRs of HIV-1/SF2
are 634 bp long and are described in detail below. The 5'-LTR functions as a
complex prom oter to induce the transcription of the full-length viral RNA
w hich serves as the genom ic RNA for progeny virions and as an mRNA for
translation. The 5-LTR is followed by a short leader region of 154-bp (nt
635-789) that is defined as the sequence between the U5 region of the 5-LTR
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Figure 2. The structure of HIV-1 proviral DNA. (A dapted from Rosen and
Pavlakis, 1990).
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an d the gag gene ATG initiation codon. The overlapping gag and pol genes
follow the leader region and account for just over 44% of the entire HIV-I
genom e (nt 790-5102). The pol/env intergenic region is 1128-bp in length (nt
5103-6231) and is the site for m ost of the small genes characteristic of
lentiviruses. This entire region is utilized by the virus to encode the vif,
vpr, and vpu genes and the first coding exons of the tat and rev genes. The

proteins produced from these genes and their roles in viral replication are
discussed later. The tat and rev genes are the only HIV-1 genes that are
interrupted by an intron. The first coding exon of tat (trans- activator of
transcription) encodes 72 am ino acids of the 86 amino acid protein. The
splice donor signal that is utilized to connect the two tat exons is followed
im m ediately by an in-fram e term ination codon. This allows the synthesis
of a functional 72 am ino acid Tat protein (Tati) from partially spliced RNAs
(see The mRNAs Produced by HIV-1). The first coding exon (25 codons) of
the rev (regulator of virion expression) gene overlaps w ith the last 75-bp of
the first coding exon of the tat gene in an alternative reading frame. The
first coding exons of tat and rev are 3'-coterminal and their second coding
exons are 5'-coterminal, since they utilize the same splice donor (nt 6053)
and acceptor (nt 8382) sites to join their tw o coding exons. The second
coding exon of rev (nt 8383-8657) encodes the majority of this protein (91
codons), whereas the second coding exon of tat encodes only 14 am ino acids
that appear to be dispensable for Tat function. The intron that separates the
two coding exons of tat and rev contains the rev responsive elem ent (RRE).
U nspliced and partially-spliced RNAs that contain the RRE are retained in
the nucleus in the absence of the Rev protein. Therefore, fully-spliced
RNAs that contain the tw o exon form of tat (Tat-2) and rev do not require
the action of Rev for their expression (see The HIV-1 Rev Protein). The
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ATG initiation codon (nt 6070) of the vpu (viral protein U) gene (nt 60706314) lies 17-bp dow nstream of the ta tl/r e v l splice donor site. The final 28
codons of vpu overlap w ith the 5'-end of the 856 codon env gene (nt 62328799). The final currently identified gene of HIV-1 is the nef (negative
effector) gene (nt 8801-9433), which im m ediately follows the env gene (nt
6232-8799) and extends into the 3'-LTR (nt 9102-9736). The nef gene ATG
codon is separated from the env gene term ination codon by a single base
pair, and the nef gene overlaps the majority of the U3 region of the 3'-LTR.
The HIV-1 LTR
The U3 region (nt 1-452) of the 634-bp HIV-1 LTR constitutes the
m ajority of the LTR and contains the viral prom oter and m ost of the cisacting elem ents involved in transcriptional m odulation by cellular factors
(Fig. 3). As m entioned above, the border betw een the U3 region and the R
region (nt 453-550) defines the transcriptional start site (+1). Imm ediately
upstream of the start site lies the TATA box (-28—>-24), the binding site for
the TATA binding protein (TBP), a com ponent of the RNA polym erase II
transcription factor TFIID. M utations in the TATA box appear to have
surprisingly little effect on basal transcription levels (Berkhout and Jeang,
1992; Olsen and Rosen, 1992), but dram atically reduce Tat-m ediated transactivation (see The HIV-1 Tat Protein). Initial analysis of deletion m utants
of the U3 region determ ined that sequences upstream of position -167,
relative to the transcription start site (+1), contain an apparent negative
regulatory element, since deletion of these sequences resulted in a 2 to 3-fold
increase in basal transcription levels (Rosen et al., 1985). LTR sequences
from -167—>-28 were identified as an enhancer element, since they are
capable of activating transcription irrespective of distance and orientation
and can also activate transcription of heterologous prom oters (Rosen et al.,
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Figure 3. The HIV-1 LTR. (A dapted from A ntoni et al., 1994).
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1985). This enhancer w as subsequently determ ined to be bipartite in nature,
consisting of tw o adjacent binding sites (-105—>-80) for the B-cell
transcription factor, NF-kB (Nabel and Baltimore, 1987), and three
contiguous binding sites (-78->-47) for the m am m alian transcription factor
Spl (Jones et al., 1986). Of the three S pl binding sites only the central site,
Spl II, contains the core consensus hexanucleotide Spl binding sequence
GGGCGG. The flanking sites, however, do exhibit a perfect match at 8 of 10
residues to the extended decanucleotide consensus S pl binding sequence
T/GGGGCGGRRY. All three sites bind purified Spl in vitro w ith the m ost
distal site, Spl III, having the highest binding affinity and the proxim al site,
Spl I, having the lowest (Jones et al., 1986). Interestingly, in reconstituted in
vitro transcription reactions, the high affinity binding site, Spl III, could be

deleted w ith only a m arginal reduction in basal transcription activity.
U nfortunately, in vivo investigations of basal transcription levels have
proven difficult due to the extrem ely low level of transcription from the
HIV-1 LTR in the absence of the viral trans-activator, Tat. Som ewhat
conflicting results have been reported on the im portance of the individual
Spl sites to Tat-m ediated trans-activation. It is generally agreed, however,
that at least one functional Spl site is required for Tat-m ediated trans
activation in non-lym phoid cells (Harrich et a l, 1989; Southgate and Green,

1991) and that NF-kB can at least partially fulfill the requirem ent for an Spl
site in cells producing high levels of this factor, such as B-cells and activated
T-cells (Parrott et al., 1991). Since the NF-kB factor is an inducible factor that
is responsive to a num ber of stim uli that activate T-cells, it is likely to be
involved in activation of transcription of latent integrated HIV-1 proviral
DNA (Antoni et al., 1994).
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A large num ber of factors have been identified to bind to the broadly
defined negative regulatory elem ent (NRE) w ithin the U3 region of the
HIV-1 LTR (-454-4-167). In several cases m ore than one factor has been
show n to bind at a single site. The physiological relevance of any of these
factors, how ever, has yet to be elucidated. A site term ed URE (upstream
regulatory element) or TCF-1 (T-cell factor 1 binding site) (-150—>-121) binds
the T cell specific factor T C F la (W aterman and Jones, 1990). Deletion of this
elem ent results in enhanced transcription from the HIV-1 LTR in T-cells
(N akanishi et al., 1991). The fact that this elem ent is duplicated in some
viral isolates obtained from infected patients (Koken et al., 1992) is
suggestive of an in vivo role for this element, although none has yet been
found. This elem ent does not fall w ithin the originally defined NRE, but
could contribute to dow n-regulation of the HIV-1 LTR.
A consensus binding site (-173—>-159) for the transcription factor USF1, originally defined as an activator of the adenovirus major late prom oter
(Carthew et al., 1985), lies upstream of the TCF-1 site. At least five different
proteins have been show n to bind to this region including the following:
the originally defined 44-kd USF-1 protein (Lu et al., 1990); sp50, a 50-kd T
cell-specific protein, (Smith and Greene, 1989); HIV-TF1, a 39-kd
phosphorylated protein (M aekawa et al., 1991); and two other proteins of 70
and 110-kd (Giacca et al., 1992). Although the precise role of these proteins,
if any, in HIV infection rem ains to be determ ined, it is interesting to note
that the T-cell-specific protein, sp50, is know n to negatively regulate the
interleukin 2 (IL-2) receptor a prom oter (Smith and Greene, 1989).
A binding site (-254—>-216) for a factor involved in activation of the
IL-2 prom oter, NFAT-1 (nuclear factor of activated T cells), lies upstream of
the USF-1 binding site. The NFAT-1 can bind to this site w ithin the LTR in
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vitro, b u t deletions of this site in infectious proviral clones indicate that this

sequence represses HIV gene expression (Lu et al., 1990). It is unclear how a
factor know n to activate expression in one prom oter (IL-2) m ay repress
transcription in another (HIV LTR). A second protein, ILF-1, has been
identified that binds the NFAT-1 sequence in both the IL-2 prom oter and the
HTV-1 LTR and represses transcription from both prom oters (Li et al., 1991).
It is conceivable that the HIV-1 LTR m ay preferentially bind the repressive
factor (ILF-1) due to either the prim ary sequence of the binding site or the
environm ent provided by other proteins bound near this region.
The sequences located from -350 to -300 in U3 contain binding sites for
the transcription factor A p l (Franza, 1988), stero id /th y ro id horm one
receptors such as COUP-TF (chicken ovalbum in upstream prom oter
transcription factor) (Cooney et al., 1991), the c-myb cellular proto-oncogene
gene product (D asgupta et al., 1990), and two novel factors, NRT-1 and NRT2 (Yamamoto et al., 1991). The novel NRT binding sites repressed
transcription w hen placed into a heterologous prom oter, b u t deletion of the
region containing these sites in an infectious proviral clone of HIV-1 did not
significantly augm ent transcription, casting doubt as to the involvem ent of
this region in negative regulation of HIV transcription.
The R region of the LTR contains the trans-activation responsive
(TAR) sequence element. A lthough proteins have been show n to bind to
TAR DNA, they d id not affect Tat-m ediated trans- activation. Rather Tat
binds to TAR RNA on nascent transcripts to activate transcription initiation
a n d /o r elongation (see The HIV-1 Tat Protein). One of the proteins that
binds to TAR DNA is the leader binding protein 1 (LBP-1) (Jones et al., 1988).
This protein binds the LTR at three sites that span the U 3 /R border region
and includes sequences near the TATA box. The LBP-1 binding sites near
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the transcription start site are high affinity sites believed to be im portant for
detectable levels of basal transcription (Boris-Lawrie et al., 1992; Jones et al.,
1988). The LBP-1 binding site that lies near the TATA box is a low affinity
binding site and appears to exert a repressive effect on transcription by
blocking access of the basal transcription factor TFIID to the TATA box (Kato
et al., 1991). The R region of the LTR also contains the AAUAAA consensus

polyadenylation signal near its 3' end. D ue to its location in the redundant
region of the viral RNA, the polyadenylation signal is present near both the
5' and 3'-term ini yet only the 3' signal results in polyadenylation. Deletion
studies in a num ber of retroviruses, including HIV, have show n that
sequences w ithin U3 and therefore only present upstream of the 3' poly
adenylation signal in the genom ic RNA, are required for efficient
polyadenylation of viral RNA (Dougherty and Temin, 1987; DeZazzo et al.,
1991).
The U5 region of the LTR has been less extensively studied in HIV
and other retroviruses, since it does not appear to perform any obvious
regulatory function in gene expression. The only im portant sequence in U5
thus far identified is the 3' term inal CA dinucleotide that is required for
integration.
The HIV-1 Tat Protein
The protein products encoded by the tat and rev genes of HIV-1 are
required for viral replication in vitro (Dayton et al., 1986; Fisher et al., 1986a;
Sadaie et al., 1988; Terwilliger et al., 1988). Both are small highly basic RNAbinding proteins translated from any of a num ber of small m ultiply-spliced
RNAs. The Tat (frfl»s-activator of transcription) protein trans -activates
transcription from the viral LTR by as m uch as 1000-fold (Arya et ah, 1985;
Sodroski et ah, 1985a). The Tat protein contains three distinct functional
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dom ains: (1) an am ino-term inal cysteine rich dom ain that has been show n
to be involved in m etal binding and dim erization in vitro (Frankel et al.,
1988); (2) a carboxyl-terminal basic region know n to be required for nuclear
and nucleolar localization of the protein; (3) a central conserved core
dom ain believed to be the transcriptional activation dom ain.
Unlike nearly all know n viral and cellular trans- acting factors, the ex
acting sequence (TAR, tran s-activation responsive elem ent) required for Tat
function is located im m ediately dow nstream of the transcription start site in
the LTR (Rosen et al., 1985). This observation led to the speculation that Tat
m ay exert its function at the level of the viral RNA rather than at the DNA
level.

The TAR RNA is capable of forming an imperfect, yet highly stable,

hairpin loop structure containing a 3-nt pyrim idine bulge near the 5'-end of
the loop and is located at the 5'-end (nt +1- +59) of all HIV-1 mRNAs (Fig. 4).
Indirect evidence for TAR function at the RNA level was provided by
m utagenesis studies that dem onstrated that the prim ary sequence of the
nucleotides (nt) involved in the predicted stem structure could be
significantly altered w ithout affecting fraws-activation as long as base pairing
was m aintained (Hauber and Cullen, 1988). In contrast, any changes in the
predicted loop sequence or 3-nt pyrim idine bulge severely affected transactivation (Feng and H olland, 1988; Berkhout and Jeang, 1989; Roy et al.,
1990a, b). Direct binding of Tat to TAR RNA has been dem onstrated in vitro
using E. coli expressed Tat and in vitro transcribed TAR RNA (Dingwall et
al., 1989). Subsequent binding experiments em ploying synthetic peptides

corresponding to portions of Tat showed that the arginine-rich basic m otif
near the carboxyl term inus of Tat is required for Tat binding to TAR (Weeks
et al., 1990; Calnan et al., 1991). M utagenesis studies of the TAR stem loop

show ed that Tat binds at the UCU bulge region (Dingwall et al., 1990; Roy et.
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Figure 4. The structure of HIV-1 TAR RNA (Adapted from Cullen, 1992).
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al., 1990b). Interestingly, m utations in the loop, previously show n to be

critical for Tat trans- activation in vivo, had no effect on Tat binding in vitro.
This indicated that there m ay be other factors required for Tat-m ediated
fnm s-activation in vivo. A t least three independent research groups have
reported cellular TAR and Tat binding proteins (Marciniak et al., 1990a;
Sheline et al., 1991; W u et al., 1991), how ever the significance of these
proteins in Tat-m ediated trans-activation and their roles in norm al cellular
gene expression rem ain to be elucidated. The reported developm ent of a
HeLa cell in vitro transcription system that supports Tat trans-activation
(Marciniak et al., 1990b) should greatly facilitate future studies.
Tat-m ediated trans-activation was initially suggested to be both
transcriptional and post-transcriptional (Cullen, 1986; Rosen et al., 1986),
how ever it is now generally accepted that the major effect of Tat is at the
transcriptional level. A num ber of researchers have reported increased
levels of HIV-1-specific RNAs in the presence of Tat ( Peterlin et al., 1986;
M uesing et al., 1987). Furtherm ore, these increases are know n to be the
result of enhanced synthesis rather than increased RNA stability (Hauber et
al., 1987). Early studies on the m echanism of Tat trans- activation

dem onstrated that Tat does not affect the overall level of transcriptional
initiation at the HIV-1 LTR, b u t rather stabilizes the elongation complex to
prevent prem ature term ination (Kao et al., 1987). That is, in the absence of
the Tat protein, transcription complexes that initiate at the HIV-1 LTR
dissociate after synthesis of the TAR structure (nt +59). Thus, the TAR
sequence w as proposed to act as a transcriptional term inator and Tat as an
antiterm inator, through a m echanism sim ilar to that found for the
bacteriophage lam bda N protein. A prediction of the anti-term ination
m odel w ould be that deletion of the TAR structure or m utations that
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d isru p t base-pairing of the TAR stem should result in constitutive high
level expression from the HIV-1 LTR. Such m utations do not result in this
predicted effect, and the subsequent finding that Tat frans-activation was
d ependent on th e positioning of TAR at the 5'-term inus of the viral RNA
dem onstrated that this m odel was insufficient to fully explain the
transcriptional activation by Tat (Selby et al., 1989).
S ubsequent experim ents perform ed both in vivo and in vitro have
dem onstrated that HIV-1 LTR-directed transcription term inates at m ultiple
and perhaps random sites dow nstream of the TAR structure (Laspia et al.,
1989; M arciniak et al., 1990b). It was suggested that the accum ulation of
TAR RNA in vivo is the result of the action of 3'-exonuclease activity on
these various prem aturely term inated transcripts w ith the TAR secondary
structure rendering this structure resistant to the action of these nucleases
(Selby et al., 1989). An alternative to the anti-term ination m odel was
proposed in which Tat acts as an RNA sequence-specific processivity factor
(Cullen, 1990). In this m odel, Tat is proposed to bind the TAR stem-loop of
the nascent RNA and recruit elongation factors to the transcription
complex, thereby allowing transcription to continue unim peded. In the
absence of Tat, the necessary factors are not recruited and the destabilized
elongation complex dissociates from the DNA tem plate at random locations
dow nstream of the TAR structure (Karn and Graeble, 1992).
A num ber of lines of evidence indicate that Tat plays a role in
activation of transcriptional initiation. Some interesting insights into the
role of Tat in transcriptional initiation have been obtained using the herpes
sim plex virus (HSV) VP16 trans -activation protein. VP16 is a m em ber of a
large group of eucaryotic trans -acting proteins that enhance transcriptional
initiation through their acidic activation domain. W hen the acidic
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activation dom ain of VP16 w as fused to the RNA binding dom ain of the
HIV-1 Rev protein, another viral trans-acting RNA binding protein, it was
able to trans -activate an HIV-1 LTR in which the TAR sequence was
replaced by a portion of the Rev-responsive elem ent (RRE) RNA (Tiley et
al., 1992a). The level of this VP16-mediated trans-activation was com parable

to the level observed w ith Tat on the w ild type HIV-l LTR and
dem onstrated position dependence of the c/s-acting RNA element. From
these d ata it m ay be inferred that Tat and VP16 activate transcription
through a com m on m echanism even though Tat does not contain the
classical acidic activation domain.
F urther evidence of Tat's involvem ent in initiation was obtained
from the analysis of HIV-1 LTR m utations of the TATA elem ent (Berkhout
and Jeang, 1992; Olsen and Rosen, 1992). A minimal prom oter for basal
transcription from the LTR has been defined as consisting of sequences from
-43 to +80 (Berkhout and Jeang, 1992). This minimal prom oter is not trans
activated by Tat despite the presence of the TAR structure. H ow ever, the
addition of a single cellular transcription factor binding site upstream of the
TATA box, such as SP1 or NF-kB, renders this prom oter inducible by Tat
indicating the potential requirem ent of an interaction betw een Tat and
another upstream prom oter binding factor for frans-activation (Berkhout
and Jeang, 1992). Replacem ent of the HIV-1 TATA elem ent and
surrounding sequences (-20 to -35) w ith TATA elements from other fully
functional prom oters resulted in the loss of Tat-m ediated trans-activation
w ithout significantly affecting basal transcription levels or prom oter
induction by upstream DNA binding factors. However, m inim al alterations
of the TATA elem ent resulted in a 3- to 10-fold reduction in Tat-m ediated
traas-activation (Olsen and Rosen, 1992).

Recently, Tat has been show n to

specifically bind the TATA binding transcription factor TFIID (Kashanchi et
ah, 1994). This binding is m ediated by the central core region believed to

include the Tat activation dom ain and m utations at a single am ino acid
residue w ithin this dom ain fail to bind TFIID. It has been suggested that
there are two distinct classes of transcription complexes assem bled on the
prom oter region of the HIV-1 LTR or that there are tw o prom oters that
share the same start site (Cullen, 1993). O ne class or prom oter has a very
low level of basal transcriptional activity and is highly processive, the other
has a high level of basal activity and is non-processive. The predom inant
role of the non-processive prom oter m ay be to provide transcripts
containing TAR that can be bound by Tat protein. The binding of TAR by
Tat w ould result in transcriptional activation of the processive prom oter,
b u t not the non-processive prom oter. The high level of transcription from
the processive prom oter w ould passively dow n-regulate the non-processive
prom oter by a com petitive m echanism. In this proposed mechanism, Tat
activates transcription at the level of initiation in m uch the same m anner as
the DN A -binding activators, b u t w ould give the appearance of being a
transcription elongation processivity factor, since m ore complete transcripts
are produced.
T he HIV-1 Rev Protein
The HIV-1 Rev (regulator of virion expression) protein is a 116 amino
acid nuclear phosphoprotein that is required for the expression of the viral
structural genes from the unspliced and singly-spliced RNAs and therefore
is required for viral replication. Early in the HIV-1 infection cycle only
m ultiply spliced RNAs encoding the Tat, Rev, and Nef (see The mRNAs
produced by HIV-1) proteins are found in the cytoplasm of an infected cell
(Kim et ah, 1989b). In studies w here the nuclear and cytoplasmic RNA have
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been exam ined, it w as determ ined that large am ounts of unspliced and
partially spliced RNA exists in the nucleus (Felber et ah, 1989; M alim et ah,
1989a). The accum ulation of the Rev protein beyond an undeterm ined
critical level results in the export from the nucleus of the unspliced gag/pol
RNA and the singly-spliced vif, vpr, ta tl and vp u /en v RNAs. These RNAs
encode the virion structural proteins (Gag, gpl60), the virion associated
enzym atic activities (RT, IN, PR), and auxiliary proteins that are involved in
virion m orphogenesis (Vpu), infectivity (Vif), and cytopathicity (Vpr).
Expression of Rev results in the transport of the under-spliced RNA from
the nucleus to the cytoplasm w ith the concom itant reduction in the levels
of the small m ultiply-spliced RNAs (Malim et ah, 1988; M alim et ah, 1989a).
Since the Rev protein reduces the levels of the m ultiply-spliced HIV-1
mRNAs in the cytoplasm, it negatively regulates its ow n synthesis.
Therefore, the HIV-1 Rev protein is involved in tem poral regulation of
gene expression allowing the expression of small m ultiply-spliced RNAs
encoding the viral regulatory proteins early in the infection cycle and
perm itting the expression of the virion associated proteins from unspliced
and singly-spliced RNAs late in the infection cycle.
Rev exerts its effect on HIV-1 gene expression by directly binding to a
specific region of viral RNA, the Rev response elem ent (RRE). The cisacting Rev elem ent consists of a 234-nt region of the env gene that lies
im m ediately upstream of the second coding exons of tat and rev (Fig. 5).
This portion of env is found only in the unspliced and singly-spliced
transcripts of HIV-1 and not in the m ultiply-spliced RNA. The RRE forms a
defined secondary structure and the prim ary high affinity Rev binding site
w ithin this structure has been determ ined to lie in a 13-nt region (Tiley et
ah, 1992b). The Rev protein appears to contain two distinct functional
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Figure 5. The structure of the HIV-1 Rev response element.
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dom ains, an am ino-term inal highly basic nuclear localization and RNA
binding m otif and a carboxyl-term inal "activation domain". W ithin a
stretch of 13 am ino acid residues of the basic region are nine arginine
residues. The im portance of this region in nuclear localization and RNA
binding has been dem onstrated through extensive m utagenesis (Malim et
al., 1989b; Perkins et al., 1989; Berger et a l, 1991). Sequences flanking the

am ino-term inal basic dom ain are know n to be involved in
m ultim erization of the Rev protein, and this m ultim erization is required
for Rev activity in vivo (Malim and Cullen, 1991). The identification of the
carboxyl-term inal dom ain as an activation dom ain is based on the
observation that m utations in this region exhibit a trans -d o m in an t
phenotype, that is unlike m utations in the RN A -binding and
m ultim erization dom ains m utations of the carboxyl-term inal dom ain
cannot be com plem ented by the addition of w ild-type Rev protein supplied
in -trans. The belief is that these m utant proteins efficiently bind the RRE
sequence in vivo, b u t are unable to efficiently interact w ith some
com ponent of the splicing or the transport m achinery and therefore behave
as com petitive inhibitors to w ild-type Rev. It appears that an arrangem ent
of leucine residues, distinct from the leucine zipper motif found in a
num ber of transcription factors, is critical for m ediating the interaction with
some cellular protein(s). Clearly, the identification and functional
characterization of a cellular Rev-interacting protein(s) will shed significant
light onto the m echanism of Rev function.
The precise m echanism of action of the Rev protein, like that of the
Tat protein, is poorly understood. It is clear that there is a requirem ent for
sub-optim al splice sites. All retroviruses use sub-optim al splicing signals to
regulate the levels of spliced and unspliced viral mRNAs. Introduction of
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consensus splicing signals into a sim ple retrovirus results in a dram atic shift
tow ard spliced RNA and little Gag and Pol proteins being produced (Katz et
al., 1988). The sub-optim al splice sites of sim ple retroviruses affords the

virus a passive m echanism to regulate the levels of spliced and unspliced
RNAs (Katz and Skalka, 1990). In the case of the complex retroviruses,
w here a relatively large num ber of alternatively spliced RNAs m ay be
generated, the Rev protein directs an active effort to m aintain a balance
betw een fully spliced and partially spliced or unspliced RNAs. The
requirem ent for sub-optim al splice sites was dem onstrated using a P-globin
expression clone containing the HIV-1 RRE (Chang and Sharp, 1989).
Introduction of the RRE into the w ild-type p-globin gene did not alter the
splicing p attern of the cytoplasmic mRNA either in the presence or the
absence of the Rev protein. M utagenesis of both splice sites, so that splicing
could not occur, resulted in transport of unspliced RNA to the cytoplasm in
a R ev-independent m anner. H ow ever, m utation of a single splice site,
resulted in the retention of the unspliced RNA in the nucleus in the
absence of Rev and export of unspliced RNA to the cytoplasm in the
presence of Rev. These findings led to the proposal that the binding of
splicing factors to the sub-optim al splice sites of HIV-1 results in the
retention of the unspliced RNA in the nucleus. The interaction of Rev
w ith the RRE m ay serve to release the unspliced RNA from slow-acting
splicing factors bound to sub-optim al splicing signals, thereby allowing the
RNA to be exported to the cytoplasm.
The above experim ents appear to indicate a requirem ent for the
presence of sub-optim al splice sites to im part Rev-dependence on mRNA,
how ever there are other factors that contribute to Rev function. A num ber
of researchers have identified RNA sequences in the gag (Maldarelli et al.,
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1991; Schwartz et a l, 1992b,c), pol (Cochrane et a l, 1991) and env (Rosen et
a l, 1988) genes that prom ote the instability of the RNAs containing them,

th at is, RNAs of the full-length and 4-kb class. W hen these sequences are
placed into heterologous constructs containing reporter genes, they result in
R ev/R R E -dependent expression of the chimeric mRNAs. For example, a
260-bp inhibitory sequence located w ithin the 3'-end of the pol gene w hen
placed in the 3'-untranslated region (UTR) of a bacterial chloram phenicol
acetyl transferase (CAT) reporter construct, resulted in an approximately 40fold reduction in CAT activity. Co-expression of Rev did not restore the
CAT activity unless the RRE was also placed into the CAT reporter construct
(Cochrane et a l, 1990).
A 218-nt inhibitory region w ithin the 5'-end of the gag gene was
show n to result in a 4-fold reduction in half-life of RNAs containing this
sequence (Schwartz et a l, 1992b). Co-expression of Rev resulted in
stabilization of mRNAs carrying the inhibitory sequence. This gag
inhibitory sequence, like th at found in pol described above has a relatively
high AU content of slightly greater than 60%, a common feature of cellular
mRNAs w ith short half-lives (Shaw and Kamen, 1986; Jones and Cole, 1987;
W ilson and Treisman, 1988). In an effort to exam ine the significance of the
AU content of the gag inhibitory sequence, site-specific m utations were
introduced at the second and third positions of gag codons to increase the
GC content of this region while m aintaining the gag am ino acid coding
sequence. Only after the introduction of 28 point m utations over a 270-nt
region of gag was R ev-independent gag expression achieved (Schwartz et a l,
1992c). N either this gag inhibitory sequence described here, nor the pol
sequence described above contain splice sites, so the Rev-dependence of
these messages cannot be explained by the binding of splicing factors. It is
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believed that cellular proteins m ay bind to the inhibitory sequences and
result in nuclear retention and degradation. Thus, the binding of Rev to the
RRE m ay provide a general m echanism of releasing HIV RNA from such
proteins as splicing factors and the putative inhibitory sequence binding
proteins, thereby allowing its efficient expression in the cytoplasm.
The HIV Rev protein has also been im plicated in the efficient
translation of HIV mRNAs by increasing the efficiency of polysom e loading.
Two independent lines of evidence have show n that the RRE-containing
RNAs fail to assemble into polysom es in the absence of Rev. In the above
studies th at determ ined the inhibitory element in gag, it w as noted that
while the level of gag RNA in the cytoplasm in response to Rev was
increased about 10-fold, the levels of the p24 gag-encoded protein increased
nearly 1000-fold. Thus, the increase in cytoplasmic mRNA expression was
insufficient to account for the net increase in Gag proteins produced
(D A gostino et al., 1992). In a separate study, it was determ ined that the large
discrepancy betw een the levels of cytoplasmic and nuclear RRE-containing
RNAs noted in non-lym phoid cells were not detected in cells of lym phoid
origin, the in vivo host cell population for HIV. In these cells the
cytoplasmic levels of the unspliced and singly-spliced viral RNAs w ere not
significantly altered by the expression of Rev, yet the proteins encoded by
these RNAs w ere not expressed in the absence of Rev (Arrigo and Chen,
1991). Both of these research groups used sucrose density centrifugation and
RT-PCR to show that the RRE-containing RNAs w ere found in complexes
of 40S to 80S that co-sedim ented w ith RNAs bound to ribosom al subunits or
a single ribosom e (monosome). In the presence of Rev, these RNAs were
efficiently loaded onto polysomes. One possible explanation for these
findings is that in the absence of Rev, RRE-containing RNAs m ay be
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transported from the nucleus w hile bound to protein factors, such as the
p utative inhibitory sequence binding protein(s) or splicing factors. The
specificity for the export of these protein-bound RNAs m ay be different
betw een cell lines, such th at they m ay be m ore efficiently transported in
lym phoid cells. In the case of the gag inhibitory sequence-containing RNAs
th at lack splicing signals, binding of the putative inhibitory sequence
binding protein in the absence of bound splicing factors m ay be insufficient
for full nuclear retention of these RNAs. The proteins bound to these
RNAs m ay serve as an im pedim ent to translation and prevent assem bly of
the RNAs into polysomes. In the presence of Rev, these proteins may be
rem oved from the RRE-containing RNAs prior to transport and thereby
rendering them available for efficient polysom e loading. Clearly, the
complex regulation im parted by the Rev protein will be the topic of
extensive investigation in the years to come.
The A uxiliary Proteins of HIV-1
In addition to Tat and Rev, HIV-1 contains at least 4 auxiliary proteins
that, although not required for HIV-1 expression, appear to play im portant
roles in infectivity, m orphogenesis, and pathology of this virus. The
auxiliary proteins of HIV-1 include the products of the vif, vpu, vpr, and nef
genes. The N ef protein, like Tat and Rev, is an early gene product,
synthesized from m ultiply-spliced RNAs that lack the RRE. This protein
w as initially identified as a negative effector of HIV gene expression, since
infectious proviral clones w ith m utations in this gene exhibited enhanced
replication rates in cultured T cells (Fisher et al., 1986b; Luciw et al., 1987).
Further studies em ploying the HIV LTR linked to a reporter gene, showed
th at LTR sequences w ithin the negative response elem ent (NRE, -156—>-356)
w ere required for N ef-dependent dow n regulation of HIV expression
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(A hm ad and Venkatesan, 1988). H ow ever, other researchers have been
unable to duplicate these N ef-dependent repressive effects on HIV
replication (Kim et al., 1989a) or HTV-LTR driven transcription (Hammes et
al., 1989). In fact, in one case the N ef protein has been show n to significantly

augm ent replication of som e viral strains in cultured cells (Terwilliger et al.,
1991). Therefore, the role of Nef in the HIV life cycle rem ains controversial.
A m ong HIV strains passaged extensively in culture, the nef gene often
acquires prem ature term ination codons indicative of lack of selective
pressure for the m aintenance of this gene in culture. H ow ever, the
conservation of this gene in all prim ate im m unodeficiency viruses is highly
suggestive of an im portant in vivo role for the N ef protein.
The nef gene encodes a 27-kd phosphoprotein that is localized to the
inner surface of the cellular plasm a m em brane through an N -term inal
m yristic acid post-translational m odification (Allan et al., 1985; Franchini et
al., 1986). N ef has been reported to bear homology to GTP-binding proteins,

m ost notably p21 Ras, that are often involved in signal transduction
pathw ays. N ef has been reported to bind GTP, to have GTPase activity, and
to be capable of autophosphorylation (Guy et al., 1987), although other
researchers have been unable to confirm this finding (Kaminchik et al.,
1990; N ebreda et al., 1991). The N ef protein has been show n to reduce the
cell surface expression of the CD4 receptor in T cells (Guy et a l, 1987; Garcia
and Miller, 1991). Recently, this reduction in CD4 has been attributed to
N ef-induced endocytosis of CD4 followed by lysosomal degradation of the
internalized receptor m olecules (Aiken et a l, 1994). Since CD4 is involved
in the regulation of T-cell activation through the T cell receptor (TCR)
complex, it has been proposed that N ef results in de-regulation of T-cell
activation and enhanced cellular transcription through the NF-kB enhancer
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(Aiken et al., 1994). This proposal gains support from the finding that
transgenic mice expressing N ef exhibit increased TCR signalling
(Skowronski et al., 1993). A significant role for N ef in the developm ent of
AIDS has been dem onstrated in rhesus m acaques infected w ith ne/-defective
sim ian im m unodeficiency virus (SIV). Anim als infected w ith nef deletion
m utants of SIV failed to develop SAIDS (simian AIDS), and animals
infected w ith SIV strains containing point m utations in N ef rapidly selected
for revertants that restored nef function (Kestler et al., 1991). Clearly, further
in vivo studies will be required to precisely identify the role of the N ef

protein in HIV infection.
The roles of the Vpr, V pu and Vif proteins in HIV-1 infection are not
well understood. These proteins, along w ith the N ef protein, have been
term ed non-essential or accessory proteins, because the genes encoding
them are often m utated in cultured virus isolates and such m utations do
not abrogate viral replication in cultured cells. H ow ever, the conservation
of these genes in natural isolates of HIV-1 indicates that they play an
im portant role in the pathogenesis of HIV-1 infection. It has recently
become apparent that the vpu, vpr and nef genes are required for efficient
viral production in prim ary m acrophage cultures, b u t not in prim ary T
lym phocytes (Balliet et al., 1994; Balotta et al., 1993), while the v if gene is
required for production of infectious virions in both prim ary cell types
(Akari et al., 1992; G abuzda et al., 1992). Therefore, each of these genes is
likely to be im portant in vivo, since HIV-1 infection of m acrophages is
believed to be im portant for viral persistence, latency, and transm ission of
the virus to the central nervous system (reviewed by G endelm an et al.,
1989).

The HIV-1 viral p rotein R (Vpr) is a 15-kd nuclear arginine-rich
protein and is found in virions at m olar ratios equivalent to the Gag
proteins (Cohen et al., 1990a; Lu et al., 1993; Paxton et al., 1993). The
carboxyl-terminal Gag protein, p6, is required for efficient incorporation of
Vpr into virions (Paxton et al., 1993). The role of the p6 Gag protein in HIV1 virion structure is unknow n, and this additional Gag protein is only
found in the prim ate lentiviruses and equine infectious anem ia virus (p9).
Co-transfection experim ents w ith Vpr expression plasm ids and reporter
plasm ids show ed that Vpr is capable of m odestly activating transcription
from the HIV-1 LTR (2-3-fold), as well as a num ber of other heterologous
prom oters (Cohen et al., 1990b). However, these results have yet to be
confirm ed by others, and the m echanism of Vpr transcriptional activation
has not been investigated. It has been suggested that virion associated Vpr
m ay activate HIV-1 gene expression im m ediately following proviral
integration allowing the Tat protein to be produced which induces high
level transcriptional trans-activation (Cohen et al., 1990a).
The HIV-1 viral protein U (Vpu) is a 16-kd integral m em brane
phosphoprotein (Strebel et al., 1989). The am ino-term inal half of the
protein contains 27 hydrophobic amino acids believed to be involved in
m em brane anchoring, w hile the carboxyl-terminal portion of the protein is
believed to form tw o am phipathic alpha helices of opposite net charge that
have been proposed to be involved in the form ation of homo-oligom ers
(Henklein et al., 1993). Vpu is unique to HIV-1, unlike the other accessory
proteins that each have hom ologs in the other prim ate lentiviruses. Vpu
appears to perform tw o distinct functions in HIV-1 infected cells. Early
studies using cloned virus isolates w ith m utations introduced into vpu
resulted in an increased intracellular accum ulation of virion proteins
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associated w ith increased cytopathicity and syncytia form ation and a delay in
the appearance of free virus particles in cell culture supernatants (Klimkait
et al., 1990; Terwilliger et al., 1989). Examination of infected cells in culture

by electron microscopy show ed that m any virions w ere bound to the outer
surface of the plasm a m em brane or sequestered w ithin intracellular
vacuoles (Klimkait et al., 1990). O n the basis of these studies, it was
concluded that Vpu is im portant for the release of m ature virions from
infected cells.
It was later found that co-expression of the HIV-1 envelope
glycoprotein, gpl60, w ith the CD4 receptor in HeLa cells resulted in im paired
gpl60 production, and that the apparent block could be relieved by co
expression of V pu (Willey et al., 1992a). CD4 and gpl60 are integral
m em brane proteins, and as such are synthesized on ER-bound ribosomes.
The interaction of the two precursor molecules w ithin the ER prevents the
proper processing and transport of both by a mechanism term ed interference
(Buonocore and Rose, 1990; Crise et al., 1990). Co-expression of Vpu results
in rapid degradation of CD4 that is complexed to gpl60 in the ER thereby
allowing efficient expression of gpl60 and contributing to the dow nregulation of CD4 observed in HIV-1 infected T-cells (Willey et al., 1992b).
A m ino acid residues in the carboxyl-terminal cytoplasmic dom ain of CD4
are necessary and sufficient to induce Vpu-m ediated CD4 degradation
(Lenburg and Landau, 1993; Vincent et al., 1993; Willey et al., 1994). The
role of Vpu in the efficient transport of CD4 is readily reconciled w ith the
fact that Vpu and gpl60 are synthesized from bicistronic RNA and thus are
coordinately regulated at the translational level (see Translation of HIV-1
mRNAs). Vpu appears at present to be a true bi-functional protein as its
role in virus release occurs at the cellular plasm a m em brane and its role in
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CD4 degradation occurs w ithin the ER. Artificial retention of Vpu w ithin
the ER prevents its function in viral release. Furtherm ore, the
phosphorylation of Vpu is required for CD4 degradation w ithin the ER, but
has little effect on the viral release properties of this protein (Schubert and
Strebel, 1994).
The HIV-1 viral infectivity factor (Vif) is a 23-kd protein that exists in
both a soluble cytoplasmic form and a m embrane-associated form
(Goncalves et al., 1994). Vif increases the infectivity of virions produced in
prim ary T-cells by as m uch as 1000-fold and has been im plicated in cell to
cell transm ission of virus (Fisher et al., 1987; Strebel et al., 1987). The Vif
protein is produced from a R ev-dependent RNA (see The mRNAs produced
by HIV-1) late in the infection cycle (Garrett et al., 1991; Schwartz et al.,
1991). Some interesting insight into the role of Vif in HIV-1 infection has
arisen from the observation that some CD4+ T-cell lines, unlike prim ary Tcells, produce highly infectious virions w hen infected w ith v if m utants
(G abuzda et al., 1992). For example, vif' HIV-1 infection of the CEM T cell
line (nonperm issive cell line), like prim ary T cells, produced virions that
w ere not infectious in any other cell line examined. However, virions
produced from the infection of the Jurkat T cell line, or from transfection of
CD4“ COS-1 monkey kidney cells (permissive cell lines), could infect
m ultiple T cell lines, including CEM (Gabuzda et al., 1992). In an attem pt to
reconcile the observation that some T-cell lines require the expression of Vif
to produce infectious virions while others do not, it was proposed that the
perm issive cell lines may contain a cellular Vif-like com pensating activity.
These experim ents, com bined w ith the fact that Vif is expressed late in
infection, have show n that Vif exerts its effect on virions during their
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assembly. That is, the effect of Vif on virion infectivity is im posed on the
virion in the producer cell not the cell being infected.
M utant viruses th at lack v if produce virions that are indistinguish
able from w ild type vif+ viruses in term s of their content of virion proteins,
genom ic RNA, and even their ability to bind and enter CD4+ T-cells (Blanc
et al., 1993; Ma et al., 1990). However, it is clear that viruses produced from
v if m utants in nonperm issive cell lines display delayed kinetics w ith respect

to the onset of viral DNA synthesis (Sova and Volsky, 1993; von Schwedler
et al., 1993). It was recently discovered that retroviral virions contain partial

reverse transcription products, indicating that viral DNA synthesis occurs to
some extent prior to or d u rin g form ation of the m ature virus particle (Lori
et al., 1992; Trono, 1992). Examination of the levels of viral DNA in virions

produced from w ild type and vif' HIV-1 isolates detected no differences,
indicating that Vif is not required to render virions com petent for DNA
synthesis (von Schwedler et a l, 1993). Thus, it is currently believed that Vif
alters virions at the time of their form ation in a m anner that m akes them
m ore com petent for DNA synthesis after being internalized in an infected
cell (von Schwedler et al., 1993). It should be noted that Vif bears some
sequence hom ology to cysteine proteases and treatm ent of HIV-l-infected
cells w ith inhibitors of cysteine proteases results in production of virions
w ith reduced infectivity (Guy et al., 1991). A lthough the viral cytoplasmic
dom ain of the HIV-1 transm em brane protein, gp41, has been reported to be
a target of Vif proteolytic activity (Guy et al., 1991), this finding has been
disputed by several research groups (Gabuzda et al., 1992; Ma et al., 1994;
von Schwedler et al., 1993). It is clear, however, that both cysteine residues
of Vif are required for its function (Guy et al., 1991; Ma et al., 1994).
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The m RN A s Produced by HIV-1
D uring HIV-1 infection three major size classes of transcripts are
produced, an d their relative abundance in the cytoplasm of an infected cell
is tem porally regulated (Kim et al., 1989b). Early in the infection only small
transcripts of approxim ately 1.8-kb in length are produced. This size class
consists of a heterogeneous group of transcripts that encodes the products of
the tat, rev, and nef genes. Once a critical level of the Rev protein has
accum ulated in the nucleus of an infected cell, the RRE-containing 9.2-kb
unspliced genom ic RNA and a num ber of RNAs of approxim ately 4-kb
accum ulate in the cytoplasm . The genomic RNA may be either directed to
the inner surface of the plasm a m em brane for packaging into progeny
virions or m ay be translated to produce the Gag capsid precursor and the
pol-e ncoded viral enzym atic activities. The 4-kb class of mRNAs, like the

1.8-kb class RNAs, is a heterogeneous class but are prim arily responsible for
the synthesis of the enz>-encoded gpl60 glycoprotein. H ow ever, som e RNAs
in this size class also encode the auxiliary proteins Vpu, Vif, and Vpr.
The various HIV-1 RNAs are produced by alternative splicing events
involving at least 5 splice donors (SD) and 11 splice acceptors (SA). The
presence of 8 com peting splice acceptors betw een the 3'-end of pol and the
5 -e n d of env leads to m uch of the heterogeneity in HIV-1 mRNAs. All
HIV spliced RNAs contain a 289-nt leader exon (exon 1) due to the presence
of a unique splice donor at nucleotide (nt) 289 of the genomic RNA (In this
section the n t designations will be relative to the transcription start site, +1).
The singly-spliced RNAs of the 4-kb size class are generated by splicing of the
leader exon splice donor to one of the various acceptors in the pol/env
intergenic region (Fig. 6). In sim plified term s, there are essentially five
classes of singly-spliced RNAs, in which the leader is spliced to a splice
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acceptor (SA) that lies upstream of the vif (SA2), vpr (SA3), ta tl (SA4), vpu
(SA5) or nef (SA7) dstrons. All b u t the nef RNA, are of the 4.0-kb size class
of HTV RNAs and are structurally multicistronic. Noticeably m issing from
the above list of cistrons that are im m ediately preceded by an upstream
splice acceptor, is the env cistron. To date no splice acceptor has been
identified to lie w ithin the 161-nt sequence betw een the initiation codon of
vpu and that of env. Thus, HIV-1 env m ust be expressed as the second

cistron in bicistronic RNAs that contain vpu as the first cistron. In an
exhaustive study Purcell and M artin (1993) have exam ined the relative
levels of each of the spliced transcripts produced by HIV-1 infection of
peripheral blood m ononuclear cells (PBMCs) using a sem i-quantitative PCR
m ethod. A lthough approxim ately 80% of the vpu/env RNAs result from
the splicing of exon 1 to the acceptor im m ediately upstream of vpu (Env 1),
another 12% also contain the first exon of rev due to splicing of exon 1 to
one of three closely-spaced acceptors lying directly upstream of the rev
initiation codon (Env 2-4) (Purcell and M artin, 1993). The 4.0-kb RNAs
encode the vpu/env, tat-1, vpr, and vif RNAs at a m olar ratio of 92:5:2:1,
therefore the vpu/env RNAs represent the vast m ajority of this class of
RN As.
In addition to the singly-spliced RNAs, the 4.0-kb class of transcripts
also contains som e m ultiply-spliced RNAs. These RNAs arise from the
inclusion of tw o small non-coding exons (exon 2 and exon 3) into a num ber
of the singly-spliced RNAs described above. Exon 2 consists of 49-nt w ithin
the pol cistron and exon 3 consists of 73-nt w ithin the v if cistron. Exon 2 is
bordered by the splice acceptor (SA2) used to produce the v if RNA described
above (Vif 2) and the second splice donor (SD2) in the full length RNA.
Since this splice donor lies upstream of the v if AUG codon, this exon does

4.0 kb class o f RNA

44 c44£
ab

3a

1 , ..l vpr,';’ revl
l

- splice
a cc ep to rs
I

v pu

I

- splice
d o n o rs

: 2

R elative

R N A s p e c ie s •

;
:
*1 i
---- \—1I"

E nv 8

Tat
Tat
Tat
Tat

f
Jad—

5
6
7
8

• i
—I..*

tm
ii

;
:
i
!
. ;

jEB gj

t
i

85
9
6
0
98

Vpr 3
Vpr 4
V if 2

t

80
5
6
1
3
0
1
5
0
1
0
0
1
0
0
0

2

r

Figure 6. The 4.0-kb size class of HIV-1 RNAs.
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not provide any translational initiation signals w hen spliced to dow nstream
exons. The Vif protein is the only HIV-1 protein produced from a spliced
RNA that can only be expressed from a single RNA (Vif 2). The Vpr protein
can be produced from tw o different transcripts. The singly-spliced transcript
described above (Vpr 3) accounts for 98% of the vpr RNA and a second
transcript containing exon 2 spliced to exon 3E (Vpr 4) accounts for only 2%
of the vpr RNA of the 4.0-kb size class. As will be discussed below, vpr can
also be expressed from RNAs of the 1.8-kb size class. The Tat-1 (72 amino
acid) protein can be produced from 4 different RNAs: the singly-spliced Tat
5 transcript described above (85%); a doubly-spliced RNA containing exon 2,
Tat 6 (9%); a doubly-spliced RNA containing exon 3, Tat 7 (6%); or a triplyspliced RNA containing both exons 2 and 3, Tat 8 (<1%). Since the vpu/env
singly-spliced RNAs are produced from 4 different splice acceptors and each
of these four transcripts m ay contain exon 2, exon 3, or both, there are 16
different vpu/env RNAs produced. H ow ever, as m entioned above, the
singly-spliced RNAs account for 92% of the total vpu/env RNAs. The only
m ultiply-spliced vpu/env RNAs found at appreciable levels are the Env 5
(3%) and the Env 8 (5%) RNAs. These RNAs contain non-coding exons 2
and 3, respectively, spliced to the major env splice acceptor (SA 5).
The 1.8-kb RNAs encode the Tat-2 (86 amino acid), Rev, Nef, and Vpr
proteins. These RNAs are identical to those of the 4-kb class described above
except for the absence of the intron located between the tw o coding exons of
Tat and Rev (SD4 to SA7, Fig. 7). This intron contains the Rev-responsive
elem ent (RRE) and a large portion of the env cistron, thus this intron will
be referred to as the e n v /RRE intron here. A lthough a m ultiply-spliced
RNA encoding Vif (1.2a.7, w here exon 2a represents an extended version of
exon 2 that contains sequences from SA2 to SD4) has been predicted
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(Schwartz et ah, 1990b), none has yet been found (Purcell and M artin, 1993).
There are tw o 1.8-kb RNAs that encode Vpr and four that encode Tat-2 that
are sim ilar to the 4-kb Vpr and Tat-1 RNAs, respectively, except that they
lack the cmzj/RRE intron. As is the case for the 4-kb RNAs, the
predom inant 1.8-kb RNAs lack the additional non-coding exons (exons 2
and 3). The predom inant 1.8-kb vpr RNA (Vpr 1) accounts for 72% of the
1.8-kb vpr RNA, while the major 1.8-kb Tat-2 RNA (Tat 1) accounts for 48%
of the total Tat-2 RNA.
The 16 vpu/env 4.0-kb RNAs give rise to tw o groups of 1.8-kb RNAs.
The 12 vpu/env RNAs that utilize splice acceptors 4a, 4b, and 4c give rise to
1.8-kb Rev RNAs (Rev 1-12), since these acceptors lie upstream of the Rev
AUG initiation codon. The other four vpu/env RNAs th at utilize SA5 lack
the Rev initiation codon and give rise to m ultiply-spliced RNAs that encode
N ef (Nef 2-5). The three 1.8-kb Rev RNAs that lack non-coding exons (Rev
1-3) account for 80% of the Rev RNAs. As m entioned above, there is a
singly-spliced form of N ef RNA that lacks non-coding exons (Nef 1),
how ever this RNA only accounts for 5% of the total N ef RNA. The
predom inant N ef RNA (Nef 2, 49%) contains a single non-coding exon
(exon 5). It is currently not clear if these non-coding exons affect the
expression of the N ef protein, b ut it seems likely that the presence of the
non-coding exon m ay reflect the inability of the cellular splicing m achinery
to com pletely overlook the extensive array of splice acceptors in the pol/env
inter genic region. All of the other spliced RNAs described herein utilize at
least one of the splice acceptors in this region.
O ne novel 1.8-kb HIV RNA w orthy of m ention results from the
inclusion of a small exon (exon 6), located in the env cistron (SA6, nt6611/SD5, nt-6724), into the Tat-2 RNA (Tat 1) betw een the tw o coding exons
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of Tat-2 (exons 4 and 7) (Schwartz et ah, 1990a). The insertion of this intron
results in a fram eshift of the Tat open reading fram e to produce a chimeric
28-kd protein, Tev or Tnv, th at contains the first 72 am ino acids of Tat, 38
codons of gp90, an d the carboxyl-terminal 91 amino acids of Rev. This
protein has been identified in HIV-infected cells and has the functions of
both Tat and Rev (Benko et ah, 1990; Salfeld et ah, 1990). These RNAs and
their corresponding proteins have only been detected w hen cells are infected
w ith one particular infectious proviral HIV clone of HIV-1 (HXB2). These
RNAs could not be detected in the sem i-quantitative PCR studies described
above, and are therefore generally believed to be cryptic splice sites that are
not broadly relevant to the majority of strains of HIV-1. A dditional splice
acceptors im m ediately upstream of SA7, SA7a and SA7b, have also been
previously reported (Schwartz et ah, 1990a). The use of these splice sites
w ould result in deleterious m utations of the essential tat and rev genes, and
w ere not detected in the semi-quantitative study. Thus, these sites are also
presum ed to be cryptic splice sites that are not generally relevant to HIV-1
replication and pathogenesis.
T ranslation of HIV-1 mRNAs
Retroviruses, in general, utilize a num ber of strategies to express a
relatively large num ber of protein products from a single prim ary transcript.
As dem onstrated above, a major strategy em ployed by HIV-1 is alternative
splicing. H ow ever, all retroviruses m ust synthesize the gag-encoded virion
core proteins and pol-e ncoded enzym atic activities from a single mRNA,
the full-length genom ic RNA. In m ost retroviruses, the gag gene encodes
four proteins, and the pol gene encodes the three viral enzymes. All of
these proteins are synthesized from the m onocistronic genomic RNA as a
single polyprotein that undergoes post-translational cleavage. The majority

42
of ribosom es that initiate at the gag AUG codon term inate translation at the
gag term ination codon to produce the Gag precursor polyprotein. However,

the gag term ination codon m ay be suppressed w ith low frequency to allow
for the synthesis of the Gag-Pol precursor polyprotein. This m echanism of
expression of the pol-e ncoded enzym es appears to fulfill tw o roles in viral
replication. First, it allows for m uch lower m olar ratios of the catalytically
active virion enzym es relative to the gag-encoded structural proteins.
Second, synthesis of a Gag-Pol fusion protein allows for the viral-encoded
enzym es to be targeted w ith the Gag precursor to the inner surface of the
cellular plasm a m em brane, so that they m ay be packaged into m ature
virio n s.
Two distinctive translational m echanisms have been identified that
allow for synthesis of Gag-Pol polyproteins in retroviruses, read-through
suppression and ribosom al fram eshifting. In read-through suppression, a
rare suppressor tRNA inserts an amino acid into the nascent Gag
polypeptide in response to the gag term ination codon. This m echanism is
utilized only by the m am m alian oncoviruses (type C retroviruses), and has
only been extensively investigated in M aloney m urine leukem ia virus
(MoMLV) (reviewed by H atfield et al., 1992). The majority of retroviruses,
including HIV-1, use ribosom al fram eshifting to express Gag-Pol fusion
proteins. A lthough ribosom al fram eshifting can result in a shift to the -1 or
+1 reading frame, only -1 fram eshifting has thus far been observed in
retroviruses. The fram eshifting event requires the presence of defined cisacting sequences in the viral RNA surrounding the fram eshift site.
Sequences im m ediately upstream of the frameshift site are characterized by
a string of identical nucleotides that are necessary b u t not sufficient to trigger
the frameshift. In HIV-1 RNA, there is a string of six uridine residues

followed by an adenine residue. It is the adenine residue in this sequence
that is read twice, once as the final nucleotide in a gag codon (UUA) and
then again after ribosom e slippage as the first nucleotide in the first codon
(AGG) of the pol reading fram e (Jacks et al., 1988). A dditional sequences
dow nstream of the fram eshifting site are also required. A lthough there is
no clear sequence conservation am ong retroviruses in this region, there is
significant structural conservation. In all retroviruses exam ined to date,
there is the potential to form a stable stem loop structure im m ediately
dow nstream of the fram eshifting site and in some cases an RNA
pseudoknot m ay be form ed (Cham orro et al., 1992). The unusually high
stability of such structures m ay result in ribosomal pausing at the frameshift
site, thereby facilitating the slippage. Some retroviruses, such as hum an T
cell leukem ia virus type 1 (HTLV-1), undergo tw o ribosom al fram eshifting
events. In these cases, the virally-encoded protease is encoded in an
alternative reading fram e betw een and overlapping both the gag and pol
cistrons. Thus, one ribosomal fram eshift occurs to produce a G ag/P rotease
precursor protein and another occurs to produce the G ag /P ro tease/P o l
polyprotein. Once synthesized, the Gag and G ag/P ol precursors are posttranslationally cleaved by the virally-encoded protease to produce the
m ature viral proteins.
M ost retroviruses produce one singly-spliced mRNA that encodes the
envelope polyprotein consisting of the surface glycoprotein (SU) and the
transm em brane glycoprotein (TM). These mRNAs are translated on
endoplasm ic reticulum (ER) bound ribosomes due to the presence of an ER
signal peptide at the am ino term inus of the SU protein. This signal peptide
is cleaved co-translationally by a cellular signal peptidase. The precursor
protein is cleaved post-translationally by an as yet undeterm ined cellular

protease to form the m ature SU and TM proteins, that rem ain associated
through disulfide bonds. In the case of HIV-1, there are m ultiple envelope
length RNAs produced, as described above. M any of these contain the
coding regions of other HTV genes and are therefore structurally
m ulticistronic. In fact, there have been no RNAs detected in HIV-1 infected
cells th at contain env as the first cistron. The sim plest env RNA described
above, Env 1 (Fig. 6), also contains the overlapping vpu gene. This RNA is
functionally bicistronic in transfected cells, producing both the Vpu and
g p l6 0 (Env) protein (Schwartz et al., 1990b). A lthough the vpu cistron is the
first cistron of this mRNA, there is very little Vpu protein produced as
com pared w ith Env. Examination of the sequence of all know n HIV-1
isolates dem onstrated that the vpu AUG initiation codon lies in a relatively
w eak context for translational initiation. The consensus sequence context
for translational initiation is CC A /G C C AUG G, w here, other than the AUG
itself, the m ost im portant residues for efficient initiation are the purine in
the -3 position, w ith adenine being preferred to guanine, and the guanine in
the +4 position (Kozak, 1986). In all of the HIV-1 strains exam ined, the vpu
AUG contains a pyrim idine, m ost often a cytidine, in the +4 position.
M utagenesis studies have show n that the conservation of a pyrim idine in
the +4 position of the vpu cistron is critical for efficient env expression
(Schwartz et al., 1992a). On the basis of these observations, it was concluded
that env is expressed from the vpu/env RNA (Env 1) by leaky ribosom e
scanning through the inefficiently recognized vpu AUG. As will be show n
below, this is a common m echanism used by HIV-1 to express m ulticistronic
mRNAs. Since there are no env RNAs that do not also encode vpu, the
synthesis of the two proteins encoded by these genes is coordinately
regulated. This w ould appear to be beneficial to efficient virion production,
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since, as discussed above, the V pu protein is believed to aide in the selective
degradation of CD4 that is complexed w ith gpl60 in the endoplasm ic
reticulum (Willey et al., 1992b).
In addition to the major env transcript (Env 1), there are three other
vp u /en v transcripts (Env 2-4) that also contain the first exon of the rev

gene. A lthough the protein coding potential of these mRNAs has not been
exam ined in detail yet, it appears likely that they will also be found to
produce the V pu and gpl60 proteins. As will be presented below, the rev
AUG codon, like that of vpu, lies in a sub-optim al sequence context
allow ing for leaky ribosom e scanning. The next largest group of the 4.0-kb
RNAs (5%) are those including the first coding exon of tat, such as Tat 5 (Fig.
6). A lthough the tat gene consists of two coding exons, the first exon of tat
encodes 72 of the 86 total am ino acids of the Tat protein. It is know n that
the first 72 am ino acids of Tat are sufficient to provide full trans-activation
of the HIV-1 LTR (Sodroski et al., 1985b), thus the first exon contains the
essential Tat residues. The splice donor site (SD 4, nt 6274), that joins the
tw o coding exons of tat, is followed im mediately by an in-fram e UAA
term ination codon, allowing for the synthesis of a fully functional 72 am ino
acid one exon Tat protein (Tati) from the Tat 5 RNA. A lthough this RNA
also contains the vpu and env cistrons, it is functionally m onocistronic in
vivo d u e to the presence of a relatively strong translation initiation codon

for the T ati protein, AA GAA AUG G, w here those nucleotides matching
the consensus sequence are underlined (Schwartz et al., 1990b; Schwartz et
al., 1992a). The coding potential of the v if and vpr 4.0-kb RNAs has not been

investigated, how ever it m ay be anticipated that the vpr RNAs will be
functionally m ulticistronic d u e to a weak AUG context (GA UAG AUG G).
The v if gene AUG codon does not appear to have a highly conserved
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sequence context. In some isolates it lies in a highly favorable context for
translation (GG AUU AUG G) while in others it does not (AA CAG AUG G).
Therefore, depending upon the strain exam ined, the v if RNAs m ay be
anticipated to be m ono- or multi-cistronic.
The RNAs of the 1.8-kb class that encode the Tat-2, Rev, and Nef
proteins are also structurally m ulticistronic as m entioned above. The RNAs
th at encode Tat-2 (Tat 1, Fig. 7) w ere shown to be m onocistronic in vivo
producing only the Tat-2 protein and very little Rev or N ef protein
(Schwartz, et al., 1990a). By analogy to the Tat-1 RNAs described above, the
inhibition of expression of the dow nstream reading fram es has been
attributed to the relatively strong context of the tat AUG initiation codon
(Schwartz, et al., 1992a). The rev/nef RNAs (i.e. Rev 1-12), on the other
hand, are functionally bicistronic expressing high levels of N ef protein
(Schwartz, et al. 1990a). The m echanism of expression of N ef from these
RNAs has been attributed to the relatively weak translation initiation
context of the rev AUG (UC CCU AUG G). In particular, the presence of a
highly conserved cytidine residue in the -3 position is believed to result in
low level initiation of rev. The conservation of this sequence context across
a broad range of HIV-1 isolates is suggestive of the presence of selective
pressure to m aintain this sequence. The significance of such selection is not
as obvious as that for the inefficient expression of the Vpu protein described
above. In that case, there are no env RNAs that do not contain vpu as the
first cistron, so that env expression is entirely dependent on leaky ribosome
scanning through the vpu AUG. H owever, the m ulticistronic rev RNAs
only m ake up only a fraction of the 4.0-kb RNAs (13%) and the 1.8-kb RNAs
(34%). The ORFs that lie dow nstream of rev in these RNAs, nam ely vpu,
env and nef, can be efficiently expressed from alternative RNAs that lack

the rev initiation codon. As m entioned above, the Env 1 vpu I env RNA
makes u p 80% of the total 4.0-kb class of RNAs and the various
m onocistronic nef RNAs m ake u p 52% of the 1.8-kb class (Purcell and
M artin, 1993). The inefficient expression of rev m ay rather reflect a need to
m aintain controlled levels of Rev to prevent large am ounts of virus
production followed by cell lysis. The Rev protein is expressed exclusively
from the 1.8-kb class of RNAs early in infection. Once a critical level of Rev
has accum ulated, the unspliced and partially spliced RNAs appear in the
cytoplasm and the virion associated proteins are produced. As the level of
Rev falls below this critical level, the export of the under-spliced RNAs
from the nucleus is prevented until the critical level of Rev is once again
attained. This allows the virus an opportunity to control the level of virion
production and affords the ability of the virus to enter latency w hen levels
of Rev are low. C onstitutive expression of high levels of Rev m ight
therefore prevent viral latency and result a highly cytopathic viral infection.
The presence of the non-coding exons 2 and 3 (Fig. 6, 7) in a num ber
of low abundance HIV-1 mRNAs does not appear to alter the translational
efficiency of any of the HIV proteins in vivo. Thus, the significance of the
these non-coding exons rem ains to be determ ined. It seems likely that they
m ust play som e significant role in HIV-1 infection, since there are no other
HIV-1 RNAs th at utilize splice donors 2 and 3. These donors are only
utilized to produce the two small non-coding exons. Their conservation in
all know n HIV-1 isolates is highly suggestive of some role in viral gene
expression.
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Equine Infectious A nem ia Virus
Historical Perspective of Equine Infectious Anem ia Virus

The disease equine infectious anemia (EIA) was first described in
France in 1843 (Lignee, 1843) and show n to be transm itted by a filterable
agent, i.e. viral, in 1904 (Vallee and Carre, 1904). There was little significant
investigation of EIA until the virus was propagated in prim ary mixed
leukocyte cultures in the late 1960's (Kobayashi and Kono, 1967). This led to
the production of a m ostly ineffective live-attenuated vaccine (Kono et al.,
1970), how ever the failure of the vaccine to provide broad protective
im m unity led to the discovery of antigenic variation in EIAV (Kono et al.,
1973). The molecular basis of this variation was later determ ined to involve
alteration of the gp90 surface glycoprotein at the genetic level (Montelaro et
al., 1984; Salinovich et a l, 1986). With the lack of an effective EIAV vaccine

the em phasis was shifted from prevention of viral disease to diagnosis and
control. In 1972 Leroy Coggins introduced the agar gel im m unodiffusion
(AGID) test for detection of EIAV antibody in infected horses (Coggins et al.,
1972). This test, commonly referred to as the Coggins' Test, is still currently
used as the standard for EIA diagnosis. In 1973 EIAV was first cultivated in
established cell lines allowing for the production of large quantities of
highly purified virus (M almquist et al., 1973). These cultured virus stocks
w ere used to dem onstrate the reverse transcriptase activity of EIAV, thereby
allowing its characterization as a retrovirus. With the discovery of the
hum an lentiviruses HIV-1 and HIV-2, there has been intensive study of
EIAV on the genetic level. The sequence of the entire proviral DNA
genom e of EIAV was first reported in 1987 (Kawakami et al., 1987). The
sequence dem onstrated that EIAV contained three short open reading
frames, S I, S2 and S3, in addition to the gag, pol and env genes common to

all replication com petent retroviruses. The predicted protein products of
the S I and S3 ORFs w ere show n to bear striking sequence homology to the
Tat and Rev proteins of HIV-1. These are obligatory RNA-binding proteins
that regulate the level of viral transcription (Tat) and the relative levels of
spliced viral RNAs (Rev).
Equine Infectious Anem ia, the D isease

Initial infection of horses w ith EIAV results in the onset of acute
disease w ithin 7-10 days post-infection characterized by fever, anemia,
throm bocytopenia, and viremia. A lthough some horses (<5%) m ay
succum b to this prim ary infection, the vast majority (>95%) recover from
this initial infection and progress to the chronic stage of disease. The
chronic stage of EIAV is unique am ongst the lentiviruses, and is
characterized by recurring episodes of fever, anemia, and viremia. These
episodes typically last for 3-5 days and the length of time between episodes
varies from several weeks to m onths (Fig. 8). Each febrile episode is
associated w ith the appearance of distinct antigenic variants of the gp90
surface glycoprotein. The variants are apparently able to escape im m une
detection and result in a bout of viremia. The chronic stage norm ally lasts
for about one year at which tim e the majority of horses become inapparent
carriers of the virus and appear clinically normal. These horses rem ain
infected for life and m ay undergo subsequent febrile episodes if sufficiently
stressed.
The Proviral G enom e of EIAV

The DNA proviral genom e of EIAV is 8.4-kb long and is flanked by
relatively small LTRs of approxim ately 300 to 320-bp dependent on the
individual isolate. The overall structure of the LTRs and the c/s-acting
sequence elem ents contained w ithin them are discussed briefly below. The
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Figure 8. Schematic representation of EIAV disease course. The rectal
tem perature of a hypothetical EIAV-infected horse is plotted as a function of
time. The base line represents norm al tem perature and the spikes indicate
febrile episodes. As indicated, various forms of stress m ay cause an
inapparent carrier to re-enter the chronic stage of the disease.
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overall genom e structure of EIAV is relatively less com plex than that of
HIV-1, in that it contains only three genes in addition to the obligatory gag,
pol and env. In EIAV these genes have traditionally been called open

reading fram es (ORFs) S I, S2 and S3 based on the order of their appearance
in the genom e from 5' to 3'. The S I and S2 genes lie w ithin the p o l/e n v
intergenic region, w hile S3 overlaps the transm em brane (TM) glycoprotein
coding region of the env gene in an alternative reading fram e (Fig. 9).
The only com plete proviral sequence of EIAV currently available
through the GenBank database (locus: EIAVCG; Accession: M16575) will be
used as a representative isolate for the purpose of this abbreviated
description of the genom e structure. This isolate is 8407-bp in length and
contains LTRs of 321-bp each. A 143 leader region (nt 322-464) lies between
the 5-LTR and the gag ATG initiation codon. This leader region contains a
single splice donor signal (nt 459) that lies im m ediately upstream of the gag
ATG codon (nt 465) and allows RNA splicing of the leader sequence to all
EIAV RNAs. The gag gene (nt 465-1925) encodes a precursor protein
(Pr55^fl^) that consists of the am ino terminal p i 5 m atrix protein (MA), the
p24 capsid protein (CA), the p l l nucleocapsid protein (NC) and the carboxyl
term inal p9 protein of unknow n function. The gag (nt 465-1925) and pol (nt
1727-5122) genes overlap by 241-bp, and pol has been proposed to be
expressed from the genom ic RNA through ribosom al fram eshifting at the
sequence AAAAAAC (nt 1721-1727). The pol gene (nt 1727-5122) encodes
the viral enzym e activities in the sequence of pro tease/rev erse
transcriptase/R N ase H /en d o n u clease sim ilar to other lentiviruses.
The pol gene term ination codon is followed im m ediately by an open
reading fram e (nt 5123-5275) w ith the potential of encoding 50 am ino acids,
how ever this open reading fram e lacks a m ethionine initiation codon.
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Figure 9. Schematic representation of the EIAV proviral genome.
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This open reading fram e (ORF), originally term ed ORF S I (Rushlow et a l,
1986) is now know n to be the second coding exon of EIAV Tat. The RNAs
encoding the Tat protein and their expression will be discussed further
below.
A m ere 7-bp dow nstream of the ORF SI term ination codon lies a
second small open reading fram e (nt 5283-5483), ORF S2, that has the
potential to encode 66 am ino acids. The second codon in this ORF
corresponds to a m ethionine residue that m ay be responsible for initiation
of its synthesis. The predicted protein product of this ORF bears no sequence
hom ology to other lentiviral auxiliary proteins, and no function has yet to
be assigned to the ORF S2 protein. The majority of ORF S2 overlaps w ith
the 5'-end of the env gene (nt 5312-7891) in an alternative reading frame.
Only 23-bp separate the first ATG of ORF S2 and the ATG initiation codon of
env. This arrangem ent of ORF S2 and env in EIAV is similar to that of vpu

and env in HIV-1. The env gene of EIAV encodes a precursor protein of
135-kd (gpl35) that contains the surface glycoprotein, gp90, at its amino
term inal end and the transm em brane protein, gp45, at its carboxyl terminal
end. O verlapping the gp45 coding region of the env gene in an alternative
reading frame, lies a third small open reading frame, ORF S3 (nt 7234-7641).
This gene has the capacity to encode a protein of 135 am ino acids, but like
ORF S I, contains no m ethionine codons. This gene is believed to encode
the EIAV Rev protein, and an initiation codon is provided to this gene by
splicing (see The EIAV S3/R ev Protein). The env gene and the 3-LTR are
separated by 17-bp that include the poly purine tract which is im portant for
reverse transcription of the genom ic RNA.
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The EIAV LTR

The EIAV LTR contains a U3 region that varies in length betw een
isolates from about 190 to 210-bp. The R region of the LTR consists of 76-bp
and the U5 region of 36-bp. The R region contains the EIAV Tat transactivation response (TAR) elem ent that has been localized to nt +4 to +22
relative to the transcription start site. Thus, like the TAR sequence of HIV1, the EIAV TAR is found in all viral mRNAs and forms a stable stem-loop
structure required for trans-activation. The T at/T A R interaction of EIAV
will be presented in greater detail below. The U3 region of all the variant
EIAV LTRs thus far exam ined contains a TATA box located approxim ately
25-bp upstream of the transcription start. Deletion analysis of the LTR
determ ined that sequences from -31 to -46 are required for both basal and Tat
frans-activated transcription from the EIAV LTR (Carvalho and Derse,
1993a). This region has been dem onstrated to bind the macrophage-specific
transcription factor PU .l (Carvalho and Derse, 1993a). Equine infectious
anem ia virus, unlike the prim ate im m unodeficiency viruses, only
replicates appreciably in m ature tissue m acrophages in vivo and not in
peripheral blood m onocytes or lymphocytes (Sellon et al., 1992). The PU .l
factor is nam ed for its ability to bind a purine rich sequence (GAGGAA) and
is a m em ber of the ets oncogene superfam ily of DNA binding proteins
(Klemsz et al., 1990). M embers of this family are activated by phorbol esters
and thus are subject to activation by stim uli that activate protein kinase C.
W ithin 5-10 n t upstream of the PU .l binding site lies an AP-1 site (-45 to -60).
AP-1 binds hom odim ers of the constituitively-expressed Jun family of
proteins or the Jun proteins m ay form heterodim ers w ith the inducible Fos
fam ily of proteins. The EIAV AP-1 site (TGACGCG) differs from the
consensus site (TGACTCA) at 2 of the 7 nucleotides that define the
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consensus. Interestingly, oligonucleotides containing the consensus AP-1
sequence do not com pete very effectively for factor binding to the EIAV AP1 sequence (Carvalho and Derse, 1993b). This suggests that a particular
F o s/Ju n family dim er binds the EIAV AP-1 m ore strongly than to the
consensus AP-1 sequence. The identification of this putative F os/Jun
protein rem ains to be determ ined.
A hypervariable region of 10 to 30-bp lies im m ediately upstream of
the AP-1 site. This region varies in length and sequence betw een various
isolates of EIAV. In the isolates characterized to date, the hypervariable
region always contains at least one duplicated factor binding site. The
sim plest m ay be a single duplicated PEA2 site (see below), while the more
complex hypervariable regions have been show n to contain additional sites
for AP-1, PU .l and PEA2 (Carvalho et al., 1993). The m ost frequent
duplications in the hypervariable region contain one or tw o additional PU .l
binding dom ains (Payne et al., 1994). The hypervariable region is flanked on
the 5' side by a PEA2 binding site in all isolates examined to date (Carvalho
et al., 1993; Payne et a l, 1994). The PEA2 factor binding site was first

identified as one of three cis -acting elements in the polyom a virus enhancer
A (PEA) (Piette and Yaniv, 1987). The binding sequence for PEA2 in the
EIAV LTR is AACCGCA. A lthough the specific factors that bind this
sequence have not yet been identified, oligonucleotides containing this
sequence specifically bind nuclear factors in extracts derived from a variety
of cell types. Functional studies, involving the EIAV LTR linked to the
bacterial CAT gene, indicate that m utagenesis of the PEA2 site results in
reduced prom oter activity of the LTR that varies in m agnitude dependent
on the cell line em ployed (Carvalho and Derse, 1993b). These data indicate
that this site is likely to play a role in EIAV gene expression.
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Early functional studies using LTR deletion m utants dem onstrated
that sequences lying betw een -110 and -76 contain a negative regulatory
elem ent (Dorn and Derse, 1988). These early studies w ere done in a feline
fibroblast cell line (FEA). Subsequent analysis of sim ilar deletion m utants in
hum an carcinoma HeLa cells and canine osteosarcom a D17 cells, indicated
that sequences w ithin this region exert a positive effect on EIAV regulation
(Carvalho and Derse, 1993b). C om puter assisted sequence analysis
determ ined that this region contains a binding site for the m ethylated DNA
binding protein (M DBP/EP/EF-C) (Ben-Levy et al., 1989), first isolated on the
basis of its preferential binding to sequences containing m ethylated CpG di
nucleotides (H uang et al., 1984). MDBP is a ubiquitous m am m aliam protein
that binds to a w ide range of related nucleotide sequences (Supakar et al.,
1988). Partially purified MDPB has been show n to bind to the enhancer
elem ents of EIAV, m ouse polyom a virus, and hepatitis B virus in a
m ethylation-independent m anner (Zhang et al., 1990). N uclear extracts
from a num ber of sources, including hum an m onocytes and B cells, form
specific complexes w ith oligonucleotides that contain the EIAV MDBP site
(Carvalho and Derse, 1993b). Thus it appears that cellular proteins interact
w ith MDBP site of EIAV and, depending on the cell type exam ined, exert a
positive or a negative effect on gene expression.
A lthough no factors have as yet been show n to b in d to the EIAV LTR
at sequences upstream of the MDBP site, there is a directly repeated sequence
(TGT/ AGGGG1T1TAT) at the 5'-end of the LTR that m ay be of potential
factor binding site (Derse et al., 1987). H owever, deletion of these sequences
from the LTR appear to have little effect on EIAV gene expression in feline
fibroblasts (Dorn and Derse, 1988). Much of the difficulty in analyzing EIAV
gene expression lies in the lack of availability of stable cell lines of equine
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monocytes. It is possible that these 5' repeats m ay have an effect on gene
expression in vivo or in cultured horse macrophages. Studies in these cell
types m ust be done to determ ine the significance of each of the factor
binding sites described above in EIAV gene expression in the infected horse.
Identification of the EIAV t a t Gene
Early studies indicated that reporter plasm ids under the control of the
EIAV LTR w ere specifically trans-activated 250 to 900-fold in feline (FEA)
and canine (Cf2 Th) fibroblast cell lines infected w ith a cell culture adapted
strain of EIAV (Derse et al., 1987). These studies indicated that EIAV
produces a factor, functionally analogous to the HIV-1 Tat protein, that can
activate the LTR in trans. To examine if the SI, S2 or S3 gene products are
responsible for this activation, restriction fragm ents from proviral clones
containing each of these genes were subcloned into eucaryotic expression
plasm ids and co-transfected into canine D17 cells w ith LTR-CAT reporter
constructs. Expression from a restriction fragm ent containing the SI and S2
genes (pSl,2) w as found to trans -activate the EIAV LTR approxim ately 10fold, w hile a fragm ent containing only SI (pSl) did not activate the LTR
(Dorn and Derse, 1988). These data appeared to indicate that the S2 gene
product m ay be involved in EIAV trans-activation, although the levels of
trans-activation were 25 to 90-fold lower than observed in EIAV infected

cells. A second research group em ployed the same strategy of expressing
proviral restriction fragm ents to assess their trans-activation potential and
also found that restriction fragm ents that contained both SI and S2 were
com petent for trans-activation. However, these researchers were able to
prevent expression of the trans -activator by inserting a stop codon into the
SI gene or by using anti-sense nucleotides directed against regions of SI

(N oim an et al., 1990a). Furtherm ore, restriction fragm ents that lacked the
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m ajority of the S2 coding fram e retained trans-activation activity. Similar
experim ents confirm ing these results w ere published nearly sim ultaneously
by the research group that initially identified ORF S2 as the gene that
encodes EIAV Tat (Dorn et al., 1990). This group claimed that their initial
characterization of S2 as encoding the trans -activator was erroneous due to a
previously undetected m utation in their pS l construct. Based upon these
findings and the observation of lim ited sequence hom ology betw een the SI
protein and the prim ate im m unodeficiency virus Tat proteins, it was
concluded that the SI gene, not S2, encodes the EIAV Tat protein. The
major problem w ith these experim ents was the use of proviral restriction
fragm ents to express the various ORF proteins. As m entioned above, the SI
and S3 genes contain no m ethionine initiation codon, indicating that these
ORFs m ay require additional 5' exons to provide translational initiation
signals. As will be discussed below, the SI protein is initiated from a nonAUG codon located w ithin the leader region that is spliced to ORF S I . The
ORF SI restriction fragm ents described here contain two contiguous UUG
codons th at m ay inefficiently initiate translation. The high fraas-activation
activity of this protein coupled with detection using an enzym atic assay,
m ay allow for detection of relatively low am ounts of protein produced from
these codons.
The independent isolation of frans-activating cDNAs from EIAVinfected cells th at contained S I, but lacked S2 led to the definitive
characterization of ORF SI as the gene that encodes EIAV Tat (Noim an et
al., 1990a; Stephens et al., 1990). These Tat cDNAs, how ever did not clearly

define the translational start site for the Tat protein. A splicing event that
resulted in the joining of the EIAV leader to SI did extend ORF SI in the 5'
direction into the leader sequence. H owever, none of the additional codons
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pro v id ed by leader sequences w as a m ethionine codon. Thus, it was
proposed th at the EIAV Tat protein m ust be initiated from a non-AUG
codon. The initiation codon of SI has been proposed to be either a CUG or
an AUC codon (Noim an et al., 1991; Stephens et al., 1990). Evidence in
su p p o rt of each will be presented briefly below (see EIAV Transcripts and
Translation), and further su p p o rt for the usage of the CUG codon to initiate
EIAV Tat synthesis is presented in the w ork described here.
The EIAV frans-Activation R esponse Region

The earliest experim ents perform ed to determ ine the location of the
EIAV trans -activation response region (TAR) show ed that sequences
dow nstream of the transcriptional start site w ere required, since deletion of
the R and U5 regions of the LTR abrogated fraws-activation (Sherm an et al.,
1988). The construction of additional deletion m utants enabled the
assignm ent of EIAV TAR to sequences w ithin R lying betw een 4 and 22-nt
dow nstream of the transcription start site (Dorn and Derse, 1988). This
region w as predicted to form a small hairpin-loop structure and m utational
analysis appeared to confirm that its form ation was required for transactivation (Carvalho and Derse, 1991). M utations that prevented basepairing in the stem resulted in loss of Tat-m ediated fra«s-activation.
C om pensatory m utations th at allowed base-pairing of the stem, b u t altered
the prim ary sequence, resulted in the restoration of trans-activation. The
EIAV TAR elem ent consists of a 10-bp stem and a short 4-nt loop (Fig. 10).
The loop is closed by tw o U-G base pairs that have been proposed to provide
a recognition signal for EIAV Tat binding, since the EIAV TAR elem ent
lacks the uridine bulge know n to be im portant for HIV-1 Tat binding to the
HIV-1 TAR. NMR and ribonuclease sensitivity assays of the 25-nt EIAV
TAR h av e confirm ed th at TAR assum es this structure in solution (Hoffman
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Figure 10. A com parison of the HIV-1 and EIAV TAR RNAs. For ease of
com parison, only the m inim al sequences required for HIV-1 Tat transactivation are show n here. (A dapted from Derse et a l, 1993).
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et ah, 1993). Although direct binding of EIAV Tat to EIAV TAR has yet to be

dem onstrated, m utations th at alter the loop-proximal U G bp to an A-U bp
result in a 68% reduction in trans-activation (Carvalho and Derse, 1991).
Unlike HTV-1 TAR (Feng an d H olland, 1988), the sequence of the loop
nucleotides appears to be of lesser im portance in EIAV. Single nucleotide
changes w ithin the loop have been show n to m odestly decrease or increase
trans-activation, how ever deletion of one of these bases to create a 3-nt loop

reduces trans-activation by 24-fold (Carvalho and Derse, 1991).
Of the lentiviruses, only the prim ate im m unodeficiency viruses
(HIV-1, -2 and SIV), the bovine immunodeficiency-like virus (BIV) and
EIAV contain trans -activation responsive regions that are localized w ithin
the 5'-end of their respective transcripts. All of the other lentiviruses and
other complex retroviruses appear to only require sequences w ithin the U3
regions of their LTRs for trans-activation. Thus, these latter viruses contain
m ore traditional D N A -binding transcriptional trans- activators. Thus, w ith
respect to their Tat proteins and TAR RNAs, EIAV and BIV are m ore closely
related to the prim ate im m unodeficiency viruses than they are to the other
ungulate lentiviruses, visna-m aedi virus and caprine arthritis enteritis
virus.
The EIAV Tat Protein

The Tat protein of HIV-1 can be divided into five dom ains from
amino- to carboxy- terminal: (1) an am ino-term inal domain; (2) a cysteinerich dom ain; (3) a conserved core activation domain; (4) a highly basic
dom ain; and (5) a carboxyl terminal domain. The Tat protein of EIAV
contains each of these dom ains except for the cysteine-rich dom ain that has
been im plicated in dim erization of HIV-1 Tat (Frankel et al., 1988). The
EIAV Tat ORF identified from cloned cDNAs has a coding potential of 83
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am ino acids (Dorn et al., 1990). Although the precise non-AUG initiation
codon utilized by Tat rem ains som ew hat controversial, deletion analyses
have clearly dem onstrated that it m ust lie upstream of Gly 16 (Dorn et al.,
1990; Schiltz et al., 1992). In this section the am ino acid designations are
relative to the Tat open reading fram e as defined by the sequence lying
betw een tw o term ination codons. That is, Gly 16 is the 16th codon from the
term ination codon that defines the 5'- border of the Tat ORF. It is generally
accepted that EIAV Tat m ost likely initiates at Leu 9 (CUG) (Carroll and
Derse, 1993; Schiltz et al., 1992). This w ould produce a Tat protein of 75
am ino acids, w here 29 am ino acids are provided by exon 1 and 46 amino
acids by exon 2. There is no homology to other lentiviral Tat proteins
w ithin the 29 am ino acids of EIAV Tat encoded by exon 1. The hom ologous
region begins 6 am ino acids into exon 2 with the highly conserved Tat core
sequence of YHCQ. Deletion analysis has show n that all of exon 1 and the
first 4 codons of exon 2 can be deleted and replaced w ith a m ethionine codon
w ithout significant loss of .trans-activation (Dorn et al., 1990). However,
deletion of sequences upstream of and including Tyr 35 in the core sequence
resulted in a 64% reduction trans- activation. Further deletions that also
include His 36 resulted in a near complete loss of trans -activation (Dorn et
al., 1990). Thus, EIAV Tat sequences upstream of Tyr 35 are non-essential

for EIAV Tat activity, and serve only to provide a translational initiation
codon.
A dditional functional characterization of EIAV Tat has come from
studies using chimeric HIV-1 Tat/EIA V Tat proteins and chimeric LTR
reporter plasm ids (Carroll et al., 1991). The w ild-type HIV-1 Tat protein is
incapable of activating the EIAV LTR and the EIAV Tat cannot activate the
HIV-1 LTR (Carroll et al., 1991; Dorn et al., 1990). H ow ever, chimeric Tat
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proteins th at contain the am ino-term inal, cysteine-rich and core dom ains of
HTV-1 Tat and the basic and carboxy-terminal regions of EIAV Tat w ere able
to trans -activate the EIAV LTR to w ithin 80% of w ild-type levels (Carroll et
al., 1991). Replacement of either EIAV Tat dom ain w ith the corresponding

HTV-1 Tat dom ain, did not result in trans -activation of the EIAV LTR.
Furtherm ore, the rem oval of the three carboxy-term inal am ino acids from
the w ild-type EIAV Tat (YLL) resulted in an 80% reduction in activity.
These results indicated th at the EIAV TAR recognition dom ain is com posed
of am ino acid residues from both the basic and carboxy-terminal domains.
The HIV-1 core region believed to be the activation dom ain can functionally
substitute for the EIAV core region indicating that these two proteins are
likely to interact w ith sim ilar cellular factors.
Little w ork has been perform ed to examine the m echanism of EIAV
Tat trans-activation. Early studies appeared to indicate both a transcriptional
an d post-transcriptional com ponent to EIAV trans -activation (Sherm an et
al., 1988). These findings w ere based upon the observation that increases in

protein production from EIAV-specific RNAs w ere greater than the
increases in RNA levels in the presence EIAV Tat. H owever, it was argued
that increases in steady-state RNA levels, either due to increased
transcription or stabilization of transcripts, can account for EIAV Tatm ediated trans-activation (Dorn and Derse, 1988). Similar disagreem ents
w ere encountered during early studies of HIV-1 Tat trans- activation. It
appears likely that the Tat proteins of the prim ate im m unodeficiency
viruses and EIAV will be found to m ediate trans -activation through similar
m echanism s, b u t additional experim ents are required to confirm this
possibility.
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The EIAV S3/Rev Protein

Lim ited am ino acid sequence hom ology of the EIAV ORF S3 encoded
protein to the HIV-1 and HIV-2 Rev proteins led to the prelim inary
characterization of the ORF S3 protein as EIAV Rev (Stephens et ah, 1990).
Indirect evidence for Rev function of the S3 protein was derived from single
cell clones of canine fibroblasts persistently infected w ith EIAV. Some of
these clones produced little or no infectious virus and produced
predom inantly small EIAV-specific mRNAs of about 1.5-kb in length.
Isolation of EIAV-specific cDNA clones from these cells dem onstrated that
the S3 coding fram e contained m utations that w ould prevent synthesis of a
norm al S3 protein (Stephens et ah, 1990). The inability of cells infected w ith
these virus isolates to express norm al am ounts of unspliced (gag/pol) and
partially-spliced (env ) transcripts, and the presence of S3 m utations was
taken as indirect evidence for a Rev-like activity of the S3 protein.
Analysis of cDNA clones containing S3 indicated that this ORF is
directly spliced to a small exon derived from sequences near the 5'-end of
the env gene (Rosin-Arbesfeld et ah, 1993; Stephens et ah, 1990). This region
of env does not contain the g p l3 5 initiation codon nor ER signal peptide,
b u t does contain an internal env m ethionine codon the could potentially
initiated the synthesis of the S3 protein. Such an env/S3 fusion protein
w ould contain 29 am ino acids derived from the gp90 coding region of env
and 136 am ino acids from ORF S3. The ORF S3 protein has been shown to
be expressed during productive EIAV infection, since sera from infected
horses specifically recognizes an ORF S3 protein expressed in E. coli (Saman
et ah, 1990). A ntisera produced against the S3 protein expressed in E. coli

(Saman et ah, 1990) or against S3-specific synthetic peptides (Rosin-Arbesfeld
et ah, 1993) show ed that an S3 protein of 18 to 20-kd is expressed in EIAV-
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infected cell cultures. The S3 protein has also been reported to be packaged
into m ature virions (Rosin-Arbesfeld et al., 1993). This surprising finding is
difficult to reconcile w ith the proposed role of the S3 protein as EIAV Rev.
The Rev proteins of other lentiviruses are nuclear proteins that are not
virion-associated.
The Rev proteins of the lentiviruses other than EIAV, unlike the Tat
proteins, are all structurally sim ilar and contain tw o distinct functional
dom ains: an am ino-term inal basic dom ain and a carboxy-term inal leucinerich activation dom ain. The EIAV S3 protein, how ever, contains no readily
identifiable activation domain. It has been docum ented that the activation
dom ains of the Rev proteins of visna virus and HIV-1 are functionally
interchangeable (Tiley et al., 1991). Interestingly, the distantly related
complex retrovirus HTLV-1 encodes a Rev-like protein, Rex, that also
contains a hom ologous activation dom ain that can functionally substitute
for the corresponding dom ain of HIV-1 Rev (Hope et al., 1991). In an
attem pt to identify a Rev-like activation dom ain in the EIAV S3 protein,
chim eric proteins w ere produced that contained the am ino-term inal visna
Rev RNA-binding motif linked to various regions of the EIAV Rev S3
protein and tested for their ability to allow expression of the visna envelope
protein (Fridell et al., 1993). W hen the entire coding region of the S3 protein
w as linked to the visna Rev RN A-binding dom ain, the visna envelope
protein was expressed at levels 30-50% of that w hen coexpressed w ith wildtype visna Rev. The m inim al S3 sequence required to allow expression of
visna envelope w as determ ined to lie between am ino acid residues 32 and
55. A lthough this region does not contain a typical Rev leucine-rich
dom ain, it does contain two leucine residues (Leu 36 and Leu 49) that have
been show n to be critical for visna envelope expression by site-specific

66
m utagenesis (Fridell et al., 1993). Interestingly, the w ild type EIAV S3 was
able to partially substitute for visna Rev in this assay indicating that EIAV
S3 m ay be able to interact w ith the visna KRE. These results indicated that
the EIAV S3 protein does indeed harbor Rev-like activity, and therefore will
be henceforth referred to as EIAV Rev.
The definitive identification of the EIAV S3 protein as a Rev-like
protein has recently been established using full-length proviral clones that
contain deletions in ORF S3 (M artarano et al., 1994). Deletions in ORF S3
resulted in a lack of Gag protein synthesis that could be restored by
providing EIAV Rev in trans. N orthern blot analysis of nuclear and
cytoplasmic RNA show ed that the S3 deletion m utants contained no
detectable cytoplasm ic RNA corresponding to the full-length 8.2-kb gaglpol
RNA or the singly-spliced 3.5-kb env RNA, b u t contained near wild type
levels of the small fully-spliced RNAs. Thus, the EIAV Rev protein
appeared to increase the steady-state level of the intron-containing RNAs in
the nucleus and prom ote their export to the cytoplasm (M artarano et al.,
1994). In contrast to the case of HIV-1 Rev, there were also m arkedly
reduced levels of the intron-containing RNAs (8.2-kb and 3.5-kb) w ithin the
nucleus.
A closer exam ination of the population of the fully-spliced transcripts
produced in the presence and absence of Rev using PCR, show ed that there
w ere tw o major transcripts produced and that their relative levels were
Rev-dependent. In the absence of a functional Rev protein, the
predom inant fully-spliced RNA contained four exons: (1) the lead er/T atl
exon; (2) the Tat2/O RF SI exon; (3) the Revl exon, derived from the 5'-end
of env; and (4) the Rev2/O RF S3 exon. This RNA is a bicistronic RNA that
produces both EIAV Tat and Rev (Carroll and Derse, 1993). In the presence

of functional Rev protein, an alternative transcript which lacks exon 3
(Revl) predom inates. Since this RNA is incapable of encoding Rev, the
EIAV Rev protein regulates its ow n synthesis through alternative splicing
(M artarano et al., 1994).
The EIAV Rev response elem ent (RRE) has not yet been clearly
defined. A large proviral DNA fragm ent that extends from the 3'-end of the
pol gene to the 5'-end of ORF S3 (nt 4473-7247) was show n to im part Rev-

dependence on a CAT-expression construct w hen placed dow nstream of the
CAT coding region. That is, low levels of CAT were expressed in the
absence of Rev from this construct, b u t providing EIAV Rev in -trans
resulted in high-level CAT expression (Rosin-Arbesfeld et al., 1993). These
results indicated th at the EIAV RRE lies w ithin this rather large region.
A ttem pts to determ ine the precise sequences involved in the form ation of
the EIAV RRE show ed that two separate regions of the env gene are
involved: (1) n t 5337-5552; and (2) nt 7241-7713. These tw o regions include
the tw o coding exons for the EIAV Rev protein, exon 3 /R e v l (nt 5437-5537)
and exon 4/R ev2 (nt 7235-7641). These regions w ere defined by m aking
deletion m utants in the env gene region of Rev-defective proviral clones
and assaying for the ability of these clones to produce EIAV Gag proteins
w hen co-transfected w ith Rev expression plasm ids. Deletion of sequences
w ithin either one of these regions resulted in reduced Gag expression, while
deletion of both yielded no Gag protein. Deletion of sequences between
these two regions (5552-7241) resulted in high level Gag expression,
indicating that these sequences are not involved in form ation of the RRE
(M artarano et al., 1994). Thus, EIAV appears to contain two distinct RREs
that can act independently, b u t only yield efficient expression w hen present
together on the sam e RNA. N o obvious highly structured regions of RNA
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have been identified to be associated w ith these regions, and it has yet to be
determ ined if there is a direct interaction betw een Rev and viral RNA.
EIAV R N A s and their Translation

Early research in EIAV gene expression was perform ed in canine and
feline fibroblast cell lines that are perm issive for infection w ith cell culture
ad ap ted strains of EIAV. N orthern blot analyses of EIAV-specific
transcription patterns in these cells have yielded variable results. Some
researchers have reported as m any as five different transcripts in EIAVinfected canine cells: 8.2-kb, 5.0-kb, 4.0-kb, 2.0-kb and 1.8-kb RNAs (Noiman
et al., 1990b).

In our laboratory, w e have exam ined EIAV transcriptional patterns in
tw o types of prim ary equine fibroblasts that differ in the type of EIAV
infection they support. O ne of these, fetal equine kidney cells (FEK), results
in a persistent infection w ith EIAV as do the canine and feline cells
m entioned above. The other, fetal donkey derm al cells (FDD), results in a
highly cytopathic infection w ith EIAV. Examination of the transcription
patterns in these equine cells, show ed only three EIAV transcripts: the 8.2kb full-length RNA; a 3.5-kb RNA; and a possibly heterogeneous group of
low m olecular w eight transcripts of approxim ately 1.5-kb (Rasty et al., 1990).
Interestingly, the 3.5-kb transcript was produced at very high levels relative
to the other transcripts in the cytopathic FDD infection. Characterization of
cDNA clones corresponding to the 3.5-kb transcript show ed that it was
produced by a single splicing event that joined the viral leader sequence
(SD1, n t 459) to a splice acceptor site (SA1, nt 5134) located w ithin the 5'-end
of ORF S I (Schiltz et al., 1992).
N orthern blot analysis of the EIAV transcripts in prim ary
m acrophage cultures infected w ith a horse virulent strain of EIAV showed
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that the full-length (8.2-kb) RNA predom inates and the low m olecular
w eight transcripts were difficult to detect (Stephens et al., 1990). Recently,
PCR has been used to exam ine the transcripts produced w ithin tissue
m acrophages from an EIAV-infected horse (Beisel et a l, 1993). This study
show ed that there are 5 EIAV-specific transcripts produced in vivo: the 8.2kb full-length RNA; a 3.5-kb singly-spliced RNA identical to that previously
cloned from FDD cells; and three separate low molecular w eight transcripts
form ed by alternative splicing of four exons. The low m olecular w eight
transcripts of EIAV are produced by the alternative utilization of 3 splice
donors and 3 splice acceptors (Fig. 11A). The three low m olecular w eight
transcripts differ in the num ber of exons that they contain. The sim plest of
these transcripts is a singly-spliced transcript w here the EIAV leader region
(SD1, n t 459) is spliced directly to exon 4 (rev-2) through a splice acceptor site
(SA3) located at nt 7234 (tm, Fig. 11B). This RNA is not believed to produce
functional EIAV Rev protein, since the ORF S3 sequences are not preceded
by a translational initiation codon. The splicing event places the trans
m em brane glycoprotein sequences in fram e w ith the first coding exon of the
EIAV tat gene. Thus, this RNA results in the synthesis of a truncated
transm em brane protein of 27-kd that has been detected in infected cells, but
its role in EIAV infection has not been determ ined (Beisel et al., 1993). A
second low m olecular w eight RNA that contains three exons encodes the
EIAV Tat protein. This RNA is produced by splicing of exon 1 (tat-1, Fig.
11B) to SA2 (nt-5134), followed by the utilization of a second splice donor
signal (SD2, n t 5276), located im m ediately dow nstream of the Tat
term ination codon, which is spliced to exon 4 (tat, Fig. 11B). The third low
m olecular w eight transcript contains four exons and encodes both the Tat
and Rev proteins of EIAV (tat/rev , Fig. 11B). This transcript results from
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Figure 11. Schematic representation of the EIAV open reading fram es and
transcripts. A. EIAV proviral DNA. The relative positions of each of the
EIAV open reading fram es are shown. A lthough the rev-1 exon is in the
sam e reading fram e as env, it is depicted as a separate exon here for clarity.
The positions of the three splice donor (SD) and acceptor (SA) sites are
show n below the open reading frames. B. The transcripts of EIAV. The
five transcripts of EIAV identified in infected horses are shown. The dotted
lines indicate the introns that are rem oved by splicing. The open reading
fram es contained in each transcript are indicated to the left.

71
the inclusion of exon 3 (rev-1, Fig. 11B), located w ithin the 5'-end of the env
gene (SA2, nt-5435; SD3, nt-5536), between exons 2 (tat-2) and 4 (rev-2) of the
RNA described above. The inclusion of the rev-1 exon in this transcript
results in the addition of 29 codons of the gp90 coding region of env being
spliced in-fram e to ORF S3. Included in these 29 codons of env is an AUG
codon that lies in favorable sequence context (AGC AUG G) to initiate
translation of the EIAV Rev protein.
The bicistronic nature of the m ultiply-spliced tat/rev RNA has
recently been confirmed both in vitro and in transfected cells (Carroll and
Derse, 1993). These researchers used site-specific m utagenesis to
dem onstrate that translation of the second cistron (S3) w as dependent upon
the translation of the EIAV Tat protein (SI) from a sub-optim al initiation
codon. In order to investigate the m echanism of translation of this
bicistronic RNA, these researchers had to first unam biguously identify the
Tat initiation codon. This w as accomplished by individually altering each of
the three m ost likely initiation codons, CUG-364, CUG-373 and AUC-388, to
a GUA valine codon. M utagenesis of CUG-364 and AUC-388 had no effect
on fraMs-activation, but alteration of CUG-373 resulted in the loss of transactivation. The dependence of expression of the EIAV Rev protein (S3) on
initiation of the Tat protein from a sub-optim al initiation codon was
dem onstrated by m utagenizing CUG-373 to an AUG codon. This alteration
resulted in dram atically reduced expression of the Rev protein in cells
transfected w ith the m utant tat/rev cDNA. These results indicate that the
EIAV Rev protein is expressed by leaky ribosome scanning through the Tat
CUG initiation codon. Furtherm ore, inefficient recognition of the Tat CUG
codon is required for the synthesis of all EIAV proteins other than Tat, since
this CUG codon is located in the viral leader region upstream of the first

72
splice donor signal. That is, this CUG codon is present in all EIAV RNAs
and is located upstream of all the other cistrons in the respective RNAs.
Research O bjectives
The overall goal of the research presented in this dissertation was to
characterize the properties of the protein products encoded by the small
open reading frames, S3, S2 and S3, and analyze the translational
characteristics of the RNAs that express these proteins. The specific goals
that are addressed in this dissertation are as follows: (1) exam ination of the
in vitro protein coding potential of the 3.5-kb RNA that contains the S3, S2

and env coding regions; (2) exam ination of the translational initiation of
the EIAV tat gene, which does not contain an AUG initiation codon; (3)
dem onstration of Tat trans-activation in prim ary equine fibroblasts that are
either persistently or cytopathically-infected w ith EIAV; (4) dem onstration
of the significance of the putative S2 protein in EIAV infection by
determ ining if sera obtained from EIAV-infected horses contain antibodies
that recognize the in vitro synthesized S2 protein; and (5) to exam ination
of the translational initiation signals for the S3 protein. Specifically, if, it can
be expressed from an e«u-encoded AUG codon by analyzing the ability of a
m onoclonal antibody directed against an epitope of the gp90 envelope
protein to detect the S3 protein produced in vitro and in vivo.

CHAPTER 2
I N V ITR O TRANSLATION OF EIAV MULTICISTRONIC RNAS

Introduction
EIAV gene expression has been prim arily studied in canine and feline
fibroblast cultures which are permissive for persistent EIAV infections.
Analyses of RNA transcription patterns in such cells yielded variable
observations in the tem poral appearance and abundance of EIAV-specific
transcripts (Dorn et al., 1990; N oim an et a l, 1990b; Stephens et a l, 1990). The
sim plest and most consistent transcription patterns were observed in EIAVinfected prim ary horse m acrophage cultures and equine fibroblasts [fetal
equine kidney (FEK) and fetal donkey derm al (FDD) cells] in which transcripts
corresponding to the 8.2-kb genomic RNA and the presum ably singly-spliced
3.5-kb envelope message w ere predom inantly synthesized (Rasty et a l, 1990;
Stephens et a l, 1990). Small multiply-spliced transcripts of 1-2 kb were present
at very low abundance and were often difficult to detect.
Previous studies show ed that infection of FDD cells with EIAV results in
severe cytopathology and eventual cell death within 14-21 days post-infection,
whereas infection of FEK cells results in persistent virus production in the
absence of any apparent cytopathology (Orrego et a l, 1982). Interestingly, in
cytopathically infected FDD cells, the proportion of the 3.5-kb mRNA to the full
length 8.2-kb transcript was found to be substantially greater than in
persistently infected FEK cells, which synthesized the tw o RNAs in
approximately equal abundance at all stages of infection (Rasty et a l, 1990).
Examination of the properties of the predom inant 3.5-kb EIAV transcript of
FDD cells m ight provide some insight into the mechanisms of cytopathicity
observed in this cell type.
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Analysis of the nucleotide sequence of cDNA clones corresponding to
the 3.5-kb RNA show ed that this RNA is structurally tricistronic, since it
contains the tat, ORF S2 and env genes (Schiltz et al., 1992). Although m any of
the RNAs of HIV-1 and other lentiviruses are structurally multicistronic, the
presence of strong translational initiation signals for the first cistrons renders
nearly all of these RNAs functionally monocistronic in vivo. (Schwartz et al.,
1990b; Schwartz et al., 1992a). The only know n exceptions to this are the HIV-1
bicistronic vpu/env and rev/nefm R N A s, each of which efficiently expresses the
dow nstream cistron by leaky scanning through the relatively weak sub-optimal
AUG initiation codons of the respective upstream cistrons (Schwartz, et al.,
1992b). The first cistron of the EIAV 3.5-kb RNA (ta t/S 2 /e n v RNA) is the ORF
SI cistron which encodes the EIAV Tat protein (referred to interchangeably as

Tat or SI in this document) (Fig. 12). This cistron is devoid of an AUG initiation
codon and has been proposed to be initiated at either a CUG or an AUC codon
(Carroll and Derse, 1993; Dorn et al., 1990; N oim an et al., 1991). Recent results
indicate that the EIAV S1/S3 (tat/rev) 1.5-kb mRNA is bicistronic in vitro and in
vivo due to leaky ribosome scanning through the Tat non-AUG initiation codon

(Carroll and Derse, 1993).
The ORF S2 cistron in the 3.5-kb RNA overlaps the env cistron in an
alternative reading frame. The ORF S2 cistron contains three AUG codons;
however, only tw o of these lie near the 5'-end of the gene and neither of these
lie in a favorable sequence context for translational initiation. The first AUG
codon of ORF S2 (AUG-1) is the second codon in the ORF and is located a mere
11-nt dow nstream of the Tat UAA term ination codon and 24-nt upstream of the
env gene initiation codon which lies in a highly favorable sequence context for

translational initiation (AAC AUG G) (Fig. 12). ORF S2 AUG-1 is also the first
AUG that w ould be encountered by scanning ribosomes in the 3.5-kb RNA,

UAA GGUU UGA IJAU AUG GGAUUAUUUGGUAAAGG GGU AAC AUG £

tat Stop

S2 AUG-1

env Start

Figure 12. Schematic representation of the EIAV 3.5-kb RNA. The arrangem ent
of the tat, S2 and env genes in the 3.5-kb transcript are show n above. L, the 133n t leader region that extends from the cap site to the UGA termination codon
th at defines the 5'-end of the tat ORF. SS, the splice site that joins the two
coding exons of the tat gene. The nucleotide sequence of the region 36-nt region
th at lies betw een the tat term ination codon and the env initiation codon is
show n below. The UAA term ination codon of the tat gene and the UGA
term ination codon that defines the 5'-end of ORF S2 are shown in bold. The
first AUG codon in ORF S2 and the env gene AUG initiation codon are also
show n in bold. The im portant context nucleotides in the -3 and +4 positions of
the AUG codons are underlined. Note the uridine residue in the -3 position of
the ORF S2 AUG codon.

w hile the highly favorable env AUG w ould be the second. The near optimal
sequence context of the env AUG w ould appear to preclude translation
initiation of ORF S2 from the second AUG codon in ORF S2. (AUG-2). Thus, it
is likely that an S2 protein expressed in vivo would have to be initiated at AUG1. Therefore, the EIAV 3.5-kb RNA is a prim e candidate to be a multicistronic
RNA, since the non-AUG initiation codon of the Tat cistron and the suboptim al AUG codon of the ORF S2 cistron w ould be anticipated to allow
appreciable leaky ribosome scanning to the favorable env AUG initiation codon.
In addition to its tricistronic nature and the involvem ent of a non-AUG
codon in translational initiation, another interesting property of the 3.5-kb RNA
is that the termination codon for the SI cistron and the translational initiation
signals of the S2 and env cistrons all lie closely together w ithin an
approxim ately 40-nt region (Fig. 12). Furthermore, this is the only RNA
identified to date isolated from either EIAV-infected cultured equine cells
(Rasty et al., 1990) or infected animals (Beisel et al., 1993) that has the capacity to
encode the S2 or env protein. In addition, the presence of ORF SI in the
tricistronic RNA m ay allow this trans-activator protein to be produced late in
infection, w hen little or no multiply-spliced (S1/S3 ) transcripts are expected to
be produced (Cullen, 1991). Clearly, this multi-functional RNA provides a
num ber of unique features that w arrant extensive investigation. In the studies
described herein, the cDNA corresponding to the 3.5-kb RNA was used to
analyze the translation characteristics of this unique mRNA in vitro.
M aterials and M ethods
Plasm id Constructs for In Vitro Transcription
The pSR-1 cDNA clone was obtained by Dr. Siyamak Rasty (Schiltz et al,
1992) and was derived from the singly-spliced 3.5-kb EIAV RNA using an envspecific prim er located immediately dow nstream of the Sma I restriction site (nt

5689-5695) and contains ORF S I, ORF S2, and env [All nucleotide sequence
designations are based on the reported proviral DNA sequence (Kawakami et
al., 1987), GenBank accession no. M16575]. The resulting cDNA was subcloned

into pUC9. The pSP-1 cDNA was obtained from Dr. Susan Payne (Case
W estern Reserve University) and was derived from the 1.5-kb multiply-spliced
ORF SI / ORF S3 EIAV mRNA. The resulting cDNA was subcloned into a
Bluescript vector (Stratagene Cloning Systems). Plasmids for in vitro
transcription were constructed by subcloning restriction fragments of the cDNA
clones pSR-1 or pSP-1 into pSP65 (Promega Corporation).
The pSR-1 cDNA clone was digested w ith either Stu I (nt 254-259) or
Sma I (nt 391-396) followed by digestion with Msc I (nt 5653-5657) to generate a

720-bp (Stu I/M sc I) or 585-bp (Sma 1 /Msc I) restriction fragment. These bluntended DNAs were subcloned into Sma I digested pSP65 generating pSP720 and
pSP585, respectively. pSR-1 was digested with BamH I (nt 386-391) to produce
a 280-bp fragm ent that was subcloned into the BamH. I site of pSP65 to generate
pSP280. A 623-bp Sma I (nt 254-259 & 5689-5695) restriction fragment was
isolated from pSR-1 and ligated to the large fragm ent of pSP280 digested w ith
Sma I to generate plasm id pSP634. pSP-1 was digested w ith either Stu I (nt 254-

259 & 8162-8167) alone or Stu I and Pvu II (nt 5159-5164), and restriction
fragm ents containing ORF S3 were isolated and ligated to Sma I digested pSP65
/

generating pSPSl-S3 and pSPS3, respectively. All ligation mixtures were
transform ed into E. coli strain DH5a, and the resulting recombinant plasm ids
w ere screened for the orientation that properly aligned the EIAV ORFs with the
SP6 prom oter using appropriate restriction enzymes.
In Vitro Transcription and Translation
All plasm ids for in vitro transcription, except pSP634, were linearized at
the H ind III site located in the vector polylinker region downstream of the

d o n ed inserts. The pSP634 plasm id was linearized at the Msc I site in the env
gene. The linearized DNAs w ere transcribed in vitro using one of several
commercially available kits [Riboprobe® Transcription System (Promega
Corporation); mCAP™ mRNA Capping Kit (Stratagene Cloning Systems);
Ambion MEGAscript™ in vitro Transcription Kit (Ambion, Inc.)] using SP6
RNA polym erase and m 7G pppG cap analog to cap the transcripts according to
the m anufacturer's recom m endations (4:1, m 7GpppG:rGTP). The transcripts
w ere purified by gel filtration through pre-packed columns of G-50 sephadex
(NICK Columns, Pharmacia LKB Biotechnology) prior to ethanol precipitation
to ensure removal of trace am ounts of m 7GpppG and rNTPs. This treatment
also perm itted accurate quantitation of the transcript concentration by
m easuring the optical density at 260 nm. The concentrations of the transcripts
were confirmed by analysis on non-denaturing agarose gels against a standard
viral RNA, brom e mosaic virus (BMV) RNA 3. In vitro translation systems
utilizing w heat germ extract (WGE) and micrococcal nuclease-treated rabbit
reticulocyte lysate (RRL) w ere purchased from Promega Corp. A typical 50 pi
WGE translation m ixture contained the following: 25 pi of WGE; 80 pM amino
acid m ixture lacking the radiolabeled amino acid; 25 pCi [35S]-methionine or 15
pCi of a [3H]-labeled amino acid (leucine, glycine or arginine); 60 mM
potassium acetate; 40 units of placental ribonuclease inhibitor (RNAsin); and
1.5 pg RNA substrate. The reaction volum e was adjusted to 50 pi with
deionized and glass distilled water. The K+ concentration of the WGE was
optim ized for the in vitro transcripts as suggested by the m anufacturer and
optim al amino acid incorporation was obtained when 60 mM K+ was added to
the translation reaction. A typical 50 pi RRL translation contained the
following: 35 pi of RRL; 20 pM amino acids lacking the labeled amino acid; 40
pCi [^S]-methionine or 25 pCi [3H]-labeled amino acid; 40 units of RNAsin;

and 1.5 fig RNA substrate. The reaction volume was adjusted to 50 fil with
deionized and glass distilled water. L-[4,5-3H]-Leucine (161 C i/m m ol; 5
m C i/m l) and L-[2,3,4,5-3H]-Arginine (62 C i/m m ol; 1 m C i/m l) w ere obtained
from Am ersham Corp.; L-[2-3H]-Glycine (49 C i/m m ol; 1 m C i/m l) was
obtained from D upont NEN® Research Products. L-^S]-m ethionine (1200
C i/m m ol; 10 m C i/m l) was obtained from either ICN Biomedicals, Inc or
D upont NEN® Research Products. RNA 4 of brome mosaic virus (BMV) was
prepared as previously described (Shih and Kaesberg, 1973). The am ount of
[3H]-leucine incorporated into trichloroacetic acid insoluble proteins was
determ ined in duplicate or triplicate samples using a modified standard filter
paper assay m ethod (Mans and Novelli, 1961).
Preparation of Antisera and Radioimmunoprecipitation Assays
Synthetic peptides corresponding to portions of the EIAV Tat, S2 and S3
proteins w ere prepared using either a SAM-II autom ated peptide synthesizer
(BioSearch), or by m anual m ethods using the RaMPS system (Dupont).
Peptides were initially purified by gel filtration on Sephadex G-25 followed by
reverse phase HPLC, and further characterized by plasm a desorption mass
spectrom etry to confirm their purity and sequence. The purified peptides were
linked to keyhole lim pet hem acyanin (KLH) using glutaraldehyde following a
standard protocol (Reichlin, 1980). The KLH-linked peptides were injected
intram uscularly and subcutaneously into N ew Zealand w hite rabbits in
Freund's complete adjuvant (FCA). The rabbits w ere boosted w ith the same
antigen in Freund's incomplete adjuvant after three weeks to produce
hyperim m une sera, which was harvested two weeks after boosting. The titer of
the sera against the peptides was determ ined by an ELISA system optim ized
for use w ith synthetic peptide antigens (Ball, 1990). High titer sera were
defined to give an OD 49onm in excess of 0.5 at a dilution of 1:10,000. The IgG
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fraction was partially purified from the sera by am m onium sulfate precipitation
and DEAE-Sephadex colum n chrom atography as previously described (Chua et
al., 1982). The radiolabeled in vitro translation products were radio-

im m unoprecipitated (RIP) w ith the appropriate antisera (typically 100 pg IgG)
by the m ethod of A nderson and Blobel (1983). Briefly, 50 |ul translation samples
adjusted to 1% SDS w ere boiled for 4 minutes. Four volum es (200 pi) of
dilution buffer (1.25% Triton X-100,190 mM NaCl, 60 mM Tris-HCl, pH 7.4,6
mM EDTA, 10 u n its/m l aprotinin protease inhibitor) at 4°C w ere added,
followed by 100 pg of IgG. The samples were incubated for at least 12 hours on
an Adams N utator mixer at 4°C. Thirty pi of a 1:1 suspension of protein ASepharose CL-4B (Sigma Chemical Co.) were added and the incubation was
continued for two hours at room temperature. The beads were w ashed four
times (1 ml per wash) with 0.1% Triton X-100,0.02% SDS, 150 mM NaCl, 50 mM
Tris-HCl, p H 7.5,6 mM EDTA, and 10 u n its/m l aprotinin at room tem perature.
A final w ash was perform ed in the same buffer lacking detergent. The beads
were resuspended in 40 pi of SDS-gel electrophoresis buffer and boiled for 4
m inutes prior to applying to slab gels.
Sodium Dodecyl Sulfate Polyacrylamide Gel Analysis of In Vitro Translation
Products
The translation products were fractionated on either a standard 15%
discontinuous gel system or a 20% sodium dodecylsulfate (SDS)-polyacrylam ide gel system (Guilian et al., 1985) to facilitate resolution of the SI (8-kd)
and S2 (7-kd) proteins. Typically, between 25k and 50k cpm of radiolabeled
protein was loaded onto a given lane. After electrophoresis the gels were
im pregnated with an autoradiographic image enhancer (National Diagnostics)
prior to drying and exposure to Kodak XAR or XRP X-ray film. Exposure was
at -70°C for 16 to 24 hours.

Densitometric Quantitation of the In Vitro Translation Products
The X-ray flourographs w ere scanned on a BioRad Model 620 video
densitom eter and the optical density (OD) of each protein band was normalized
on the basis of the num ber of leucine residues in each protein to obtain a molar
OD for each protein. The m olar OD for each individual protein was divided by
the total m olar OD of all three EIAV proteins in a given experim ent to
determ ine the molar fraction of each protein produced. Each of the three
pSP720-derived proteins is presented as a percentage of the total EIAV protein
produced in a particular translation experiment.
Automated Protein Sequencing
The EIAV Tat protein was synthesized in w heat germ extracts
program m ed w ith pSP720 RNA in the presence of [3H] arginine, as described
above. The pSP720 transcript encodes both Tat and S2, which are difficult to
completely resolve on SDS gels. Due to the similarity in the gel mobilities of the
Tat and S2 proteins, the Tat protein was im m unoprecipitated from the
translation m ixture prior to gel electrophoresis. The S2 protein was synthesized
in the presence of [3H] glycine from pSP585 RNA, which lacks sequences
required for Tat expression. The Tat and S2 proteins were fractionated on 15%
discontinuous gels which upon completion of electrophoresis w ere placed
directly into Autoflour (National Diagnostics) image enhancer for 30 minutes.
The dried gels were exposed to Kodak XAR film and placed at -70°C overnight.
Using the autoradiograph as a template, the appropriate protein band was cut
from the dried gel and rehydrated in a minimal volume of water. The gel slice
was crushed, and the labeled proteins eluted in 2-3 ml of Tris saline buffer (50
mM Tris-HCl, pH 7.5; 100 mM NaCl) at 37°C for 3 hours w ith constant mixing.
The gel fragments were rem oved by centrifugation, and the supernatant was
lyophilized and resuspended in 100 gl of 1 m g /m l bovine serum album in (BSA)

to act as a carrier protein. The protein m ixture was desalted by passing it
through a G-10 Sephadex column. Radioactive fractions were pooled,
lyophilized, and resuspended in 50-100 pi of doubly distilled deionized water.
These samples were subjected to autom ated amino terminal sequence analysis
on an A pplied Biosystems 470A Protein Sequencer. Radioactivity from each
cycle of the sequencer was determ ined by adding the cycle eluate to 3 ml of
L iquisdnt scintillation cocktail (National Diagnostics) and counting in a
Beckman LS 6000IC liquid scintillation counter.
Results
Expression of the ORF SI, ORF S2, and env Genes from the In Vitro
Transcripts
Synthetic transcripts corresponding to the 3.5-kb RNA were produced in
order to determ ine if this RNA is functionally tricistronic in vitro. Towards this
end, a Stu 1/ Msc I restriction fragm ent of the cDNA was subcloned into the in
vitro transcription vector pSP65 generating pSP720 (the numerical portion of the

plasm id designation indicates the approxim ate num ber of base pairs of the full
length 3.5-kb cDNA present in the construct). The Stu I site, located in the R
(redundant) region of the LTR, lies 47-bp dow nstream of the EIAV transcription
start site (nt 210); therefore the in vitro transcripts produced from pSP720 lack
the first 47-nt of the 5'-UTR (untranslated region) which include the 5'-terminal
trans-activation responsive stem-loop structure (+1-+25). The Msc I site lies
w ithin the gp90 coding region of the env gene, therefore a truncated gp90
protein w ould be produced from these transcripts. Thus, the pSP720 in vitro
transcription construct contains the extended ORF S I, the entire ORF S2, and a
3'-truncated env gene. This env truncation results in the synthesis of a 15-kd
protein (Agp90) that can be readily examined under the gel electrophoresis
conditions required for Tat (8.5-kd) and S2 (7-kd) resolution. The pSP720-

derived in vitro transcripts contained 25-nt of vector-derived sequence at their
5'-ends followed by the rem aining portion of the R region (29-nt), the U5 region
(36-nt), the leader region (24-nt), and the extended ORF SI (252-nt) (Fig. 13). A
second transcription plasm id, pSP585, was constructed by subcloning of the
Sma I /M s c I restriction fragm ent into the Sma I site of pSP65. The Sma I site (nt-

394) lies w ithin the extended portion of ORF SI immediately dow nstream of the
AUC codon proposed by N oim an et al. (1991) to initiate Tat synthesis.
Therefore, transcripts produced from this construct w ould be devoid of both
proposed Tat initiation codons. In both the pSP720 and pSP585 constructs, ORF
S2 (198-nt) begins a m ere 7-nt downstream of the Tat UAA termination codon.
This ORF contains 66 potential codons the second of these is a m ethionine
codon. The env gene overlaps the majority of ORF S2 and begins 26-nt
dow nstream of the Tat termination codon. The fourth codon in the env ORF is a
potential AUG initiation codon. Truncation of the gp90 coding region of the
env gene at the Msc I site results in only the first 117 codons of this ORF being

present in the in vitro transcripts. Linearizing the tem plate DNAs at the H ind
III site w ithin the pSP65 polylinker resulted in the extension of the Agp90 ORF
by three codons (G, I, and L) (Fig. 13). Therefore, the in vitro transcripts
em ployed contain a truncated env ORF of 120 codons w ith an apparent
m olecular m ass of approximately 15-kd on SDS-polyacrylamide gels.
The pSP720 and pSP585 plasm id DNAs were em ployed as transcription
templates to produce synthetic capped RNAs, which were translated in wheat
germ extracts in the presence of [3H]-leucine. In vitro translation of pSP720
RNA resulted in the synthesis of three major polypeptide products w ith relative
molecular w eights of 15-kd, 8.5-kd, and 7-kd (Fig. 14, lanes 1 and 8). These
products correspond closely to the predicted sizes of Msc I truncated gp90
envelope protein (Agp90), the EIAV Tat protein, and the putative S2 protein,

Figure 13. Schematic diagram of the pSP720 in vitro transcription vector and
nucleotide sequence of the corresponding in vitro transcript. The upper portion
of the figure depicts the open reading frames present in the pSP720 in vitro
transcription vector and shows the restriction sites used to produce this
construct. The stippled box represents the SP6 prom oter and the solid black
boxes represent the poly-cloning site of the pSP65 vector. The nucleotide
sequence of the pSP720 transcript is shown below. The nucleotides derived
from the pSP65 vector are shown in italics and the DNA restriction sites used to
produce the pSP720 DNA are indicated. The Sma I and BamH I restriction sites
involved in the construction of the pSP585 and pSP634 transcription plasmids
are also indicated. The CUG and AUC codons that have been independently
reported to initiate Tat synthesis are underlined along w ith their respective -3
and +4 context nucleotides. The first AUG in ORF S2 and the env AUG are also
underlined w ith their context nucleotides. The termination codons for the Tat,
S2, and Agp90 proteins are underlined. The cloning results in the extension of
the gp90 coding region into the pSP65 poly-cloning site. This results in the
addition of three non-native gp90 amino acids ( GI L) being added to the
carboxy-terminal end of the Agp90 protein. The amino acid sequence of the
carboxy-terminal end of Agp90 is shown below the nucleotide sequence. The
poly-cloning site also provides an in-frame UAG termination codon. The
am ino acid sequence of an epitope of gp90 recognized by monoclonal antibody
86 (mab 86) is also shown below its nucleotide sequence. The num bers above
the nucleotide sequence indicate the nucleotide num ber in the pSP720 RNA.
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respectively. The pSP585 RNA supported translation of only tw o of these
products, the 15-kd and 7-kd polypeptides (Fig. 14, lane 5). The 15-kd product
from both pSP585 and pSP720 RNA program m ed translation reactions was
specifically im m unoprecipitated with a monoclonal antibody directed against
an epitope of the gp90 envelope protein m apping to a region approximately 50
am ino acids from its amino term inus (Ball, 1990) (Fig. 14, lanes 2 and 6).
The 8.5-kd band specific for pSP720 RNA translation was immunoprecipitated
by a rabbit polyclonal antisera produced against a synthetic peptide (Fig. 15)
corresponding to a predicted immuno-reactive dom ain of the EIAV Tat protein
(Fig. 14, lane 3). The 7-kd protein common to both pSP720 and pSP585 RNA
translation reactions was im m unoprecipitated by a combination of low titer
rabbit polyclonal antisera produced against three different overlapping
synthetic peptides (Fig. 15: S2a, S2b, S2c) that span the entire ORF S2 amino
acid sequence (Fig. 14, lane 4). This combination of ORF S2 antisera did
dem onstrate some cross-reactivity w ith the EIAV Tat protein product (Fig. 14,
lane 4 and lane 7). However, a high titer ORF S2 antiserum (S2d) obtained
m ore recently dem onstrated no cross-reactivity with EIAV Tat (Fig. 14, lane 9).
This ORF S2 antiserum also specifically precipitates tw o m inor products with
mobilities of 5.5- and 4-kd, which are presum ed to be S2-related peptides
produced by either translational initiation at the internal AUG codons of S2 or
degradation products of S2. Lanes 8 and 9 of figure 14 were intentionally over
exposed to dem onstrate the specificity of the antiserum. These data indicate
that a single cDNA species corresponding to the 3.5-kb singly-spliced mRNA of
EIAV is capable of directing the synthesis of EIAV Tat, the S2 protein, and the
envelope protein in vitro. Furthermore, since no EIAV Tat protein is detected
upon translation of pSP585 RNA, sequences located between the Stu I site in R

Figure 14. Translation of the pSP720 and pSP585 RNAs in w heat germ extracts
and identification of the protein products by im munoprecipitation.
Fluorograph of an SDS-PAGE analysis of w heat germ extracts program m ed
w ith pSP720 (lanes 1 and 8) and pSP585 (lane 5) synthetic transcripts in the
presence of [3H]-leucine. Radioimmunoprecipitation of labeled translation
products w ith a monoclonal antibody directed against the gp90 envelope
glycoprotein (lanes 2 and 6) and rabbit polyclonal antisera specific to the Tat
(lane 3) or S2 (lanes 4,7, and 9) protein products. Molecular w eight m arkers (M)
are BRL [14C]-labeled low m olecular w eight standards.

0RFS1
EGRRPYLFNLADDRRIPGTAEENFQKSS
GGVPGQNTG G Q EARPNYHCQLCFLRSLG
I DYLDASLRKKNKQRLKAI QQGRQPQYLL

ORF S2
S2d
S2aY MG L F G K G V T W S A S H S

M. G G S Q'

S2d
G E S Q P L L P N S Q K N L S V R R T Q C V
------------------------------------- S2b---------------------------------S2cN L |IV II M T V R |T A W Q N R R K Q E T K1 K

Figure 15. Predicted am ino acid sequences of the tat and S2 ORFs and location
of the synthetic peptides used for anti-sera preparation. The synthetic peptide
corresponding to the carboxy-terminus of Tat is underlined. The four different
synthetic peptides, S2a-d, corresponding to the putative S2 protein are m arked
w ith brackets.

and the Sma I site in tat, which include the predicted CUG and AUC initiation
codons, are required for in vitro expression of the EIAV Tat protein.
A m ino-term inal Sequencing of the In Vitro Synthesized EIAV Tat and ORF
S2 Polypeptides

In order to gain a better understanding of the expression of the ORF S I,
ORF S2, and envelope proteins from the tricistronic 3.5-kb RNA, I
determ ined the presum ptive translational initiation sites of the in vitro
synthesized SI and S2 proteins by amino-terminal sequencing of radiolabeled
polypeptides. The radioactive amino acid of choice for sequencing of the S2
protein was [3H] glycine, since the first methionine codon in ORF S2 is followed
im m ediately by a glycine codon and three of the first seven codons correspond
to glycine residues. The S2 protein was synthesized from pSP585 RNA and
approximately 7 x 104 cpm of gel purified protein w as subjected to amino
term inal sequence analysis. The sequencer fraction corresponding to the first
am ino acid residue registered in excess of 7 x 103 cpm, while further peaks of
radioactivity were observed for amino acid residues 4 and 6 (Fig. 16). The
anticipated am ino acid sequence of the S2 polypeptide initiating at the first
methionine codon of this ORF i s M G L F G K G . Assuming the amino
peptidase activity of the w heat germ extract has cleaved the initiator
m ethionine residue from this protein, the peaks of radioactivity occur precisely
as expected, that is, in fractions 1,4, and 6. Additional peaks of radioactivity
were noted in fractions 16,17, and 20, which are also predicted sites of glycine
residues in the ORF S2 protein (Fig. 16). These data confirm that the in vitro
synthesized polypeptide assigned to be encoded by ORF S2 on the basis of its
ability to specifically react w ith ORF S2-specific peptide antisera, is indeed the
S2 protein, and its synthesis in vitro is apparently initiated at the first
methionine residue in this open reading frame.
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Figure 16. Microsequence analysis of the [3H]-glycine labeled S2 protein. The
[3H]-labeled S2 protein was gel-purified and subjected to autom ated protein
sequence analysis. The fractions obtained from the sequencer were dispensed
into 3 m l of Liquiscint scintillation solvent (National Diagnostics) and m easured
for the presence of radioactivity. The am ount of radioactivity in counts per
m inute (CPM) is shown for each fraction. For convenience the predicted amino
acid sequence of the S2 protein is plotted on the x-axis rather than the residue
num ber.

The ORF SI protein, EIAV Tat, was of particular interest to sequence,
since it is believed to be initiated at a non-AUG codon, b u t the precise codon
utilized h ad not been determ ined. The m ost likely candidate was a CUG codon
at n t 373 that lies in a favorable sequence for translational initiation, AAC CUG
G, that is with an adenine nt in the -3 position and a guanine nt in the +4
position (Kozak, 1986). Initial attem pts to sequence the SI protein synthesized
from pSP720 RNA and labeled with [3H] glycine were ham pered by difficulties
in resolving SI and S2 completely on 15% preparative discontinuous SDSpolyacrylam ide gels. As a result, sequence analysis of gel-purified SI gave
some low level peaks of radioactivity in fractions 1,4 and 6, which were
rem iniscent of those seen for S2 sequencing (Fig. 6A). H ad SI been initiated at
CUG 373,1 would have expected a peak of radioactivity corresponding to
glycine num ber one of SI in fraction num ber seven or eight from the sequencer
depending on the absence or presence of the initiator m ethionine on the m ature
protein. N o peak was noted in this position despite the fact that in excess of 1 x
105 cpm of radioactive product was loaded onto the sequencer (Fig. 17A). To
confirm that SI w as indeed purified from the gel, 2 x 104 cpm of gel-purified SI
w as run on a 15% analytical discontinuous gel w ith 2 x 104 cpm of gel-purified
S2. The fluorograph of the gel clearly showed differential migration of the two
bands suggesting that the major portion of the SI preparation was indeed SI
and that S2 was only a m inor contam inant of this preparation (Fig. 17B). The
contam inating S2 protein also served as a control for the am ino acid sequencer
dem onstrating that the instrum ent was functioning properly. These data
suggested that the SI protein may be amino terminally blocked preventing
analysis of its am ino acid sequence.
The possibility that the amino terminus of the SI protein was acetylated
was investigated by perform ing translation in w heat germ extracts pre-
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Figure 17. Microsequence analysis of the [3H]-glycine labeled SI and SDSPAGE of purified SI and S2 proteins. A. Counts per m inute (CPM) of tritium
in each fraction of the autom ated sequencing of the gel purified SI protein
plotted against the amino-terminal amino acid residues of the predicted SI
protein initiated at CUG-373 and the S2 protein. B. SDS-PAGE analysis of the
gel purified SI and S2 proteins. Two exposures of the sam e fluorograph are
shown in m irror image. The left panel was exposed for 16 hrs, while the right
panel was exposed for one week.

incubated w ith citrate synthase (CS) and oxalacetate (OAA) to deplete the
extracts pool of acetyl-Coenzyme A (Palmiter, 1977), the acetyl donor for the
acetyltransferase reaction. The SI protein synthesized under these conditions
d id appear to yield some low level peaks of radioactivity in fractions
corresponding to predicted glycine residues assum ing that the SI protein was
initiated at CUG-373 and the initiator methionine was rem oved by the extract's
am ino peptidase activity (data not shown). However, the majority of the SI
protein produced still could not be sequenced. This could indicate that the
am ino term inal blocking group is not an acetyl group. W ithout a positive
control, however, such as a know n acetylated protein, it is difficult to
determ ine the effectiveness of the acetyl coenzyme A depletion system.
To prevent confusion of SI sequence data by peaks of contaminating S2,
I repeated SI sequencing experim ents with SI labeled in the presence [3H]
arginine. This am ino acid w as chosen because there are no arginine residues in
S2 w ithin the first 35 am ino acids, whereas there are two adjacent arginine
residues in the predicted sequence of CUG-373-initiated EIAV Tat located at
am ino acid positions three and four. In addition, the translation reaction was
term inated after 45 m inutes, w hen the rate of synthesis was still near maximal,
by a 5 m inute 100°C incubation in the presence of 1% SDS. Such treatm ent may
yield a fraction of EIAV Tat that is not amino terminally blocked. The
effectiveness of this treatm ent should depend upon w hether the blocking
reaction w as a co- or post-translational process. That is, this treatm ent would
not have the desired effect if the blocking reaction is a highly efficient cotranslational process. The EIAV Tat protein was im m uno-precipitated from the
pSP720 RNA directed in vitro translation products labeled w ith [3H]-arginine
and subjected to amino term inal sequencing. Isolation by im m unoprecipitation
w as necessary to purify EIAV Tat from a num ber of comigrating wheat germ

proteins, which become am ino terminally modified w ith labeled arginine
through the action of an arginine terminal transferase activity present in w heat
germ extracts (Elias and Ciechanover, 1990). Amino-terminal sequencing of 5 x
104 cpm of EIAV Tat protein prepared in this m anner resulted in tw o clear,
consecutive peaks of radioactivity, each of approximately 2 x 102 cpm,
corresponding to the third and fourth residues of the polypeptide (Fig. 18). The
position of these peaks are consistent with translational initiation at CUG-373,
presum ing amino peptidase processing of the initiator m ethionine residue. A
considerable am ount of radioactivity was detectable in the fraction
corresponding to the fifth residue. It is common to have some carry over in
sequence analyses of this type due to incomplete coupling efficiencies,
particularly after consecutive labeled residues. However, the relative size of
this peak is somew hat larger than w ould be expected from such carry over.
Taken together w ith the fact that the second peak of radioactivity is slightly
higher than the first peak, an unexpected finding, it was concluded that there
w ere likely to actually be three populations of SI protein in this experiment.
The major population is the blocked protein that cannot be sequenced. This is
evident by the low level of radioactivity recovered from the sequencer. The
second population is the unblocked SI protein that lacks the initiator
methionine, as evidenced by the peaks of radioactivity in the third and fourth
fractions. A third population of SI protein appears to still bear the initiator
methionine and w ould contribute to the radioactive peaks corresponding to
residues four and five. This observation w ould appear to be logical, since the
treatm ent used to prevent efficient blocking should also prevent efficient
amino peptidase-m ediated removal of the initiator m ethionine residue. In
summ ary, it appears that EIAV Tat synthesized in vitro initiates at CUG-373 in
the EIAV leader region and m ay be amino terminally blocked by an
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Figure 18. M icrosequence analysis of the [3H]-arginine labeled SI (EIAV Tat)
protein. Counts per m inute (CPM) of tritium plotted against the predicted
am ino acid residue of the protein, assum ing that translation initiates at CUG373 and the amino-terminal m ethionine is rem oved by the am ino peptidase
activity of the w heat germ extract.

as yet undeterm ined functional group. Limited translation time followed by
heat treatm ent m ay have allowed a fraction of the newly synthesized EIAV Tat
protein to be captured in an unblocked form.
Comparison of Translation of the pSP720 RNA in Wheat Germ Extracts and
Rabbit Reticulocyte Lysates
The pSP720 RNA was translated in w heat germ extracts or rabbit
reticulocyte lysates in the presence of [^Hj-leucine rather than the more
commonly used [35s]-methionine, since the SI protein is devoid of methionine.
In w heat germ extracts, under conditions empirically determ ined to optim ize
am ino acid incorporation (2.1 mM Mg++ and 114 mM K+), the SI, S2, and
Agp90 proteins appeared as bands of different intensities on fluorographs of
SDS-polyacrylamide gels (Fig. 19A). The SI protein appeared as the m ost
intense band, the S2 band was the second m ost intense and the Agp90 band was
the least intense. W hen accounting for the leucine content of each protein, SI
and Agp90 each w ith nine and S2 with five leucine residues, it was determ ined
that the S2 protein w as actually the most abundant protein produced,
accounting for approximately 42% of the total EIAV protein, while the SI
protein accounted for 38% and Agp90 only 20% of the total (Fig. 19B). The CUG
initiation codon of the SI protein and the sub-optimal AUG of the S2 protein
appear to be efficiently recognized under these in vitro conditions.
In contrast to the relatively efficient translation of the pSP720 RNA
transcript in w heat germ extracts, I was unable to obtain significant levels of
am ino acid incorporation in the rabbit reticulocyte lysate system. The levels of
incorporation w ere consistently less than two-fold over the background
incorporation of a control translation sample lacking exogenously added RNA.
Nevertheless, I attem pted to visualize EIAV-specific proteins on SDS-PAGE
gels and w ere able to detect the SI and S2 proteins after exposure of the
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Figure 19. Q uantitation of the SI, S2, and Agp90 proteins produced from the
pSP720 RNA in wheat germ extracts. A. Flourograph of an SDS-PAGE gel of
the pSP720 translation products synthesized under standard translation
conditions that optim ize am ino acid incorporation. B. Graphical representation
of the relative molar abundance of the SI, S2 and Agp90 proteins shown in A.
These values w ere determ ined by densitometric scanning of the fluorograph in
panel A.

fluorograph for three weeks (data not shown). It is not possible to load larger
volum es of the lysate reaction mixture because of the high concentration of
hemoglobin in the lysate that interferes w ith proper protein m igration in the
range below 15-kd. In this system the SI protein appeared as the predom inant
product, and the S2 protein was barely detectable. I was unable to detect the
Agp90 protein using the lysate system. These results w ere obtained using
several different lots of reticulocyte lysate obtained from two different suppliers
(Promega Corporation and Green Hectares). Thus, the tricistronic pSP720 RNA
appeared to be translated inefficiently in reticulocyte lysates in contrast to its
efficient translation in the w heat germ system.
The Effect of m 7G pppG Cap Analog on the T ranslation of the pSP720 RNA
in W heat Germ Extracts
The relative translational efficiency of the S I, S2, and env cistrons in the
presence of the cap analog m 7GpppG was exam ined in order to determ ine
w hether the analog w ould affect the translation of the three cistrons equally as
one w ould anticipate if leaky scanning accounts for the translation of each of
the dow nstream cistrons. Alternatively, the internal cistrons could be initiated
in a cap-independent m anner through an internal initiation mechanism. In
order to address these possibilities, I translated the pSP720 RNA in w heat germ
extracts in the presence of increasing concentrations of m 7GpppG. The results
show ed that addition of cap analog in the range of 0.5 to 2.0 mM led to a non
linear decrease in the am ounts of amino acid incorporation (Fig. 20A). At a
m 7GpppG concentration of 0.5 mM, the level of translation decreased to 52% of
the control translation containing no m 7GpppG. Increasing the level of
m 7G pppG in the translation to 1.0 mM reduced translation to 44% of the
control, while the maxim um level tested, 2.0 mM, resulted in 39% of the control
translation. These findings are consistent with cap-dependent translational
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Figure 20. Effect of m 7G pppG cap analog on the pSP720 RNA translation.
pSP720 RNA was translated in w heat germ extracts in the presence of
increasing concentrations of m 7GpppG cap analog. A. Plot of the incorporation
of [3H]-leucine into acid insoluble protein versus the concentration of cap
analog added to the translation mixture. The axis on the right hand side
indicates the relative incorporation of radioactive amino acid as compared with
a control translation that lacks cap analog. B. Fluorograph of an SDS-PAGE gel
showing the relative abundance of SI, S2 and Agp90 at various cap analog
concentrations. Lane 1, N o cap analog; lane 2, 0.5 mM cap analog; lane 3,1
mM cap analog; lane 4 ,2 mM cap analog.
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initiation of at least one of the three cistrons. In order to determ ine if the
relative ratios of the proteins produced by the three cistrons w ere altered by the
presence of the cap analog, equivalent am ounts of acid insoluble radioactivity
w ere exam ined on SDS polyacrylam ide gels. The resulting fluorograph (Fig.
20B) show ed th at the levels of the proteins corresponding to the internal
cistrons, S2 and env, w ere not increased relative to the SI protein by the
addition of cap analog. This result is consistent w ith cap-dependent leaky
scanning (Kozak, 1989a), but an analysis of this type cannot rule out the
possibility of a term ination-reinitiation mechanism (Kozak, 1987; Peabody and
Berg, 1986). H ow ever, taken together w ith compelling recent evidence
supporting leaky scanning through the SI CUG for translation of the S3 protein
in the bicistronic S1/S3 mRNA of EIAV (Carroll and Derse, 1993), it appears
likely that leaky scanning by initiating ribosomes is responsible for the in vitro
translation of the internal cistrons of the pSP720 tricistronic mRNA.
T he Effect of the Potassium Ion Concentration on T ranslation of the pSP720
RNA.
Based on the observation that m any viruses produce structural proteins
in greater abundance than the nonstructural regulatory proteins, one might
expect that the gpl35 protein w ould be the predom inant product of the 3.5-kb
tricistronic mRNA in vivo. Since the 3.5-kb RNA species, represented by the
pSP720 RNA, is the only envelope length RNA thus far detected in EIAVinfected horses (Beisel, et al., 1993) and cultured equine cells (Rasty et ah, 1990),
it w ould appear reasonable to assume that the EIAV envelope protein is
predom inantly, if not exclusively, synthesized from this RNA. Since in vitro
translation conditions that optim ize amino acid incorporation favored
translation of the SI and S2 cistrons at the expense of the env cistron, I w anted
to determ ine w hether the relative ratios of the three proteins could be altered
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under different conditions. Since sub-optimal AUG and non-AUG initiation
codons can be efficiently utilized for translational initiation under certain ionic
conditions in cell-free systems (Kozak, 1989b; Peabody, 1989). The effects of
varying the concentrations of mono- and di-valent cations on the translation of
the three EIAV proteins produced by the pSP720 RNA w ere examined in the
w heat germ system. The effect of K+ concentration on the translation of the
pSP720 tricistronic m essage w as examined by varying the level from 54 mM to
154 mM while m aintaining the M g++ concentration at 2.1 mM. The w heat germ
extract is supplied by the m anufacturer as a buffered solution containing 107.5
mM K+ and 4.2 mM Mg++, and the extract m ade up 50% of the final translation
reaction volume. Therefore, the lowest attainable concentrations of K+ and
Mg++ in this system w ere 54 mM and 2.1 mM, respectively. Additional
potassium acetate (KAc) was added to separate translation reactions at 25 mM
increments and the level of [3H]-leucine incorporation was determined.
M aximum am ino acid incorporation was obtained w hen the final K+
concentration was 114 mM, w hereas further increases of the K+ concentration
resulted in reduced incorporation.
An apparent effect of K+ on translation of the pSP720 RNA w as a
decrease in the level of the SI protein produced as the level of K+ w as increased
(Fig. 21 A). Concomitant w ith this decrease in SI expression was an increase in
the levels of S2 and Agp90 expression. At 54 mM K+, the lowest concentration
tested, the SI protein was the predom inant translation product representing
51% of the total protein produced, while the S2 and Agp90 proteins represented
37% and 12%, respectively (Fig. 21B). As the am ount of K+ added to the
translation m ixture was increased to 79 mM, the first and second cistrons
appeared to be translated at nearly equivalent efficiencies, each contributing
about 42% of the total translation product, while the Agp90 protein contributed
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Figure 21. Effect of potassium ion concentration on the translation of pSP720
RNA in w heat germ extracts. A. Fluorograph of an SDS-PAGE gel of pSP720
RNA translation products translated in the presence of increasing
concentrations of potassium acetate. The am ount of amino acid incorporated
into protein was m easured by a filter paper assay after translation, and
equivalent am ounts of acid insoluble radioactivity was loaded into each lane of
the gel to facilitate direct comparison. The three EIAV proteins are indicated to
the left of the figure. The final concentration of potassium acetate in each
translation reaction is as follows: Lane 1,54 mM; lane 2,79 mM; lane 3,104
mM; lane 4,129 mM; lane 5,154 mM. Lane M, [14C]-labeled low molecular
w eight protein standards (Life Technologies, Inc.). B. The fluorograph in A
w as scanned w ith Bio-Rad model 620 video densitom eter and the optical
density (OD) reading for each of the EIAV proteins was divided by the num ber
of leucine residues in the protein to obtain a molar OD for each protein. The
m olar OD for each protein w as divided by the total molar OD of the three
EIAV proteins and m ultiplied by 100% to obtain the relative m olar percentage
of each EIAV protein is each lane. The percentage of each EIAV protein
produced is plotted against the various potassium ion concentrations. SI, Solid
columns; S2, hatched columns; Agp90, shaded columns.
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about 16%. At a K+ concentration of 104 mM, the S2 protein was the
predom inant product at about 47%, while the SI and Agp90 proteins
represented 36% and 18% of the EIAV protein produced, respectively. Further
increases in K+ resulted in only m odest enhancem ent of S2 expression, but
continued to decrease the level of SI and increase the level of Agp90 produced.
At the highest K+ concentration tested, 154 mM, the S2 protein accounted for
51% of the total protein produced, while the Agp90 protein surpassed the SI
protein in efficiency representing 29% of the total, and the SI protein accounted
for only 21% of the total EIAV protein synthesized from the tricistronic mRNA.
In sum m ary, low K+ concentrations appear to favor that the three EIAV
proteins be produced based prim arily on their position in the message, that is
the first cistron is translated m ore efficiently than the second and the second
m ore efficiently than the third. W ith increasing levels of K+ the CUG codon of
the first cistron becomes less efficiently translated, until finally at near
physiological concentrations of K+ (Bernstein, 1954; W ickson-Ginzburg, 1963),
it is the least efficiently translated of the three cistrons. Even at the highest
levels of K+ tested, the Agp90 protein is still relatively poorly translated in the
w heat germ system due to efficient recognition of the S2 sub-optimal AUG
codon. However, its efficiency was im proved about 2.5-fold from the lowest
(54 mM) to the highest (154 mM) K+ concentrations examined here.
The Effect of M agnesium Ion Concentration on T ranslation of the pSP720
RNA.
Non-AUG and sub-optimal AUG initiation codons are more efficiently
recognized in w heat germ extracts at elevated m agnesium concentrations
(Kozak, 1989b). In order to assess the effect of m agnesium ion (Mg++)
concentration on the pSP720 RNA translation, I perform ed translation reactions
at m agnesium acetate (MgAc2) concentrations ranging from 2.1 to 4.1 mM and
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a constant KAc concentration of 114 mM. As m entioned above, the minimal
M g++ concentration that could be attained was fixed at 2.1 mM. This level was
determ ined by the m anufacturer to give the best amino acid incorporation for
the BMV RNAs, their standard test RNAs. Additional MgAc2 was
supplem ented to a series of translation reactions at 0.5 mM increments. Amino
acid incorporation results show ed that increased Mg++ levels resulted in
significant reduction of translation (data not shown). The lowest tested Mg++
level of 2.1 mM was the best of the tested concentrations for the translation of
the pSP720 RNA. The levels of incorporation at 3.6 and 4.1 mM Mg++ dropped
to 45% and 34%, respectively, of that obtained at 2.1 mM Mg++.
U nder standard translation conditions, that is w ith 2.1 mM Mg++ and 114
mM K+, the S2 protein was the predom inant product at 42% of the total EIAV
protein translated, closely followed by the SI protein at 38%, while the Agp90
protein accounted for 20% of the total EIAV protein synthesized (Figs. 19B and
22). A n increase in the M g++ level to 2.6 mM results in a significant rise in SI
expression to 55% that is accompanied by sizable decreases in S2 and Agp90
expression to 33% and 12%, respectively. An increase in M g++ to 3.1 mM
further favors the expression of SI to 60% , while S2 and Agp90 drop to 26%
and 8%, respectively. A ddition of Mg++ above 3.1 mM m ade accurate
analysis of the protein ratios increasingly difficult due to the appearance of a
num ber of unidentified low molecular w eight products. In sum m ary, the m ost
equitable distribution of production of the three proteins was obtained at the
lowest possible Mg++ concentration (2.1 mM) in this w heat germ translation
system. As the level of M g++ was increased, translation initiation from the first
cistron, S I, was enhanced w ith concomitant reduced expression from the S2
and env cistrons. In all cases the third cistron, the env cistron, was translated
least efficiently.
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Figure 22. Effect of m agnesium ion concentration on pSP720 RNA translation
in w heat germ extracts. A. The pSP720 RNA was translated in wheat germ
extracts in the presence of increasing concentrations of m agnesium acetate. A.
Fluorograph of an SDS-PAGE gel where equivalent am ounts of acid insoluble
radioactivity were analyzed in each lane. The three EIAV proteins are indicated
to the left of the figure. The final concentration of m agnesium acetate in the
translation reaction loaded onto each lane of the gel is as follows: Lane 1,2.1
mM; lane 2,2.6, mM; lane 3,3.1 mM; lane 4,3.6 mM; lane 5,4.1 mM. Lane M,
[14C]-labeled low molecular w eight protein standards (Life Technologies, Inc.).
B. The relative molar percentage of each EIAV protein translated at each
m agnesium acetate concentration is shown (refer to legend to Fig. 21). SI, solid
columns; S2, hatched columns; Agp90, shaded columns.

% Each EIAV Protein

[Mg++], mM
o
00

109
C o-translation of the pSP720 RNA w ith BMV RNA 4
In m y early experiments I was intrigued with the relatively high
translation efficiency of the EIAV tricistronic message as com pared w ith BMV
RNAs provided by the m anufacturer as the test RNAs for the translation
system (50-70% of BMV RNA incorporation). In order to obtain a more
quantitative m easure of the efficiency of the EIAV tricistronic mRNA in the
w heat germ system, I perform ed co-translation experim ents of this RNA w ith
BMV RNA 4. The latter is a com ponent of the BMV RNA m ixture and is a
highly efficiently translated message in the w heat germ system (Shih and
Kaesberg, 1973). In addition, this RNA was a convenient choice since it results
in the synthesis of a viral capsid protein of 20-kd that can be readily observed in
the gel electrophoresis system used to resolve the pSP720 RNA proteins. The
BMV RNA was added to the w heat germ translation mixtures at molar ratios of
1:10,1:2, and 1:1 relative to the pSP720 RNA, which w as added at the saturation
concentration of 30 p g /m l.
To simplify the comparison, and also for the purpose of determ ining the
efficiency of utilization of the SI CUG codon as com pared with the BMV RNA 4
AUG codon in the w heat germ cell-free system, the relative translational
efficiency of only the SI cistron was compared to that of BMV RNA 4. The
densitom eter readings for the SI protein and the BMV coat protein were
norm alized for the num ber of leucine residues in each protein to allow direct
com parison of the two proteins on a molar basis. At a one tenth molar ratio of
BMV RNA 4 to the pSP720 RNA very little BMV coat protein was detected (Fig.
23A, lane 2). Q uantitation of these bands showed that there was more than 10fold m ore SI produced than BMV coat protein (Fig. 23B). Increasing the level of
BMV RNA 4 to one half m olar equivalent resulted in a large increase in BMV
coat protein expression (Fig. 23A, lane 3) to a point where it was expressed at a
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Figure 23. Co-translation of pSP720 RNA w ith BMV RNA 4 in w heat germ
extracts. A. The pSP720 RNA was translated in w heat germ extracts in the
presence of increasing am ounts of BMV RNA 4. Equivalent volumes of
translation m ixture were analyzed on an SDS-PAGE gel. Lane 1, no BMV RNA
added; lane 2, 0.1 molar equivalents of BMV RNA added; lane 3,0.5 molar
equivalents of BMV RNA added; lane 4, equal m olar am ounts of pSP720 RNA
and BMV RNA 4 added. Lane M, [14C]-labeled low molecular weight protein
standards (Life Technologies, Inc.). The positions of the BMV RNA coat protein
and the EIAV proteins are indicated to the left. B. Q uantitation of the relative
m olar am ounts of BMV coat protein and SI protein synthesized in each
translation mixture. The fluorograph in panel A was scanned with a Bio-Rad
m odel 620 video densitom eter and the optical density readings for the BMV
coat protein and the EIAV SI protein were normalized by dividing each by the
num ber of leucine residues they contain. Each molar OD w as divided by the
sum of the m olar OD readings of the tw o proteins to determ ine the relative
percentage of these two proteins in a given translation experiment. SI, solid
columns; BMV coat protein, hatched columns.
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level 1.7-fold greater than the SI protein. At an equimolar ratio of the two
RNAs the BMV coat protein was produced at a level approximately 5-fold
greater than that of the SI protein. Under the translation conditions em ployed
in this experiment, translation of the SI cistron in the pSP720 RNA was 20% as
efficient as the translation of the BMV coat protein from BMV RNA 4 w hen
both viral RNAs w ere present at an equimolar am ount in the same translation
mixture.
EIAV Tat Synthesis Initiates at a CUG Codon and not an AUC Codon in
Wheat Germ Extracts
The pSP720 in vitro transcription construct contains the entire ORF SI,
while the pSP585 construct lacks sequences upstream of the Sma I site (nt 393)
near the 5' border of ORF SI (nt 346). The data reported here dem onstrate that
SI sequences upstream of the Sma I site are required for EIAV Tat synthesis in
w heat germ extracts. These sequences include CUG-373 and AUC-388, each of
which has been independently reported to be responsible for initiation of Tat
synthesis (Noiman et al., 1991; Carroll and Derse, 1993). In order to determine
if AUC-388 can initiate Tat synthesis in the w heat germ system, the in vitro
transcription construct pSP634 was generated. AUC-388 lies within a BamH I
site that is immediately upstream of the Sma I site used to produce pSP585.
Therefore by subcloning the 280 bp BamH I fragment of the pSR-1 cDNA clone
into the BamH I site of the pSP65 polylinker, a construct was generated that
contains the AUC codon of ORF S I, but lacks CUG-373. Since there is a second
BamH I site in the cDNA clone within the overlapping region of ORF S2 and
env, a 623-bp Sma I fragm ent of pSR-1 that includes sequences immediately

dow nstream of the BamH I site near the 5' end of SI to the Sma I site of env that
lies 36-bp dow nstream of the Msc I site used to produce pSP720 and pSP585. A
com parison of the 5' end sequences of the pSP720, pSP585, and pSP634 RNAs is

show n in Figure 24A. As can be seen in this figure, the EIAV sequences (non
italicized) of pSP634 RNA begin tw o nucleotides upstream of AUC-388. A
consequence of this cloning scheme is that the adenine residue in the -3 position
w ith respect to the putative AUC initiation codon has been replaced by a
guanine residue. In general adenine residues are preferable in the -3 position of
initiation codons, but either purine can result in efficient translation initiation
(Kozak, 1986). Translation of pSP634 RNA in w heat germ extract resulted in
the production of the S2 and Agp90 proteins, but not the Tat protein (Fig. 24B,
lane 2). These data indicate that AUC-388 does not act as the Tat translation
initiation codon in this in vitro system, and that sequences upstream of AUC388 are required for Tat synthesis in vitro. These upstream sequences include
CUG-373, the codon dem onstrated likely to initiate Tat synthesis based on the
am ino terminal sequence data presented in Figure 18 above.
The S3 Protein Synthesized In Vitro Initiates from an AUG C odon Provided
b y env Sequences
The S3 open reading fram e overlaps the env gene in an alternative frame
near its 3' end and consists of 135 potential codons, none of which correspond
to methionine. A m ultiply-spliced RNA has been described that contains ORF
SI and ORF S3 (Stephens et al., 1990). This RNA contains four exons: 1, the 5'

leader sequence and coding exon 1 of ORF SI; 2, coding exon 2 of ORF SI; 3, a
101-nt exon that places 33 codons of gp90 in frame with ORF S3, the fourth of
which is a methionine; 4, the major coding exon of ORF S3. The env sequences
spliced to S3 contain two in-frame m ethionine codons corresponding to the
third and fourth codon of the env-S3 fusion ORF, AUG-5447 and AUG-5480.
An epitope recognized by the monoclonal antibody used to identify the Agp90
protein produced from the pSP720 transcript (refer to Fig. 12), lies between
these two AUG codons (nt 5459-5485). Therefore, if the S3 protein is initiated at
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Figure 24. Translation of EIAV Tat is not initiated at AUC-388 in vitro. A . A
com parison of the nucleotide and amino acid coding regions of the pSP720,
pSP585 and pSP634 in vitro transcripts. Sequences in italics are derived from
the pSP65 in vitro transcription vector poly-cloning site. The UGA stop codon
in pSP720 that defines the 5'-end of the EIAV tat gene that encodes the SI
protein is indicated w ith an asterisk. CUG-373 of pSP720 and AUC-388 of
pSP720 and pSP634 are underlined along w ith their -3 and +4 context
nucleotides. B. Fluorograph of an SDS-PAGE gel of the translation products of
the pSP585 (lane 1), pSP634 (lane 2), and pSP720 (lane 3) in vitro translation
products synthesized in w heat germ extracts. The EIAV proteins are indicated
to the right of the figure.
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the first of these tw o AUG codons, then it w ould contain this monoclonal
epitope near its amino terminus. In order to address this possibility, a cDNA
clone corresponding to the 1.5-kb cDNA S I/S3 was obtained and an 800-bp
Pvu U/ S t u I restriction fragm ent was subcloned into the Sma I site of pSP65 to

give pSPS3. The Pvu II site lies near the 5' end of the second exon and the Stu I
site lies in the 3' redundant region. Therefore, this construct lacks sequences
required for SI expression. The pSPS3 plasm id was linearized w ith H ind III
w ithin the vector polylinker region and used as a template for in vitro
transcription. The transcripts were translated in w heat germ extracts in the
presence of [35S]-methionine and analyzed on a SDS-polyacrylamide gel. The
resulting autoradiograph showed that a protein of approximately 20 to 21-kd
was synthesized (Fig. 25, lane 2). This apparent molecular w eight is in
accordance with the previously reported size of the S3 protein (Saman et al.,
1990). This protein can be im m unoprecipitated w ith the gp90 monoclonal
antibody (Fig. 25, lane 3) and a S3-specific peptide antisera directed against a
carboxyl-terminal peptide of S3 (Fig. 25, lane 4). The monoclonal antibody also
precipitated a large num ber of lower molecular w eight products that w ere not
recognized by the rabbit peptide antisera. These products are likely to be
carboxyl terminal truncations of S3 resulting from proteolysis, prem ature
translational termination, or synthesis from a partially degraded in vitro
transcript. The data indicate that the S3 protein produced in w heat germ
extracts is likely to be initiated at AUG 5459, the third AUG codon of the gp90
cistron w hich results from a splicing event that juxtaposes 33 internal codons of
the gp90 cistron (splice donor 5537) to the S3 cistron (splice acceptor 7235).
D iscussion

The translational coding potential of the EIAV 3.5-kb transcript of FDD
cells was examined using a cDNA clone and in vitro expression techniques. The

Figure 25. In vitro translation and immunoprecipitation of the S3 protein. A
Pvu U / S t u I restriction fragm ent of a cDNA clone, that was derived from a
multiply-spliced RNA of EIAV that places a region of the env gene in-frame
w ith the ORF S3 gene, was ligated into the pSP65 vector to produce pSPS3. In
vitro transcripts were synthesized from this plasm id construct and translated in
w heat germ extracts. The translation products were imm unoprecipitated (IP)
w ith either a monoclonal antibody (mab86) that recognizes an epitope of the
gp90 envelope protein or a synthetic peptide antisera that was produced
against a peptide corresponding to the predicted ORF S3-encoded protein, the
ding to containing the coding region. Lane M, [14C]-labeled low molecular
w eight protein standards (Life Technologies, Inc.); lane 1, a translation reaction
that lacked exogenously added RNA; lane 2, pSPS3 translation products; lane
3, IP w ith mab86; lane 4, IP w ith ORF S3 synthetic peptide antisera.
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results clearly indicate that this transcript is tricistronic in vitro, since it directs
the synthesis of EIAV Tat, S2, and a truncated envelope protein (Agp90) in the
w heat germ cell-free translation system. The translational initiation site for the
ORF S I -encoded EIAV Tat protein has been localized to sequences between the
Stu I (nt 256) and Sma I (nt 393) sites of the viral leader sequence, since it is

produced from the pSP720 RNA b u t not the pSP585 RNA. The observation that
the Tat initiation codon lies upstream of the Sma I site has been confirmed by
other researchers in studies of the bicistronic EIAV tat/rev (SI/S3) mRNA (Dorn
et a l, 1990).

O ne research group (Noiman et a l, 1991) has reported that EIAV Tat
synthesis is initiated from an AUC codon (AUC-388, n t 388-390) that lies
im m ediately upstream of the Sma I site (nt 393). This finding is somewhat
surprising since AUC-388 lies in a less favorable context for translation
initiation [AGG AUC C, w here underlined nucleotides m atch the consensus
sequence for translational initiation (Kozak, 1986)] than does an upstream CUG
codon (AAC CUG G). Previous studies have shown that the presence of a
purine residue in the -3 and a guanine residue in the +4 positions are critical for
the recognition of non-AUG codons in vivo (Mehdi et a l, 1990). I was unable to
detect Tat synthesis in vitro from AUC-388 using the pSP634 RNA, a synthetic
transcript that contains AUC-388 but lacks sequences further upstream
including CUG-373.
Sequence analysis of the amino terminus of in vitro synthesized EIAV Tat
presented here is consistent w ith initiation at CUG-373, but not compelling due
to an apparent amino terminal blocking group present on the majority of the
Tat polypeptides produced under these conditions. I was, however, able to
obtain the lim ited sequence data presented here by m anipulating the in vitro
translation conditions in a m anner that apparently allowed the synthesis of a
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small am ount of the Tat protein in an unblocked form. I also show here that the
blocking group does not appear to be an acetyl group, since w heat germ
extracts that were pre-treated to reduce the endogenous pool of acetylCoenzyme A did not produce Tat protein that was m ore readily sequenced.
The precise identity of this blocking group and the determ ination of whether
this blocking reaction occurs in vivo, as well as in vitro, will require further
investigation. The recently published data of Carroll and Derse (1993) appear
to clearly confirm that CUG-373 is indeed responsible for initiation of the EIAV
Tat protein. In this study, site-specific mutagenesis was used to alter CUG-373
to a GUA valine codon resulting in the total loss of trans-activation of the EIAV
LTR in transient transfection experiments. Furtherm ore, these researchers
show ed that m utagenesis of AUC-388 to a GUA codon did not result in reduced
trans-activation. It is unclear w hy N oim an et al. (1991) were able to detect high

levels of trans-activation in deletion m utants that lacked CUG-373, but
contained AUC-388. The only significant differences between these two
investigations is the use of different expression plasm ids to produce the m utant
Tat proteins in transfected cells, and the use of different cell lines to assay the
trans-activation activity of the mutants. One possibility m ay be that the

eucaryotic expression plasm id that was used m ay contain a cryptic splice donor
that allows an alternative initiation codon to be placed in-frame w ith the second
exon of the tat gene.
Translational initiation at non-AUG triplets has been shown to occur in
both viral an d cellular systems. One of the capsid proteins of adeno-associated
virus (Becerra et al., 1985) and the C' protein of Sendai virus (Curran and
Kolakofsky, 1988; G upta and Patw ardhan, 1988) initiate translation at ACG
codons. Some cellular regulatory proteins involved in various stages of signal
transduction pathw ays have been shown to initiate translation at CUG codons.
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In m ost of these cases, the CUG initiation codons lie upstream of in-frame AUG
codons that are responsible for the majority of translation of these proteins. The
CUG codons result in the synthesis of amino-terminally extended proteins with
as yet undefined functions. This was shown to be true for the hum an basic
fibroblastic grow th factor gene which directs the synthesis of at least three
polypeptides in vivo. Two of these are produced from upstream CUG codons
(Florkiewicz and Sommer, 1989; Prats et al., 1989). The c-myc nuclear
transcription factor gene results in the synthesis of two proteins, one of which is
initiated from an upstream CUG codon (Hann et al., 1988). While these
extended proteins are presum ed to perform unique functions in the cell, this
rem ains to be proven experimentally. M ore recently, the m urine Itk receptor
tyrosine kinase has been show n to initiate translation exclusively at a CUG
codon in vitro and in vivo (Bernards and de la Monte, 1990). The EIAV Tat
protein is the first example of the utilization of a non-AUG codon in
retroviruses, and like the m urine Itk receptor, the synthesis of the Tat protein is
initiated exclusively at the CUG codon. That is, there is no trans-activation of
the EIAV LTR observed if CUG-373 is m utagenized to a non-initiator codon
(Carroll and Derse, 1993).
Translation of the pSP720 RNA in w heat germ extracts under conditions
that optim ize amino acid incorporation results in synthesis of all three EIAV
proteins, w ith both the EIAV Tat and S2 proteins being produced at a near tw o
fold greater molar ratio than Agp90. The relatively efficient translation of the
pSP720 RNA in the wheat germ system is contrasted by a dramatically reduced
ability of the RNA to be translated in rabbit reticulocyte lysates. The reduced
translational efficiency of the pSP720 RNA in the lysate system may be due to
the presence of low am ounts of double stranded RNA that often contaminate
RNA synthesized in vitro using bacteriophage RNA polymerases (Gunnery et
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al., 1990). Such contamination previously led to the belief that the HIV-1 trans-

activation response (TAR) RNA stem-loop structure, located at the 5' end of all
HIV-1 RNAs, results in inhibition of translation in the reticulocyte lysate system
d u e to activation of a double-stranded RNA-activated inhibitor (DAI) of
translational initiation (Edery et al., 1989; SenGupta et al., 1989; SenGupta et al.,
1990). U pon rigorous purification of the in vitro transcripts, no such inhibition
was detected. In fact, it now appears clear that elevated levels of highly
purified TAR RNA can actually prevent activation of DAI (Gunnery et al., 1992),
although others have claimed that an as yet undefined heat labile inhibitor is
responsible for HIV-1 RNA translation inhibition in rabbit reticulocyte lysates
(Geballe and Gray, 1992). It w ould be interesting to see if extensive
purification of the pSP720 RNA to remove the putative contaminating dsRNAs
im proves its ability to be translated in reticulocyte lysates. The w heat germ
system m ay be less sensitive to such contaminants, thereby allowing for
efficient translation of the pSP720 RNA in this system.
The observation that addition of m 7GpppG cap analog to the translation
reaction decreased expression of each of the three EIAV ORFs in the pSP720
RNA nearly equivalently is consistent with a leaky scanning mechanism for
translation of the dow nstream ORFs. Compelling evidence for leaky scanning
through the EIAV Tat CUG of the bicistronic S1/S3 EIAV RNA has recently
been published (Carroll and Derse, 1993). These researchers found that cell
cultures transfected w ith S1/S3 expression vectors produced very low levels of
SI protein as com pared to the S3 protein. Site-specific m utagenesis of the SI
initiator CUG to an AUG greatly increased the am ount of SI produced and
nearly completely prevented synthesis of the downstream S3 protein. By
analogy, leaky scanning through the SI CUG of the pSP720 RNA is likely to
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result in S2 synthesis, and leaky scanning through both the SI CUG and the S2
AUG to result in Agp90 synthesis.
O ther know n examples of functionally bicistronic RNAs in lentiviruses
are the HIV-1 vpu/env and rev/nef B N A s (Schwartz, et a l, 1990b; Schwartz et a l,
1992a). In both cases the evidence indicates that the dow nstream protein is
efficiently translated in vivo due to leaky ribosome scanning through a suboptim al AUG initiation codon for the upstream protein. Specifically, the Rev
initiation sequence contains a cytidine in the -3 position (CU CCU AUG G) and
that for V pu contains a cytidine residue in the +4 position (AU GUA AUG C).
The arrangem ent of the S2 and env genes of EIAV is very similar to that of the
vpu and env genes of HIV-1 in that they are expressed from overlapping reading

frames w ith the S2 or Vpu AUG initiation codon preceding that of the
respective envelope polyprotein. The EIAV S2 AUG, like that of Vpu, lies in an
unfavorable context for initiation due to the presence of a uridine residue in the
-3 position. Furthermore, there is no evidence for the presence of any splice
acceptor sites in the 23-nt span between the S2 and gpl35 initiation codons.
Therefore, it is likely that efficient gpl35 expression in EIAV requires low level
recognition of both the Tat CUG initiation codon as well as the sub-optimal S2
AUG initiation codon by scanning ribosomes. M ore detailed analyses
involving the characterization of site-specific m utants of the Tat and S2 initiator
codons are necessary to clearly define the precise mechanisms involved in the
translation of this tricistronic mRNA.
The EIAV 3.5-kb RNA bears a strong structural similarity to a singlyspliced message of HIV-1 (Tati) that contains the first exon of tat as its first
cistron, vpu as the second cistron, and env as the third cistron. While this HIV-1
mRNA is functionally tricistronic in vitro, it is monocistronic in vivo due to
faithful translational initiation at the relatively strong Tat AUG initiation codon
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of the first cistron (Schwartz, et al., 1990b). M utagenesis of bases at the -3 or +4
position of the Tat AUG results in leaky ribosome scanning to the downstream
Vpu and Env proteins (Schwartz et al., 1992a). In the case of HIV-1 a num ber of
alternatively spliced envelope transcripts devoid of the Tat initiation codon are
responsible for Env translation. However, to date the tricistronic 3.5-kb EIAV
RNA studied here has been the only ewz;-containing RNA detected in infected
animals (Beisel, et al., 1993). EIAV appears to have evolved a m echanism to
express its envelope protein from a tricistronic message that involves the use of
a non-AUG codon for the synthesis of the EIAV Tat and a sub-optimal AUG
codon for that of S2, thereby enabling this virus to replicate w ith a relatively
sim ple mRNA splicing scheme as com pared to the prim ate lentiviruses.
Increases in the potassium ion concentration in the in vitro translation
reaction to near physiological levels (Bernstein, 1954; W ickson-Ginzburg and
Solomon, 1963) resulted in m arkedly reduced expression of the Tat and S2
proteins w ith concomitant enhanced expression of the env cistron. Elevated
levels of m agnesium appeared to favor translation from the Tat CUG codon at
the expense of the dow nstream ORFs. It has previously been determ ined that
levels of Mg++ greater than 3 mM in w heat germ extracts resulted in enhanced
initiation of translation from non-AUG and sub-optimal AUG codons placed
upstream of the chloramphenicol acetyl transferase AUG codon (Kozak, 1989b).
However, a M g++ level of 1.9 mM resulted in infrequent initiation from these
anom alous codons and thereby more accurately reflects the in vivo situation. In
the present study, the Tat and S2 proteins were efficiently translated at 2.1 mM
Mg++, the lowest level attainable in these extracts. The Tat and S2 proteins each
comprised nearly 40% of the total EIAV protein synthesized, while the Agp90
protein was only 20% of the total. Although this level of Mg++ was only slightly
above the 1.9 mM previously determ ined by Kozak for near faithful initiation of
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the particular synthetic test RNAs, the levels of Tat and S2 synthesized w ere
m uch greater than w ould norm ally be anticipated in vivo. It should be noted
that 2.1 mM M g++ was the optim al concentration tested here for amino acid
incorporation for the pSP720 RNA and BMV RNAs. The previous studies
noted a reduction in am ino acid incorporation at 1.9 mM Mg++ as com pared to
3 mM Mg++. In the extracts em ployed in this study, increasing the Mg++ levels
from 2.1 mM to 3.1 mM resulted in a considerable reduction in am ino acid
incorporation. These discrepancies m ay reflect differences in the preparation of
the extracts, and m ay indicate that Mg++ levels lower than 2.1 mM m ay be
required for obtaining a ratio of the three EIAV proteins similar to w hat m ight
be expected in vivo. Nevertheless, I was clearly able to alter the relative levels of
the three EIAV proteins by varying the concentrations of Mg++ and K+,
suggesting that translation of each of the three cistrons m ay be affected or
regulated by specific cellular ionic conditions. For the w heat germ extract
system em ployed in the present studies the lowest attainable Mg++ level of 2.1
mM and the highest tested K+ level of 154 mM yielded the highest proportion
of the envelope protein and appeared to m ost closely approxim ate w hat one
m ight anticipate to occur in vivo.

CHAPTER 3
IN VIVO EXPRESSION OF THE EIAV ORF PROTEINS
Introduction
W hen the research described in this dissertation was first begun, the
sequence inform ation leading to the discovery of the small open reading frames
(ORFs) in EIAV had only recently been published (Kawakami et al., 1987;
Rushlow et al., 1986). At that time no protein products had yet been show n to
be encoded by these ORFs, and the roles of these putative proteins in EIAV
infection w ere unknown. Shortly after this sequence information was
published, Derse et al. (1987) dem onstrated that the EIAV LTR could be
specifically activated in EIAV-infected canine and feline fibroblast cell lines.
These data indicated that EIAV, like other lentiviruses, encodes a trans-activator
protein that is functionally homologous to the HIV-1 Tat protein. Thus, one of
the ORF proteins was presum ed to be this viral trans-activator.
Early experiments by Dorn and Derse (1988) using restriction fragments
from proviral clones appeared to indicate that the S2 protein m ight be this
trans-activator. However, it was not until the isolation of cDNA clones
corresponding to the 1.5-kb S1/S3 mRNA, that the ORF SI-encoded protein was
unam biguously identified as EIAV Tat (Dorn et al., 1990; Stephens et al., 1990;
N oim an et al., 1991). N oim an et al. (1991) used a pool of antisera produced
against three different synthetic peptides of the predicted Tat protein to detect a
very low abundance 8-kd protein in EIAV-infected canine cells. The molecular
w eight of this protein correlates well with in vitro synthesized Tat protein
(Schiltz et al., 1992). This is the only report to date of the direct detection of the
tat gene product in vivo.

The putative S2 protein has yet to be detected in vivo or assigned a
function in EIAV infection. Saman et al. (1990) have speculated that ORF S2
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m ay be the first exon of a putative EIAV Rev protein, and that ORF S3 w ould be
the second exon of EIAV Rev. These researchers suggested that ORF S2
contains a consensus splice donor signal at nt 5345 that could be spliced to a
consensus splice acceptor near the 5'-end of ORF S3 (nt 7235). Such a splicing
event w ould allow 17 codons of ORF S2 to be spliced to 135 codons in ORF S3.
The ORF S2 sequences could provide a translational initiation codon for the
synthesis of the putative Rev protein, since ORF S3 is devoid of methionine
codons. To date, no cDNAs have been isolated from EIAV-infected cells that
utilize this proposed splice donor site. Close inspection of this site shows that it
is not a consensus splice site, since it lacks a critical uridine residue. The
consensus sequence for a splice donor site is AGGU, where the splicing occurs
betw een the two guanine residues, and the GU dinucleotide is absolutely
conserved (Mount, 1982; Oshim a and Gotoh, 1987). The sequence of the
proposed splice donor w ithin ORF S2 is AGGG and is therefore unlikely to be
functional. Since there do not appear to be any other potential splice donor
sites in ORF S2 it should produce a unique protein if it is expressed in vivo.
The 20-kd S3 protein w as detected in EIAV-infected cells using both
synthetic peptide antisera (Stephens et al., 1990) and antisera directed against a
portion of the S3 protein expressed in E. coli. (Saman et al., 1990). Saman et al.
also dem onstrated that sera from EIAV-infected horses could specifically
recognize the E. coli expressed S3 protein, indicating that the S3 protein is
expressed during productive EIAV expression. The isolation of cDNAs
corresponding to the multiply-spliced S I/S3 1.5-kb transcript of EIAV has
shown that an AUG initiation codon of an internal region of the env cistron is
spliced in-frame w ith the ORF S3 coding region (Rosin-Arbesfeld et a l, 1993;
Stephens et al., 1990). Thus, a portion of the env gene consisting of 29 codons
constitutes the first coding exon of rev (rev-1), and not ORF S2 as previously

127
proposed (Saman et al., 1990). Stephens et al. (1990) show ed that the predicted
S3 protein contained sequence homology w ith the H3V-1 Rev protein, but it has
only recently become apparent that the S3 protein is functionally homologous
to the Rev proteins of other lentiviruses (M artarano et al., 1994; Fridell et al.,
1993).
Since I had an ongoing interest in com paring EIAV infection in prim ary
cultures of equine fibroblasts that support either persistent or cytopathic
infection, I examined the ability of these cells to trans-activate the EIAV LTR
using a pLTR-CAT reporter plasm id. I examined the possibility that the 3.5-kb
RNA m ight encode the Tat protein by determ ining the levels of trans-activation
throughout the course of a cytopathic infection of FDD cells. In these cells, the
3.5-kb RNA is expressed at very high levels late in the infection cycle, while
there is little change in the expression level of the multiply-spliced 1.5-kb RNA
(Rasty et al., 1990). A significant increase in the Tat activity concomitant with
increased expression of the 3.5-kb RNA w ould provide indirect evidence for the
expression of the Tat protein from this RNA. I also expressed restriction
fragm ents from a cDNA that corresponds to the 3.5-kb RNA in uninfected FDD
cells along w ith the pLTR-CAT reporter plasm id to determ ine if the Tat protein
is encoded by the 3.5-kb RNA. I used deletion m utants to examine which
sequences in cDNA w ere required for Tat expression.
In the previous c h a p te r, I established that the EIAV 3.5-kb RNA is
tricistronic in vitro. A desired goal of this research was to determ ine if this RNA
is also tricistronic in vivo. In order to accomplish this goal, I first had to devise a
m ethod of detecting the various proteins encoded by the 3.5-kb RNA. In this
chapter I will described my efforts to detect the three ORF proteins in vivo using
immunological techniques.
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Materials and Methods
Virus Strains and Cell Cultures
Canine (Cf2Th) and feline (FEA) fibroblast cultures that w ere either
persistently infected w ith EIAV or uninfected were a gift from Larry A rthur
(Program Resources, Inc., Frederick Cancer Research Facility, Frederick, MD).
Prim ary cultures of fetal donkey dermal (FDD) cells and fetal equine kidney
(FEK) cells were obtained from Dr. C. J. Issel (formerly of the Departm ent of
Veterinary Science, Louisiana State University, Baton Rouge, LA and currently
w ith the D epartm ent of Veterinary Science, Gluck Equine Research Center,
University of Kentucky, Lexington, KY). All cells were m aintained in Eagle's
minimal essential m edia supplem ented with 10% fetal calf serum. Two related
strains of EIAV, referred to here as the prototype strain and the FDD-adapted
strain, were used during these studies. The prototype strain was generated by
propagation of the W yoming cell-adapted strain of EIAV (Malmquist et al.,
1973) in prim ary cultures of fetal equine kidney (FEK) cells, and the FDDadapted strain was derived from the prototype strain by serial passage in FDD
cells. Confluent monolayers of equine cells were infected w ith the indicated
virus strain at a multiplicity of infection of one.
Chloramphenicol Acetyl Transferase Reporter Gene Plasmids
Plasm id vectors containing the bacterial chloramphenicol acetyl
transferase (CAT) gene under the control of the SV40 im m ediate early prom oter
(pSV2CAT) or w ith no prom oter (pSVOCAT) were purchased from the
American Type Culture Collection, Rockville, MD. The plasm id pLTRCAT was
constructed by subcloning the EIAV LTR from a lam bda proviral genomic clone
(A.12) into the unique H ind III site of pSVOCAT located im m ediately upstream
of the CAT gene. The proviral clone was digested with BsiN I and Pvu II and a
478-bp fragm ent was isolated containing the entire 321-bp EIAV 5-LTR flanked

129
by 175-bp of cellular DNA 5' to the LTR and 1-bp of the EIAV leader region.
The BsfN I site was converted to a blunt-end using T4 DNA polymerase.
Following the addition of H in d HI linkers (New England Biolabs), the LTRcontaining fragm ent w as ligated to H ind HI digested pSVOCAT.
Eucaryotic Expression Plasmid Constructs.
Eucaryotic expression plasm ids were constructed by subcloning
restriction fragments of the cDNA clone pSR-1 into an SV40 replacement vector,
pSV2ACAT, derived from pSV2CAT (Gorman et ah, 1982). The pSV2ACAT
vector provided by Keith Rushlow (formerly of the Departm ent of Molecular
Genetics and Biochemistry, U niversity of Pittsburgh School of Medicine,
Pittsburgh, PA) was produced by digestion of pSV2CAT w ith H ind III and
Hpa I to rem ove the CAT gene, followed by insertion of a synthetic linker that

regenerates each of these sites and also provides a unique Xho I site. The
eucaryotic expression plasm ids described here are analogous to the in vitro
transcription plasm ids described in Chapter 2. The 720-bp Stu l/M s c I and the
585-bp Sma I/M sc I of the pSR-1 cDNA were ligated to Stu I digested
pSV2ACAT generating pSV720 and pSV585, respectively. The Stu I site of
pSV2ACAT lies betw een the SV40 prom oter and the unique H ind HI site. The
plasm id pSV634 was produced by digesting pSP634 (see Chapter 2: Materials
and M ethods) w ith EcoR I and Msc I and converting the EcoR I site to a bluntend using the Klenow fragm ent of E. coli DNA polym erase I. The EcoR I site of
pSP634 is located w ithin the pSP65 m ultiple cloning site upstream of the EIAV
sequence, and the M sc I site is the same site used to produce pSV720 and 585
and is located w ithin the EIAV env gene. The blunt-end fragm ent was ligated
to Stu I digested pSV2ACAT to produce pSV634.
The plasm id pSV585met was constructed through m ultiple cloning
steps, b u t the net result is the placement of a consensus translational initiation
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signal (GCC GCC ACC AUG G) into the Stu I/S m a I site of pSV585. This was
accomplished by first subcloning a 280-bp BamH I restriction fragm ent of the
pSR-1 cDNA into the unique Bgl II site of the vector pSV2met (provided by
Keith Rushlow) to produce pSV2met280. pSV2met is a derivative of the
aforem entioned pSV2ACAT vector. A synthetic linker containing a consensus
ATG initiation codon was placed into Stu I/H in d HI digested pSV2ACAT to
produce pSV2met. The nucleotide sequence of this synthetic linker is the
following: CCT GCC GCC ACC ATG GAG ATC TCA. The ATG codon is
im bedded in a Nco I site (CCATGG) and a Bgl II site (AGATCT) immediately
follows this codon. There are two BamH I sites in the pSR-1 cDNA, one is
located im m ediately upstream and overlaps the Sma I site in the leader region
(GGATCCCCGGG) and the other is located in the region w here ORF S2 and env
overlap. In order to m ake a construct that contains the same ORF S2 and env
sequences as the pSV585 and pSV720 clones, pSV2met280 was digested with
Sma I and Xho I. The Sma I site lies imm ediately dow nstream and overlaps the
Bgl

n / BamH I hybrid site that lies im m ediately dow nstream of the consensus

ATG codon, and the Xho I site lies dow nstream of the BamH I /B g l II site at the
3'-end of the 280-bp insert from pSR-1. Thus, the net result is the rem oval of all
of the pSR-1 cDNA sequences except for half a BamH I site and half a Sma I site
that overlap each other (ACC AUG GAG ATC CCC, the sequences from pSR-1
are underlined). A Sma I/S a l I restriction fragm ent of pSP720 was then ligated
to the large fragm ent of Sma I / X h o I digested pSV2met280 to produce
pSV585met. The Sma I site of pSP720 is the same Sma I site found in the leader
sequence of the pSR-1 cDNA and the Sal I site of pSP720 lies immediately
dow nstream of the M sc 1 / Sma I hybrid site. Therefore, the pSV585met plasmids
contains the same EIAV sequences as pSV585 w ith the addition of two codons
(ATC CCC) provided by the overlapping BamH I and Sma I sites of pSR-1. This
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plasm id is predicted to produce an amino-terminally truncated form of the
EIAV Tat protein that is initiated from a consensus AUG methionine codon.
The cloning scheme introduces two non-native codons into the 5'-end of the tat
gene, the AUG itself and a GAG codon which w ould encode a glutam ate
residue.
The plasm id pSVS3 was produced by ligating the Pvu 11/Stu I fragment
of pSP-1 (S1/S3 cDNA) to Stu I digested pSV2ACAT. The plasm id pSV3.5kb
w as constructed by digesting a complete proviral clone that was introduced
into the pSV2ACAT vector (pSV2provirus, provided by Keith Rushlow) to
com pletion w ith Sma I. Sma I cuts the proviral DNA in the leader region, in the
pol gene, and in the 5'-end of the env gene. The fragm ent containing the pSV2

sequences, the EIAV LTRs, and the truncated leader region and env genes was
isolated and ligated to an 800-bp Sma I fragm ent from the pSR-1 cDNA clone to
produce the pRLS plasm id. This construct is capable of producing authentic
3.5-kb RNA as a prim ary transcript that is initiated from the EIAV 5-LTR and
polyadenyla ted from the EIAV 3'-LTR. For expression in COS-7 cells the pRLS
plasm id was digested w ith Stu I which cuts in the R region of both LTRs. The
resulting 3.5-kb fragm ent w as subcloned into Stu I digested pSV2ACAT to
produce pSV3.5kb. This construct produces the EIAV 3.5-kb RNA that is
initiated from the SV40 im m ediately early prom oter and polyadenylated by the
SV40 poly A signal.
The S3 frame-shift plasm id, pSV3.5kbAS3, was derived from
pSV3.5kb/LTR. The strategy for creating the frame-shift mutations was to
digest the ORF S3 region w ith Apa I which cuts im m ediately dow nstream of the
splice acceptor site at the 5'-end of ORF S3 (nt 7235). The 4-bp 3'-overhangs
were rem oved w ith T4 DNA polym erase and the plasm id was religated to
create the frame-shift. However, the SV40 polyadenylation signal of pSV3.5kb
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also contains an Apa I site, so the SV40 polyA signal was replaced w ith the
EIAV 3-LTR prior to m aking the frame-shift mutation. This was accomplished
by digesting pSV3.5kb with Spe I and EcoR I to release the SV40 polyA signal
region. The Spe I site lies near the 3'-end of the env gene and the EcoR I site lies
in the vector sequences dow nstream of the polyA site. This sequence was
replaced with a Spe 1/EcoR I restriction fragm ent from the pRLS plasm id
containing the 3' env gene sequences and the EIAV 3'-LTR. The resulting
plasm id was referred to as pSV3.5kb/LTR and was used directly to create the
ORF S3 frame-shift m utation as described above. All transfection plasmids
w ere purified by two rounds of cesium chloride (CsCl) density centrifugation
as previously described (Fordis and H ow ard, 1987).
Plasmid DNA Transfection and CAT Assays
CsCl density gradient purified DNA was used to transfect 60 m m petri
dishes of cells by the calcium phosphate coprecipitation m ethod (Fordis and
H ow ard, 1987). For transfection of EIAV-infected and control uninfected
fibroblasts, ten micrograms of the indicated plasm id DNA was transfected. For
co-transfection experiments of FDD cells, eleven micrograms of the following
combination of plasm ids was transfected: pLTRCAT (5 (ig); pSV(3-gal (1 (ig);
pSV720, pSV585, pSV634, or pSV2ACAT(5|ig). The pSVp-gal plasm id (Promega
Corporation), which contains the bacterial p-galactosidase gene under the
control of the SV40 im m ediate early prom oter, was added to each transfection
to control for transfection efficiency. Cell lysates were prepared 48 hours post
transfection as previously described (Fordis and H ow ard, 1987), and the pgalactosidase activity of the cell lysates from each transfection was m easured
according to the suppliers recommendations (Promega Corporation). The
pSV2CAT (5pg) plasm id was used as a positive control DNA for CAT activity
and w as cotransfected with pSV2Acat (5 (ig) and pSVp-gal (1 |ig). Lysate
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volumes containing equivalent levels of (Lgalactosidase activity w ere assayed
for CAT enzym e activity by the solvent partition m ethod (N eum ann et ah, 1987)
using [14C]butyryl coenzyme A (New England Nuclear, Dupont) and
chloramphenicol (Sigma Chemicals) as substrates.
Results and Discussion
Expression of EIAV Tat in EIAV-infected Primary Equine Cells
W hen this project was initiated the roles of the three ORF proteins in
EIAV infection w ere unknow n, and viral trans-activation of the EIAV LTR had
not yet been dem onstrated for EIAV. During the course of the early
experiments described here, it was reported the EIAV LTR could be transactivated in canine and feline fibroblast cell lines that w ere persistently infected
w ith EIAV (Derse et al., 1987). I examined the ability of persistently-infected
FEK cells and cytopathically-infected FDD cells to exhibit viral trans-activation
by transfecting these cells w ith a CAT reporter plasm id linked to the EIAV LTR.
I was particularly interested in determ ining if indeed these equine cells
expressed trans-acting factors, since low molecular weight multiply-spliced
transcripts, that by analogy to HIV-1 and other lentiviruses w ould presum ably
encode these factors, were present at very low levels and often were un
detectable (Rasty et a l, 1990). This is in contrast to other lentiviruses in which
low molecular w eight transcripts are found at levels similar to other viral
transcripts (Arya et ah, 1985; Davis et ah, 1987).
An examination of trans-activation in a num ber of EIAV-infected
fibroblast cell types was perform ed in order to show that EIAV-infected equine
fibroblasts express a virally-encoded trans-acting factor. Persistently infected
canine (Cf2 Th), feline (FEA), and equine (FEK) cells or cytopathically infected
FDD cells were transfected w ith the pLTRCAT plasm id or a positive control
plasm id, pSV2CAT, that contains the CAT gene under the control of the SV40
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im m ediate early promoter. In order to determ ine the basal transcriptional
activity of the EIAV LTR. in these various fibroblastic cells, uninfected cells of
each cell type w ere transfected with the same plasmids. A t 48 hours post
transfection equivalent levels of total cellular protein w ere assayed for CAT
activity. The data are presented as the CAT activity of each lysate versus time
points taken at ten m inute intervals during the assay (Fig. 26). The data
indicate that the EIAV LTR is an exceedingly weak prom oter in all uninfected
cells tested, since transfection w ith pLTRCAT in these cells showed no
detectable CAT activity under the conditions of this assay (Fig. 26, A-D open
squares). Other assays perform ed using larger am ounts of cell lysate a n d /o r
longer incubation time show ed that the pLTRCAT plasm id does direct CAT
gene expression at very low levels, but clearly above the background level of a
promoterless CAT construct, pSVOCAT (data not shown). The basal level of
CAT expression directed by pLTRCAT in FDD cells was calculated to be 2.2%
of the level from the pSV2CAT plasmid. This is in agreem ent with previously
reported results for the canine and feline cell lines, where the basal level of CAT
expression from the EIAV LTR was m easured at 2.0% and 2.7%, respectively, of
the level of expression from the control pSV2CAT plasm id (Derse et al., 1987).
Clearly, each of the infected cell types dem onstrated distinctive fra«s-activation
of the EIAV LTR (Fig. 26, closed squares), as dem onstrated by CAT activity
several fold higher than that of the positive control plasm id, pSV2CAT (Fig. 26,
closed circles). The highest overall levels of CAT activity directed by the EIAV
LTR w ere detected in FDD cells.
One of the original goals of this line of research, was to quantitatively
com pare the fra^s-activation levels of persistently and cytopathically infected
equine cells. It is customary to use SV40 based plasm ids, such as pSV2CAT, as
a reference to compare relative CAT activities and to control for variation in

Figure 26. CAT assays of uninfected and EIAV-infected cells. A. Canine fetal
thym us fibroblasts (Cf2Th); B. Feline embryonic fibroblasts (FEA); C. Fetal
donkey derm al cells; D. Fetal equine kidney cells. Cells were transfected with
CAT expression plasm ids under control of the EIAV LTR (pLTRCAT) or the
SV40 im m ediate early prom oter (pSV2CAT) and cell lysates were assayed for
CAT activity by the solvent partition m ethod at 48 hours post-transfection. □,
pLTRCAT in uninfected cells; ■ , pLTRCAT in EIAV-infected cells; O,
pSV2CAT in uninfected cells; • , pSV2CAT in EIAV-infected cells.

136

4020 -

CPM [14C] Butyryl Chloramphenicol (x103)

10 -

12 10 -

80
604020-

7
6

5
4
3
2

10

20

30

40

Time (minutes)

137
transfection efficiency. This is believed to be a valid means of quantitating CAT
activity and trans-activation levels from a single cell line, b u t it m ay not be valid
for com parisons m ade betw een cell lines, since the pSV2CAT plasm id contains
the SV40 enhancer element that is know n to exhibit differential activity in
various cell types (Davidson et ah, 1986; Ondek et ah, 1987). Furthermore, it is
difficult to accurately determ ine the precise trans -activation levels of the EIAV
LTR in infected cells due to the barely detectable basal activity of the EIAV LTR
in uninfected cells. The level of CAT activity of the persistently infected FEK
cells w as m ore than 10-fold lower, than that in FDD cells (Fig 26 D., closed
squares). However, the low levels of CAT activity in FEK cells are due in large
part to a resistance of these cells to be transfected by foreign DNA, as evidenced
by the absence of CAT activity directed by the positive control plasm id
pSV2CAT (Fig. 26D., circles). A great deal of time and effort was spent
attem pting to im prove the transfection efficiency of FEK cells. Included in
these attem pts w ere the following: variation in the length of time the cells were
exposed to the calcium phosphate precipitate; variation in the length of time of
the glycerol shock perform ed after removal of the precipitate; pre-treatm ent of
the cells w ith DEAE-dextran at various concentrations; DEAE-dextranm ediated transfection under a num ber of conditions; and cationic liposomem ediated transfection. Another member of our research group has attem pted
to use electroporation to introduce DNA into FEK cells w ithout success. The
CAT assay data presented here represent the best transfection results obtained
and w ere the result of prolonged exposure of the cells to a calcium
phosphate/D N A precipitate (12-18 hours). Due to this resistance of FEK cells
to take u p foreign DNA by any of the m ethods and conditions tested, I decided
not to pu rsu e quantitative comparisons of trans-activation levels in FEK and
FDD cells.
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Infection of FDD cells w ith an FDD-adapted strain of EIAV results in
severe cytopathology and subsequent cell death w ithin about 14 days post
infection. Previous experiments show ed that viral RNA could be detected at 4
days post-infection and appeared to reach maximal levels at 6 days post
infection. This high level expression of viral RNA was m aintained at 8,10, and
12 days post-infection (Rasty et al., 1990). In order to determ ine the levels of
trans-activation through the course of cytopathic infection, a time course
experim ent was perform ed in which EIAV-infected FDD cells were transfected
w ith the pLTRCAT reporter plasm id at 3 to 12 days post-infection, and cell
lysates were harvested for assay of CAT activity 48 hours post-transfection. For
the purpose of this experiment, equal am ounts of total protein from each lysate
was subjected to a one hour CAT assay, and the level of CAT activity m easured
at the end of this hour are represented graphically (Fig. 27). The results of this
experim ent indicate that the level of CAT activity expressed from the EIAV LTR
increases as the infection progresses. The highest level of CAT activity was
attained at 14 days post-infection at a time w hen most cell were exhibiting
severe cytopathology.
The data presented here w ere the first dem onstration of EIAV transactivation in cells of equine origin and dem onstrate that equine fibroblast cells
produce EIAV Tat despite a low abundance of low molecular weight
transcripts. The isolation of the pSR-1 cDNA clone corresponding to the 3.5-kb
RNA that is the predom inant transcript in EIAV-infected FDD cells, and the
finding that this transcript was capable of encoding the EIAV Tat protein in
vitro, led to the proposal that EIAV may express Tat from this envelope-length

message in vivo. The experiments described below involve the utilization of
SV40 replacem ent vectors to express the pSR-1 cDNA in uninfected FDD in

Days Post-infection

Figure 27. Time course of EIAV Tat trans-activation in cytopathically-infected
FDD cells. EIAV-infected FDD cells w ere transfected with the pLTRCAT
plasm id at various time points after infection. 48 hrs post-transfection the cells
w ere harvested and the CAT activity of the lysates w as determined. In this
figure, the final am ount of chloramphenicol converted to [14C]-butyryl
chloramphenicol after a one hour assay is plotted against days post-infection,
which is the num ber of days from infection of the cells w ith EIAV to the time
that they were harvested for CAT analysis.

140
order to determ ine if the 3.5-kb transcript m ay encode the EIAV Tat protein in
vivo.

Expression of EIAV Tat from the Tricistronic pSR-1 cDNA In Vivo
As previously stated, the pSR-1 cDNA clone that I have characterized,
corresponds to the singly-spliced 3.5-kb EIAV mRNA and contains the ORF SI,
ORF S2, and env genes. Other research groups have cloned cDNAs
corresponding to the major m ultiply-spliced EIAV transcript and have shown
that this transcript is capable of encoding the ORF SI and ORF S3 proteins
(Dorn et a l, 1990; Noim an et ah, 1991). The first splicing event in this SI I S3
transcript joins the viral leader to the ORF SI coding sequences and is identical
to the single splicing event identified in the 3.5-kb RNA (Schiltz et al., 1992).
Thus, the 1.5-kb transcript can be derived directly from the 3.5-kb RNA by
additional splicing events involving splice donors and acceptors located
dow nstream of ORF SI. Since it is now clear that the EIAV ORF SI protein is
the viral trans-activator, EIAV Tat (Dorn et al., 1990), and that the 3.5-kb and 1.5kb RNA are identical through the SI gene, I was interested to ascertain if the
pSR-1 cDNA clone could direct the synthesis of the Tat protein in cultured FDD
cells. Towards this end, restriction fragments of the pSR-1 cDNA sequence
w ere subcloned into a eucaryotic expression plasm id, pSV2ACAT. The
construct pSV720 is analogous to the pSP720 transcript described earlier and
contains the 720-bp Stu 1/Msc I restriction fragm ent of pSR-1 subcloned into the
unique Stu I site of pSV2ACAT located between the SV40 im m ediate early
prom oter and polyadenylation signal. Two additional subclones were
constructed, pSV585 and pSV634, which are essentially 5'-deletions of the
pSV720 construct (Fig. 28A). These constructs w ere m ade to determ ine which
sequences are required for EIAV Tat expression in vivo. The pSV585 construct
lacks cDNA sequences between the Stu I (nt 256) restriction site located in the

Figure 28. RNAs corresponding to Tat cDNA expression plasm ids and CAT
assays. A. The 5'-ends of the RNAs expected to be produced in vivo from the
cDNA expression constructs. The first 45 nt of each construct (bold, italics) are
derived from the SV40 im m ediate early leader region. This sequence contains
no AUG codons that m ight serve to initiate EIAV Tat synthesis. The sequence
following the leader region in pSV720 and pSV585 is derived directly from the
pSR-1 cDNA by ligation of the Stu I and Sma I restriction sites, respectively, of
this cDNA to the Stu I site of pSV2CAT. The pSV634 vector contains some
sequences derived from the polylinker of pSP65 (italicized, not bold) that lie
between the SV40 leader and the cDNA sequences. The UGA termination
codon that m arks the 5'-end of the Tat open reading frame is indicated by an
asterisk and is only present in pSV720. The single letter am ino acid codes are
presented beneath the tat codons. pSV634 encodes some additional amino
acids (italicized) not found in pSV720 due to the presence of the pSP65
sequences. The positions of the proposed CUG and AUC translational
initiation codons are underlined along w ith the context nt in the -3 and +4
positions. B. CAT assays of lysates from transfected FDD cells. The cDNA
constructs described above were transfected into FDD cells along w ith
pLTRCAT and an SV40 directed beta-galactosidase expression plasmid. Cell
lysates were assayed for beta-galactosidase expression and volumes of lysate
corresponding to equivalent units of beta-galactosidase activity w ere assayed
for CAT enzym e activity by the solvent partition m ethod of N eum ann et al.,
1987. ■,pSV720; • , pSV634; O, pSV585; □ , pSV2CAT.
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term inal redundant region (R) and Sma I (nt 393) restriction site located in the
leader region. The CUG codon (nt 373-375) and the AUC codon (nt 388-390),
that have independently been proposed to initiate EIAV Tat synthesis (Carroll
and Derse, 1993; N oim an et al., 1991), lie between these tw o restriction
endonuclease cleavage sites, so the pSV585 construct lacks both of these codons.
The pSV634 construct contains the AUC codon b u t lacks the upstream CUG
codon (Fig. 28A). All three constructs are 3'-coterminal extending to the MscI
(nt 5655) restriction site w ithin the env gene. If EIAV Tat synthesis is initiated at
the suggested CUG codon, then pSV720 would contain all the necessary genetic
inform ation for EIAV Tat expression while pSV585 and pSV634 w ould lack the
translational initiation codon for this protein. If EIAV Tat synthesis is initiated
from the AUC codon, then both pSV720 and pSV634 should be able to direct the
synthesis of the Tat protein.
Monolayers of FDD cells were cotransfected with either pSV720, pSV634
or pSV585 and the pLTRCAT reporter plasmid. Cotransfection of pSV720 with
pLTRCAT clearly results in frans-activation of the EIAV LTR as evidenced by
an increase in CAT enzym e activity of more than 60-fold as compared to
transfection w ith the pLTRCAT plasm id alone (Fig. 28B). Cotransfection of
pSV585 resulted in no significant trans-activation of the LTR, suggesting that
sequences residing between the Stu I site within the EIAV R region of the LTR
and the Sma I site w ithin the leader, which include the CUG and AUC codons,
are absolutely required for expression of EIAV Tat from this cDNA clone in
cultured FDD cells. Cotransfection of pSV634 with pLTRCAT resulted in CAT
activity similar to that of the pSV585 cotransfection experiment, indicating that
the AUC codon is incapable of directing the synthesis of the EIAV Tat protein
in FDD cells. These data are consistent with initiation of the EIAV Tat protein
at the CUG codon located w ithin the EIAV leader region.
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I have dem onstrated EIAV Tat synthesis in vivo by cotransfection of the
cDNA corresponding to the 3.5 kb transcript into FDD cells w ith a plasm id
directing CAT gene expression prom oted by the EIAV LTR. The resulting
trans -activation of the LTR, as evidenced by a 60-fold increase in CAT

expression, dem onstrates that functional EIAV Tat protein encoded by ORF SI
is produced. The relatively low levels of trans-activation observed for EIAV as
com pared to those reported for HIV m ay reflect differences in the am ount of
trans-activator protein produced as a result of initiation at the sub-optimal CUG

codon in the EIAV case.
H orses Infected w ith EIAV Produce A ntibodies against the ORF S2 Protein
The predicted protein product of ORF S2 bears no significant sequence
homology to any know n lentiviral protein, and to date no protein product has
been show n to be encoded by ORF S2 in vivo. In an effort to establish w hether
an ORF S2 encoded polypeptide is produced during productive EIAV infection,
I exam ined sera from EIAV infected horses for the presence of antibodies to the
putative ORF S2 gene product. I accomplished this goal by examining the
ability of these sera to recognize the in vitro translated product in an
im m unoprecipitation reaction.
The ORF S2 polypeptide and a portion of the gp90 envelope protein
w ere synthesized in w heat germ extract from a synthetic RNA similar to that
produced by the pSP585 plasm id described above. The transcription template
em ployed in this experiment, pSPS2env, differs from pSP585 in that it includes
sequences from the MscI (5655) to the first Hind III (5775) restriction
endonuclease digestion site in the env gene. This additional envelope sequence
results in the synthesis of a truncated gp90 protein with an apparent molecular
w eight of approximately 20-kd on SDS-polyacrylamide gels, as opposed to the
15-kd truncated gp90 protein of pSP585. The [^Si-labeled in vitro translation
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products w ere im m unoprecipitated with sera obtained from an EIAV-infected
horse followed by SDS-PAGE analysis. Analysis of the in vitro translation
products show ed the synthesis of the 20-kd truncated envelope protein and the
7-kd ORF S2 polypeptide (Fig. 29, lane 1). These labeled products were
im m unoprecipitated w ith increasing concentrations of partially purified IgG
obtained from the serum of an EIAV-infected horse (see Chapter 2 Materials
and M ethods). As anticipated, the truncated gp90 envelope protein reacts
strongly w ith the EIAV-infected horse IgG (IH IgG) fraction at all
concentrations tested (Fig. 29, lanes 2-5). The ORF S2 protein was only faintly
im m unoprecipitated by 8 pg of EIAV-infected horse IgG (Fig. 29, lane 2), but
was clearly im m unoprecipitated with 40 pg of the IgG (Fig, 29, lane 3).
Interestingly, further increases in the am ount of IgG resulted in dramatically
reduced precipitation of the 7-kd S2 protein w ith the concomitant appearance
of a slightly larger (approximately 9-10 kd) protein (Fig. 29, lanes 4 and 5). At
the highest concentration of IgG (400 pg), there was no detectable precipitation
of the 7-kd S2 protein, but a relatively large am ount of the higher molecular
w eight protein. A lthough I cannot be certain that this higher molecular weight
protein is related to the S2 protein, the concomitant disappearance of the 7-kd
S2 protein gives indirect support to the notion that the EIAV-infected horse
anti-sera m ay contain an activity that results in covalent modification of this
protein. Preliminary experiments using the non-binding supernatants from IH
IgG im m unoprecipitations to react with anti-S2 peptide antisera, dem onstrate
that this protein can be precipitated w ith S2-specific antisera and therefore is
S2-related (data not shown). Further experiments will be required to clearly
determ ine if this product is indeed related to the S2 protein and the precise
nature of the putative modification. N either the truncated gp90 nor the
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Figure 29. Imm unoprecipitation of in vitro translated ORF S2 protein with
EIAV-infected horse IgG. M, [14C]-labeled molecular weight standards; lane 1,
[35S]-labeled in vitro translation products from w heat germ extract program m ed
w ith pSPS2env RNA; lane 2, immunoprecipitation (IP) w ith 8 jig of infected
horse (IH) IgG; lane 3, IP w ith 40 |ig of IH IgG; lane 4, IP w ith 80 |ig of IH IgG;
lane 5, IP w ith 400 jig IgG.
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S2 protein dem onstrated any reactivity with control sera from normal
uninfected horses (data not shown).
It has been presented here that the in vitro synthesized S2 protein can be
specifically im m unoprecipitated by EIAV-infected horse sera. Other
researchers in our laboratory have shown that sera from both naturally infected
and experim entally infected horses react w ith synthetic peptides corresponding
to regions of the S2 protein (J. Ball, unpublished results). Characterization of
viral envelope variants propagated from horse m acrophage cultures infected
w ith horse virulent EIAV, has show n that although a num ber of m utations arise
throughout the gp90 coding sequence and in the major coding exon of the S3
protein, no m utations were found in the region where ORF S2 and env overlap
(Alexandersen and Carpenter, 1991). Taken together these data strongly
indicate a role for the ORF S2 gene product during EIAV infection, although no
function has as of yet been defined for this protein.
A ttem pts to Detect the ORF S I, S2 and S3 Proteins In Vivo
M any attem pts were m ade to identify the ORF proteins in vivo both in
EIAV-infected equine cells and in various type of transfected cells. The most
extensive trials involved im m unoprecipitation of cell lysates with ORF-specific
peptide antisera followed by fractionation on SDS-polyacrylamide gels and
transfer to nitrocellulose m em branes for W estern blot detection of the
im m unoprecipitated proteins w ith the same peptide antisera used for
im m unoprecipitation. Early experiments of this type were perform ed using
[125I]-protein A, and later experiments used the more sensitive chemilum inescent detection systems. In short, none of these experiments resulted in
detection of the ORF proteins. There m ay be a num ber of potential reasons for
the inability to detect each of these proteins. In infected cells, these proteins
m ay be temporally regulated and expressed at high levels at only specific times
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during infection. These proteins are also either know n to be or presum ed to be
regulatory proteins, and such proteins often have short half-lives to aid in the
regulation of their activities.
It w as hoped that high level expression of the ORF proteins from SV40based transfection plasm ids expressed in COS-7 cells m ight help to overcome
some of these problems. This expression system typically affords high-level
expression of protein because the plasm ids contain the SV40 origin of
replication, and the COS-7 cells constituitively express the SV40 large T antigen
that is required for replication of the plasm id DNA. Unlike other transient
expression systems, this system allows the plasm id DNA to replicate after
entering the cell, thereby increasing the copy num ber of the transfecting
plasm id in the cell. The ORF proteins expressed from SV40-based plasm ids
w ere not detected by any of the following m ethods using the synthetic peptide
antisera: (1) combined im m uno-precipitation/W estern blotting as described
above; (2) in vivo metabolic cell labeling with [35S]-methionine and [35S]cysteine followed by immuno-precipitation; (3) immunofluorescence assay
(IFA).
One problem w ith transient expression of proteins by DNA transfection
is that at best about 10% of the cell population will take up and express the
transfecting DNA. It is also cumbersome to transfected large num bers of cells
by this method. Most of the transfections described here were perform ed in
small petri dishes of 60 m m in diameter. In order to produce larger quantities
of EIAV Tat (SI), canine fibroblast cells were cotransfected w ith the pSV720 Tat
expression plasm id and a neomycin resistance gene expression plasm id pJNL-1
(kindly provided by Gus Kousoulas, Departm ent of Veterinary Microbiology
and Parasitology, Louisiana State University School of Veterinary Medicine,
Baton Rouge, LA). By propagating the transfected cells over an extended

149
period of time in m edia supplem ented w ith the neomycin analog G418, cells
that had integrated copies of the neomycin resistance gene into their genomes
w ere selected. Single cell clones of the neomycin resistant cells were isolated
and allowed to divide into a clonal population of neomycin resistant cells.
These clonal populations w ere then transfected w ith the pLTRCAT plasm id to
determ ine if they had also inserted the EIAV tat gene into their genomes. CAT
assay results from a num ber of clones showed that they did indeed express the
EIAV tat gene (data not shown). These cells, that constituitively express the tat
gene, should provide a m eans to isolate a large am ount of the EIAV Tat protein,
since every cell expresses the protein. Large quantities of cell extract were
im m unoprecipitated w ith the SI peptide rabbit IgG followed by W estern
blotting w ith the same antibody preparation. Unfortunately, these attem pts
also failed to detect the Tat protein.
The expression of EIAV Tat from a non-AUG codon is likely to result in
very low intracellular protein levels. Although some proteins are known to be
expressed efficiently in vitro from non-AUG codons, they are not expressed at
high levels in vivo (Bernards and de la Monte, 1990; Florkiewicz and Sommer,
1989). Thus, I turned m y attention to im proving the translational initiation
sequence of Tat in an attem pt to elevate its synthesis to m ore readily detectable
levels. Towards this end, I produced a plasm id construct, pSV585met, that
places the tat gene in-frame with a consensus AUG methionine codon. The net
result of the cloning m anipulations employed to generate this construct (see
Materials and Methods) is a 24-bp insertion into the Stu 1 /Sma I hybrid
restriction site of pSV585 (Fig. 30A). Included in this 24-bp sequence is a
Kozak's consensus m ethionine AUG initiation codon (GCC GCC ACC AUG G).
This m anipulation resulted in replacement of the first five codons of EIAV tat
(LADRR) with codons for a methionine and a glutam ate residue (M J , The
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Figure 30. Expression of EIAV Tat from a consensus m ethionine codon. A. A
schematic diagram of the structure of the pSV585 plasm id is shown at top with
the nucleotide sequence containing the consensus methionine codon that was
inserted into the Stu I /S m a I site shown below. The isoleucine (I) and proline
(P) are part of the native Tat structure. The m ethionine (M) and glutam ate (E)
residues are added to the am ino term inus of Tat as a result of the cloning.
B. CAT assay of pSV585met transfected into FDD cells. ■, pLTRCAT
cotransfected w ith pSV2ACAT; a , pLTRCAT cotransfected w ith pSV720; • ,
pLTRCAT cotransfected w ith pSV585met.
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ability of the pSV585met construct to express Tat was examined by
cotransfection of this plasm id w ith pLTRCAT into FDD cells. The pSV585met
plasm id resulted in trans-activation levels of the EIAV LTR that were on
average 5 to 6-fold greater than those of the pSV720 plasmid (Fig. 30B)
However, attem pts to detect the Tat protein produced by pSV585met directly
by im m unoprecipitation and W estern blotting of transiently transfected FDD
cells, yielded no detectable EIAV Tat protein.
All of these efforts w ere dependent upon detection of the Tat protein
using rabbit antisera produced against a synthetic peptide corresponding to a
region of the Tat protein. Although this peptide antisera was reactive with the
in vitro synthesized Tat protein (see Chapter 2, Fig. 12), a relatively large

am ount of in vitro translation product was required to precipitate this protein.
A fairly low percentage (approximately 5-10 %) of the in vitro synthesized Tat
protein was precipitated even w hen using 100 pg of partially purified IgG.
These findings indicated that although the antibody was highly specific for the
Tat protein, either its affinity for the protein a n d /o r its titer in the overall pool
of rabbit IgG was not very high. In an attem pt to circumvent potential
problem s w ith antibody affinity, the Tat protein was expressed as a fusion to 5
repeated copies of a 13 am ino acid sequence of the c-Myc oncoprotein that
contains an epitope recognized by a monoclonal antibody. The resulting fusion
protein contains 65 am ino acids placed amino-terminal to the Tat protein
coding region. This w ork w as perform ed in collaboration w ith Pat DiMario,
w ho routinely uses Myc-tagged proteins for detecting proteins expressed in
Xenopus oocytes. This expression system involves the microinjection of in vitro
transcripts into oocytes followed by detection of the tagged protein by
immunofluorescence. In vitro transcripts containing the Myc-tagged Tat protein
and provided to Pat DiMario for analysis. However, no Tat protein could be
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detected in this system. I am currently confirming the integrity of the in vitro
transcription plasm id by DNA sequencing. The in vitro transcripts could also
be tested by in vitro translation followed by im m unoprecipitation w ith either SI
peptide antisera or c-Myc monoclonal antibody. In sum m ary, a wide variety of
techniques have been em ployed in order to detect the Tat protein in vivo, but
none of these were successful.
Early experiments for the detection of the S2 protein in transfected cells
w ere perform ed using the pSV585 expression construct. This construct was
preferred over the pSV720 construct, since it is not capable of Tat synthesis and
the ORF S2 cistron w ould be the first cistron in an S2/env bicistronic RNA. The
subsequent cloning and characterization of Tat cDNAs (Stephens et al., 1990;
N oim an et al., 1991) show ed the presence of a functional splice donor
im m ediately dow nstream of the Tat UAA termination codon. There is also a
functional splice acceptor located in the region w here the ORF S2 and env genes
overlap. The presence of these splicing signals indicates that the prim ary
transcript encoded by the pSV585 construct could be spliced in a m anner that
results in the removal of the ORF S2 and env translational initiation codons.
Depending upon the efficiency of this splicing event, it m ay not be possible to
express sufficient S2 protein from this construct to detect by the immunological
m ethods em ployed here.
By analogy to HIV-1, the expression of proteins from partially-spliced
envelope-length RNAs could be achieved through the action of a Rev-like
protein. A lthough the S3 protein had not been directly show n to have Rev-like
function in EIAV at the time that these experiments were perform ed, there was
some indirect evidence for Rev function from S3 defective proviruses and from
lim ited sequence homology w ith the HIV-1 Rev protein (Stephens et al., 1990).
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A plasm id w as constructed that was analogous to pSV720, b ut contained
the entire envelope coding region. This construct, pSV3.5kb, was expected to
produce a prim ary transcript of approximately 4.0-kb that could be spliced to
produce 1.8-kb EIAV S1/S3 mRNA. If the EIAV S3 protein does indeed harbor
Rev-like activity, then its synthesis from the spliced transcript should allow the
expression of unspliced 4.0-kb RNA. COS-7 cells w ere transfected with the
pSV3.5kb plasm id DNA and total cellular RNA was isolated 48 hours post
transfection for analysis by N orthern blot hybridization. The hybridization
probe used was a 400-bp random prime-labeled Nco I/S s p I restriction fragment
from pSV720. The Nco I site of pSV720 lies about 45-bp upstream of the SV40
early transcription initiation site and the Ssp I site lies near the end of ORF SI
about 10-bp upstream of the splice donor used to produce the S1/S3 RNA. The
choice of a probe that hybridizes to sequences in the 5'-end of the transcripts
upstream of all splicing signal allows for equivalent hybridization of the probe
to either spliced or unspliced transcripts. The results clearly indicate the
presence of three EIAV-specific transcripts (Fig. 31). The predom inant
transcript w as the 4.0-kb full-length unspliced RNA and the small 1.8-kb
m ultiply-spliced transcript w as present, but at levels that were several fold
lower than the unspliced RNA. An additional transcript of interm ediate size
(2.2-kb) was also observed and is likely to represent a partially-spliced
transcript, that is only one of the two introns are removed.
These data indicate that the pSV3.5kb plasm id directs the synthesis of
high levels of unspliced RNA in COS-7 cells. However, I was not able to detect
synthesis of the S2 protein from transfected COS-7 cells by either W estern
blotting of im munofluorescence assays. It is likely that the level of expression
of the S2 protein is adversely affected by the presence of uridine residue in the
-3 position relative to the AUG initiation codon. Expression strategies designed
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Figure 31. N orthern blot analysis of pSV3.5kb RNAs in transfected COS-7 cells.
Lane 1, RNA isolated from control untransfected COS-7 cells; Lane 2, RNA
isolated from COS-7 cells transfected w ith pSV3.5kb; M, RNA molecular weight
standards in kilobase pairs (Life Technologies, Inc.).
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to im prove the context of the S2 initiation codon may aide in detection of this
protein.
The S3 protein was not detected in EIAV infected equine cells or COS-7
cells transfected w ith the pSVS3 plasm id using rabbit antisera produced against
a synthetic peptide. The pSVS3 plasm id contains the S3 sequences taken from a
cDNA clone corresponding to the S I/S3 transcript. This transcript results from
the splicing of four exons: (1) the EIAV leader exon; (2) the ORF SI exon; (3) an
exon derived from the gp90 coding region of the env gene; (4) the ORF S3 exon.
The envelope sequences from exon 3 are spliced in-frame with the ORF S3
coding sequences and could provide a translational initiation codon for
expression of the S3 protein. I available a panel of monoclonal antibodies that
w ere produced to m ap epitopes on the EIAV gp90 envelope glycoprotein (Ball,
1990). One of these, mab86, recognizes an epitope, gp90A, located w ithin the
region of gp90 that is spliced to ORF S3. Therefore, this antibody may not only
react the gp90 protein, but m ay also recognize the S3 protein. This monoclonal
antibody was used in an attem pt to detect the S3 protein in EIAV-infected
equine cells. EIAV-infected FDD cells harvested at 6 days post-infection and
persitently-infected FEK cells w ere lysed in a detergent buffer and equivalent
am ounts of protein from each lysate were im m unoprecipitated with the mab86
monoclonal antibody. The im m une-precipitates were fractionated on a 15%
polyacrylam ide gel and transferred to a nitrocellulose mem brane for W estern
blot detection of the im m unoprecipitated protein. The blot was probed with
the mab86 monoclonal antibody followed by a rabbit anti-mouse IgG antibody
and finally w ith a goat anti-rabbit peroxidase conjugated antibody. The blot
was visualized by incubating with a peroxidase-activated chemiluminescent
detection reagent. A protein of approximately 20-kd was detected in both
EIAV-infected FDD cells (Fig. 32, lane 2) and FEK cells (Fig. 32, lane 4) b u t not
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Figure 32. W estern blot analysis of the S3 protein in EIAV-infected equine cells.
Lane 1, uninfected control FDD cells; lane 2, EIAV-infected FDD cells 6 days
post-infection; lane 3, control FEK cells; lane 4, EIAV-infected FEK cells.

157
in uninfected control cells (Fig. 32, lanes 1 and 3). The molecular w eight of this
protein is similar to that previously reported for the S3 protein (Saman et al.,
1990). Since I was unable to detect this protein with S3 peptide antisera, I
cannot definitively rule out the possibility that this protein m ay be a
degradation product of the gp90 envelope protein. Interestingly, the gp90
protein was unable to be detected in this experiment. The interaction of gp90
w ith the gp45 transm em brane protein is known to be easily disrupted. It m ay
be that the extensive w ashing of the cells prior to lysis m ay have rem oved the
majority of the gp90 protein. Alternatively, the gp90 protein may have been
unable to efficiently enter the 15% gel used in this experiment or m ay have not
been efficiently transferred to the nitrocellulose membrane. The intense band
near the top of the autoradiograph, that is found in all lanes, represents the
heavy chain of the monoclonal antibody used to im m unoprecipitate the S3
protein. This protein is recognized by the rabbit anti-mouse IgG used in the
detection process. The appearance of this band at near equivalent intensity in
each lane indicates that near equivalent am ounts of antibody were used to
im m unoprecipitate each sample and that the recovery of the im m une
complexes, their application to the gel, and the transfer of the fractionated
proteins to the m em brane were similar for each of the four samples. The 20-kd
detected in this experim ent actually appears as a doublet w ith the upper band
being the major protein. This lower band may represent an unphosphorylated
form of the EIAV Rev (S3) protein. The HIV-1 Rev protein is know n to be
phosphorylated on serine residues, and the phosphorylation can be augm ented
by phorbol esters suggesting phosphorylation by protein kinase C (Hauber et
al., 1988). I have analyzed the amino acid sequences of both the HIV-1 Rev

protein and the EIAV S3 protein for the presence of consensus phosphorylation
sites. Both proteins contain three potential phosphorylation sites for casein
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kinase H (S, T X X D, E; w here X may be any amino acid), and the HIV-1 Rev
protein contains tw o potential protein kinase C phosphorylation sites (S, T X R,
K) while S3 contains three. Thus, it appears that the S3 protein has the potential
to be phosphorylated, b u t no such modification has yet been reported for the
EIAV S3 protein.
By analogy to HTV-1 and other lentiviruses, the EIAV Rev (S3) protein is
expressed from a multiply-spliced transcript and is expected to be present early
in the infection cycle. The FDD cells used above were harvested at 6 days postinfection at a time w hen all of the viral RNAs are expressed at high levels
(Rasty et ah, 1990). In order to examine the tem poral expression of the 20-kd
protein detected above, lysates of FDD cells harvested at various times after
infection w ere subjected to W estern blot analysis w ith the mab86. Each time
point corresponded to cells from a single 75 cm2 flask of cells, and all cell
lysates w ere norm alized to contain equivalent levels of protein. The 20-kd
protein was clearly evident at 20 hours post-infection (Fig. 33, lane 4) and was
unable to be detected at the previous time point of 8 hours post-infection (Fig.
33, lane 3). The level of the protein continues to increase throughout the early
phase of the infection cycle and appears to reach a m axim um somewhere
betw een 2 and 5 days post-infection (Fig. 33, lane 6-7). The appearance of this
protein w ithin 8-20 hours post-infection, at a time w hen the 3.5-kb env RNA can
not be detected (Rasty et ah, 1990), is consistent w ith w hat one w ould expect for
the expression of the S3 protein from an early viral mRNA and strongly argues
against this protein being a gp90 degradation product.
As a m eans to obtain m ore compelling evidence that the 20-kd protein
detected in equine cells is indeed the S3 protein, COS-7 cells were transfected
w ith a S3 cDNA expression plasm id, and the S3 protein produced was
com pared to that produced in equine cells. Although the cDNA em ployed in
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Figure 33. Time course of S3 expression in EIAV-infected FDD cells.
Individual 75 cm2 flasks of FDD cells w ere infected with an FDD-adapted strain
of EIAV at a multiplicity of infection of 1. Cells were harvested at the indicated
times after infection and lysed in a detergent buffer. Equivalent am ounts of
protein from each time point was subjected to im m unoprecipitation w ith the
M86 monoclonal antibody, fractionated on a 15% polyacryalm ide gel,
transferred to a nitrocellulose m embrane, and the m em brane probed w ith the
M86 antibody. Lane 1, uninfected control FDD cells; lane 2 ,4 hours post
infection; lane 3 ,8 hours post-infection; lane 4,20 hours post-infection; lane 5,
24 hours post-infection; lane 6,48 hours post-infection; lane 7,5 days post
infection; lane 8 ,7 days post-infection; M, prestained rainbow m olecular
weight standards (Amersham Corporation).
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this experim ent is derived from the S1/S3 multiply-spliced RNA, the pSVS3
plasm id was designed to lack sequences required for expression of the Tat
protein. The SI I S3 cDNA w as digested with Pvu II in the SI coding region and
Stu I in the redundant region of the 3-LTR. The resulting S3-containing

fragm ent was subcloned into the Stu I site of pSV2ACAT to generate pSVS3.
This plasm id was transfected into COS-7 cells, and cell lysates w ere subjected to
im m unoprecipitation/W estern blot detection w ith mab86 48 hours post
transfection. The W estern blot result indicates that transfected COS-7 cells
specifically express a protein of approximately 20-kd that reacts w ith mab86
(Fig. 34A, lane 4). This protein does, however, appear to m igrate slightly faster
than the 20-kd protein detected in EIAV-infected FDD cells (Fig. 34A, lane 2). It
is difficult to precisely com pare the mobilities of the proteins detected into these
two samples because of the large am ount of the protein precipitated by mab86
antibody from both cell types.
In a separate experim ent using less cellular lysate, it was m ore obvious
that the two proteins do not have the same mobility (Fig. 34B). In this gel
system, the two forms of the 20-kd protein produced in EIAV-infected FDD
cells were also more clearly resolved, although there is very little of the lower
molecular weight form in this particular sample (Fig. 34B, lane 1). The S3
protein produced in the transfected COS-7 cells does appear to co-migrate w ith
the low molecular weight form of the 20-kd protein produced in FDD cells, and
there is a very small am ount of protein in the pSVS3-transfected COS-7 that
does co-migrate with the high molecular form detected in FDD cells.
From these data, it is tem pting to speculate that the mab86-reactive 20-kd
proteins of EIAV-infected FDD cells and pSVS3-transfected COS-7 cells may
indeed be S3-related proteins that differ in their phosphorylation state. It is
possible that some virally-encoded factor, that w ould be lacking in the
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Figure 34. Com parison of the S3 proteins expressed in EIAV-infected FDD cells
and COS-7 cells transfected w ith a S3 cDNA expression plasmid. A. Lane 1,
U ninfected FDD cells; lane 2, EIAV-infected FDD cells; lane 3, untransfected
COS-7 cells; lane 4, COS-7 cells transfected w ith the pSVS3 cDNA expression
construct. B. Lane 1, EIAV-infected FDD cells; lane 2, pSVS3 transfected COS7 cells.
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transfected COS-7 cells, may be required for efficient post-translational
modification of the S3 protein. Alternatively, there m ay be inherent differences
between FDD and COS-7 cells that result in differential post-translational
modification of the S3 protein.
Earlier in this section, the plasm id construct pSV3.5kb w as described
which prim arily expresses an unspliced 4.0-kb envelope-length RNA in
transfected COS-7 cells. I speculated that the synthesis of the S3 protein from a
fully-spliced RNA early after transfection m ight allow the accumulation of the
unspliced RNA, if S3 functions in a m anner analogous to HIV-1 Rev. The
ability of the pSV3.5kb construct to direct the expression of S3 protein in
transfected COS-7 cells was examined. This construct produces an S3 protein
w ith similar mobility to that produced in EIAV-infected FDD cells (Fig. 35, lane
3). Thus, there do not appear to be cell-specific differences between FDD and
COS-7 cells that allow for proper modification of the S3 protein in FDD cells. If
indeed there are virally-encoded factors that aide in post-translational m odi
fication of the S3 protein, then those factors m ust also be encoded by the
pSV3.5kb construct. It is tem pting to speculate the S2 protein m ay play such a
role, since it has yet to be assigned a function in viral infection. Further
experim entation will be required to explore this possibility.
Further support for the identification of the 20-kd protein as the S3
protein was obtained from m utational analysis of the pSV3.5kb construct. The
unique Apa I restriction site in this construct found im mediately dow nstream of
the splice acceptor site within ORF S3 was used to create a frameshift mutation.
The pSV3.5kb vector was digested w ith Apa I and the 4-base cohesive ends
w ere rem oved w ith T4 DNA polymerase. The plasm id was religated and
resulted in a 4 bp deletion near the 5'-end of the major ORF S3 coding exon.
This deletion also results in frameshift m utation of the gp45 protein but does
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Figure 35. Expression of the S3 protein in transfected COS-7 cells. The S3
protein was detected in transfected COS-7 cells w ith mab86 by W estern
blotting. Lane 1, control COS-7 cells; lane 2, pSVS3-transfected cells; lane 3,
pSV3.5kb-transfected cells; lane 4, pSV3.5kbAS3-transfected cells.
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not affect the gp90 coding region. This plasm id (pSV3.5kbAS3) was transfected
into COS-7 cells that were subsequently analyzed for expression of the 20-kd
protein. The results show ed that no 20-kd protein was produced by this
construct (Fig. 35, lane 4). This plasm id was, however, able to efficiently
produce the Tat protein as evidenced by trans-activation of the EIAV LTR upon
co-transfection of the plasm id w ith a pLTRCAT construct (data not shown).
This indicates that this plasm id is capable of expressing EIAV-specific
transcripts and proteins. The lack of detection of the 20-kd protein when
disrupting the S3 reading fram e w ithout affecting the gp90 coding region,
argues that this protein is indeed S3 and not a degradation product of gp90.
There are at least three possibilities that might explain the differential mobility
of the S3 proteins produced in COS-7 cells from the pSVS3 and pSV3.5kb
constructs. The first is that there could be some sequence aberration in the
pSVS3 construct that produces an altered protein. It seems unlikely that a
m utant protein w ould produce co-migrating species that differed in relative
abundance in FDD and COS-7 cells (Fig. 34). A second possibility is that the
splice sites utilized in the RNA from which the S3 cDNA was cloned m ay be
different from those actually utilized in these cells. This also seems an unlikely
possibility, since cDNAs identical to this one have been independently cloned
by a num ber of other laboratories (Stephens et a l, 1990; N oim an et al. 1991;
Biesel et a l, 1993) and no alternatives have yet been identified. Furthermore,
the higher m olecular weight product is not likely to be produced by cell-typespecific alternative splicing since it can be detected in all three different cell
types examined: FDD, FEK and COS-7. The third possibility is that there may
be a virally-encoded protein that regulates the post-translational modification
of the S3 protein. Since the pSVS3 construct is only capable of encoding the S3
protein, the putative protein that modifies S3 w ould not be present in cells
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transfected w ith pSVS3 alone. This putative factor w ould have to be produced
by the pSV3.5kb construct, since this construct does produce the higher
molecular w eight form of the S3 protein. This construct contains the env gene
and three small ORFs S I, S2 and S3, it is tem pting to speculate that the S2
protein m ay be this putative regulator since the role of the others are well
defined.
The results presented here confirm that the S3 protein uses a small
region of the enu-coding region to provide a translational initiation signal, and
th at the S3 protein can be detected with a monoclonal antibody that recognizes
an epitope of gp90 that lies near its amino terminus. The monoclonal antibody
recognizes tw o forms of the 20-kd S3 protein that are similar in molecular
weight. The relative distribution of these two forms can be altered by
expression of other EIAV proteins either by viral infection or transfection of
cDNA expression vectors. The low molecular weight form predom inates in the
absence of other EIAV proteins, while the high molecular form is favored when
the Tat, S2, and envelope proteins are co-expressed with the S3 protein.

CHAPTER 4
SUMMARY, CONCLUSIONS, AND FUTURE STUDIES
Sum m ary and Conclusions
In this dissertation, the coding potential of the singly-spliced EIAV 3.5kb RNA was examined in vitro. Restriction fragments of a cDNA
corresponding to the 3.5-kb RNA were subcloned into the pSP65 in vitro
transcription vector. The pSP720 transcription plasm id contains the entire SI
and S2 open reading frames (ORFs) and a 5' portion of the env gene. Synthetic
transcripts produced from this plasm id were translated in w heat germ extracts
and show n to encode three distinct proteins. These were identified by
im m unoprecipitation as the ORF SI-encoded EIAV Tat (SI) p ro te in , the ORF
S2-encoded polypeptide (S2), and a truncated gp90 envelope protein (Agp90).
Interestingly, the Tat protein was efficiently produced in the w heat germ
in vitro translation system even though the tat ORF lacks an ATG initiation
codon. The pSP585 transcription plasmid, which lacks the first 1.6 codons of the
tat ORF, was unable to produce the Tat protein in vitro. These first 16 codons

include a CUG (CUG-373) codon and an AUC (AUC-388) codon each of which
has independently been claimed to initiate Tat synthesis. The in vitro
transcription plasm id pSP634 was constructed to address w hether AUC-388
could initiate Tat synthesis in the w heat germ in vitro translation system. This
construct is similar to the pSP585 construct, but it only lacks the first 14 codons
of the tat ORF. AUC-388 is the 15th codon in the tat ORF, so the pSP634
construct retains AUC-388 while the pSP585 construct lacks it. In vitro
translation of pSP634 RN A resulted in the synthesis of the S2 and Agp90
proteins only. The inability of this construct to direct the synthesis of the Tat
protein suggests that the presence of AUC-388 is insufficient for the initiation of
Tat translation in the w heat germ system.
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The in vitro analysis of the sequences required for the expression of the
Tat protein w ere also confirmed in vivo. The same cDNA restriction fragments,
that w ere used to create the in vitro transcription plasm ids described above,
w ere subcloned into a eucaryotic expression vector and transfected into FDD
cells w ith a pLTRCAT reporter plasmid. Cell lysates w ere assayed for CAT
activity to determ ine the fraws-activation capabilities of these constructs. These
experim ents show ed that only the pSV720 plasm id, which contains the entire
tat ORF w as capable of trans-activating the EIAV LTR. The pSV585 plasm id

which lacks CUG-373 and AUC-388 and the pSV634 plasm id that contains
AUC-388 but lacks CUG-373 were incapable of trans-activating the EIAV LTR.
These findings indicate that AUC-388 is insufficient to direct Tat synthesis in
vivo as well as in vitro and suggest that CUG-373 may be the Tat initiation

codon.
The amino-terminal sequence of the in vitro synthesized Tat and S2
proteins w ere analyzed in order to determ ine their respective initiation codons.
The S2 protein was readily sequenced, and was found to initiate from the first
AUG in ORF S2. This AUG codon lies in an unfavorable sequence context for
translation initiation (UAU AUG G) due to the presence of a uridine residue in
the -3 position, however the S2 protein was readily detectable in w heat germ
extract translations program m ed with the pSP720, pSP634 and pSP585 RNAs.
The Tat protein was initially unable to be sequenced, m ost likely due to the
presence of an unknow n blocking group on the amino terminal residue. The
possibility that this blocking group m ight be an acetyl group was examined by
translating pSP720 RNA in w heat germ extracts that had been depleted of the
acetyl group donor acetyl coenzyme A. However, this treatm ent did not result
in the production of Tat protein that was m ore amenable to sequence analysis,
suggesting that the putative blocking group is not an acetyl moiety. Limited
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amino-term inal sequence analysis of the Tat protein was obtained by stopping
the translation reaction after 30 m inutes of incubation, while the rate of
synthesis was still near maximal. It was hoped that the rate of translation at
this tim e m ay be greater than the rate of the reaction that results in the addition
of the blocking group. This could allow some Tat protein to be trapped in an as
yet unblocked form. Sequence analysis of [3H]-arginine labeled Tat protein
prepared in this m anner, clearly dem onstrated two consecutive peaks of
radioactivity corresponding to the second and third amino acid residues of the
protein. This arrangem ent of arginine residues is precisely w hat w ould be
expected if the Tat protein initiates from CUG-373 and the initiator methionine
is rem oved by the am ino peptidase activity of the w heat germ extract. From
these data we conclude the EIAV Tat protein initiates from CUG-373 and that
the am ino term inus is blocked by an undeterm ined functional group.
One of the original goals of this research was to com pare the efficiency of
translation of the various cistrons of the pSP720 RNA in the w heat germ and
rabbit reticulocyte in vitro translation systems. This synthetic transcript was
translated efficiently in w heat germ extracts as evidenced by amino acid
incorporation levels that w ere on average 20 to 30% of those of BMV control
RNAs. The CUG initiation codon of the tat cistron and the sub-optimal AUG
codon of the ORF S2 cistron were apparently efficiently recognized by the
w heat germ ribosomes, since these tw o proteins accounted for about 80% of the
total protein synthesized, while the Agp90 protein accounted for only 20%.
Translation of this RNA in reticulocyte lysates resulted in very low levels of
am ino acid incorporation. Limitations on the am ount of lysate that can be
loaded onto polyacrylamide gels w ithout appreciable distortion from unlabeled
hem oglobin in the lysate, m ade analysis of the reticulocyte translation products
difficult. Some data was obtained by exposing autoradiographs for extended
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periods of time, how ever the lack of complete resolution of the Tat and S2
bands m ade quantitation of these proteins impractical. The limited data that
w as obtained d id appear to be similar to that obtained in the w heat germ
system. Specifically, the CUG-initiated Tat protein appeared as the m ost
prom inent band, while significantly less S2 protein was synthesized, and no
detectable Agp90 protein w as produced.
The mechanism of translation of the three dstrons in w heat germ
extracts w as exam ined by translating the pSP720 RNA in the presence of
m 7GpppG cap analog. In nearly all cases, eucaryotic translation initiation is
believed to occur by binding of the 40S ribosomal subunit to the 5' cap structure
of the mRNA followed by its scanning to the first AUG codon in a favorable
context for translational initiation (Kozak, 1992). M ore recently, capindependent internal initiation models have been proposed for a num ber of
viral and cellular RNAs (reviewed by O h and Sam ow, 1993). Addition of cap
analog to the translation m ixture should severely reduce cap-dependent
translation initiation, but have little effect on internally initiated cistrons. In the
case of the pSP720 RNA, the overall translation level was severely reduced by
the addition of cap analog and gel analysis indicated that each of the three
cistrons w ere proportionately affected. These results argue against an internal
initiation mechanism for the translation of either the ORF S2 or env cistrons,
and support a leaky ribosom e scanning mechanism for translation of these
cistrons. The EIAV Tat protein and the ORF S3-encoded Rev-like protein have
been show n by other researchers to be encoded by a small bicistronic RNA of
about 1.5-kb in length (Carroll and Derse, 1993). These researchers have used
site-specific m utagenesis to change the Tat CUG codon to an AUG and have
concluded that the synthesis of the Rev protein is dependent upon a weak
translation initiation codon for the Tat protein. Similar m utational studies on

170
the Tat and S2 initiation codons in the tricistronic 3.5-kb RNA should be
perform ed to m ore precisely delineate the mechanism of translation of the
cistrons in this RNA.
In vitro translation systems are know n to utilize non-AUG codons and

AUG codons in sub-optimal sequence contexts much more readily than they are
utilized in vivo (Kozak, 1989b). However, the ionic conditions of the w heat
germ translation system m ay be altered to more accurately reflect in vivo
translational initiation from these codons (Kozak, 1989b). The effect of changes
in m agnesium and potassium ions in the translation reaction on the relative
initiation efficiency of each of the three cistrons of pSP720 RNA was examined.
Low levels of potassium ion were found to favor translational initiation at the
CUG codon of the SI Tat protein. Increases in potassium ion concentration
resulted in decreased translation from the CUG codon associated w ith a
concomitant increase in the levels of the S2 and the Agp90 proteins. Increases in
the m agnesium ion concentration favored synthesis of the CUG-initiated Tat
protein. Thus, the CUG codon was least efficiently recognized at the lowest
concentration of m agnesium ion tested and the highest level of potassium ion
tested. The efficiency of translational initiation from the Tat CUG codon in the
pSP720 RNA was analyzed by perform ing co-translation experiments of this
RNA w ith brom e mosaic virus (BMV) RNA 4. W hen the tw o RNAs were
present in equim olar am ounts, the Tat protein was found to be produced at a
level of approxim ately 20% of that of the BMV coat protein that was encoded
from BMV RNA 4. These data quantitatively confirmed that the CUG initiation
codon of the pSP720 RNA is recognized w ith high efficiency in the w heat germ
in vitro system under conditions that optimize amino acid incorporation.

The first dem onstration of EIAV Tat activity in equine cells is presented
here. The Tat activity in cytopathically-infected equine cells was shown to
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increase throughout the infection cycle. These increases in Tat activity parallel
increases in the level of the 3.5-kb, which is unusually high in FDD cells. The
levels of the m ultiply-spliced tat/rev RNA do not change appreciably during
this same time span. These data provide indirect evidence that the 3.5-kb RNA
m ay indeed produce the Tat protein in vivo. The in vitro synthesized S2 protein
was show n to react w ith sera obtained from ELAV-infected horses. Although
there has been no direct identification of the S2 protein in EIAV-infected cells,
the fact that EIAV-infected horses produce antibody to this protein provided
evidence that this protein is produced during infection.
The expression of the EIAV S3 (Rev) protein from an AUG codon
provided by the env gene through an RNA splicing event was examined in vitro
and in vivo using a monoclonal antibody directed against the gnu-encoded gp90
protein. W heat germ extracts program m ed w ith an in vitro transcript derived
from a Rev cDNA resulted in the translation of a 20-kd protein. This protein
could be im m unoprecipitated w ith peptide antisera directed against sequences
encoded by ORF S3, the second coding exon of Rev (rev-2), and a monoclonal
antibody directed against an amino-terminal epitope of the gp90 envelope
protein. These results indicate that env gene sequences provide the first coding
exon of the EIAV rev gene. The 20-kd Rev protein could also be detected in
cells transfected w ith a Rev cDNA expression vector and in EIAV-infected cells.
The Rev protein detected in infected cells occurs in tw o forms w ith similar
sizes, the larger form being the m ost abundant. The Rev cDNA expression
vector (pSVS3) was only capable of producing the lower molecular weight
form. An expression vector that produces the 3.5-kb RNA, which can be spliced
in vivo to the 1.5-kb tat/rev RNA, was able to produce the higher molecular

w eight for of Rev. These data m ay indicate that the Rev protein is specifically
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m odified in EIAV-infected cells by a protein encoded by the 3.5-kb RNA or its
spliced derivatives.
In conclusion, the EIAV 3.5-kb has been shown to be tricistronic in vitro,
since it is capable of encoding the Tat (SI), S2 and envelope proteins. The Tat
protein does not appear to be initiated from AUC-388 in vitro or in vivo, and
am ino-term inal sequence analysis is consistent with initiation at CUG-373. The
Tat protein produced in vitro appears to be blocked by an undeterm ined
functional group. U nder standard translation conditions that optim ize amino
acid incorporation, the Tat, S2, and Agp90 proteins were synthesized at a molar
ratio of approxim ately 2:2:1. Alterations in the levels of potassium and
m agnesium ions of the translation system could reduce the translational
efficiency of the CUG-initiated cistron w ith a concomitant increase in the
efficiency of expression of the dow nstream cistrons. The S2 protein produced
in vitro could be specifically im m unoprecipitated w ith sera obtained from

EIAV-infected horses indicating that this protein is produced during infection.
The ORF S3-encoded Rev protein could be detected both in vitro and in vivo
w ith a monoclonal antibody directed to an epitope located near the amino
term inus of the gp90 protein. Thus, the Rev protein is produced from an AUG
initiation codon provided by sequences w ithin the env gene of EIAV through an
RNA splicing event.

Future Studies
A goal of this research, that was not able to be attained, was to determine
w hether EIAV 3.5-kb RNA was tricistronic in vivo. A num ber of obstacles m ust
be overcome before this question can be addressed. O ne of these obstacles is
the lack of high titer antisera that will allow the detection of the SI Tat protein
and the S2 protein. The one research group that has been able to detect the Tat
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protein in vivo used a combination of antisera produced against a num ber of
synthetic peptides (Noiman et al., 1991). This could be a possible future
strategy, b u t such combinations of antisera typically result in high backgrounds
due to cross-reactivity to other cellular proteins. Perhaps the synthetic peptide
antisera, that w e now have in hand, may be more useful if we affinity purify the
antibody using the synthetic peptide immobilized to a column resin. Another
option w ould be to express these ORF proteins in E. coli and use the purified
expressed protein to produce high titer polyclonal antisera. The preferred
option w ould be to produce monoclonal antibodies that recognize specific
epitopes on these proteins. There is also the possibility of using an epitope
tagging strategy to detect these proteins. This strategy m ay be open to some
criticism since the natural proteins w ould not be used. It w ould, however,
have the advantage of allowing for the possibility of detecting all three ORF
proteins using a single antibody. This w ould be particularly im portant if an
analysis of the relative expression of the three EIAV proteins from the
tricistronic RNA was an experimental goal. The use of different antibodies with
different affinities to the target proteins could never yield quantitative data of
this type. One w ould need to be cautious to insure that the monoclonal epitope
is equivalently recognized in the different environments of the various
peptides. Most immunological detection strategies em ploy a denaturation step
before or during antibody detection. For example, in W estern blotting the
protein sample is first run on a denaturing polyacrylamide prior to transfer to a
m em brane and probing w ith antibody. Antibody incubations of
im m unoprecipitation reactions are normally perform ed in buffered solutions
containing a num ber of detergents. Denaturation of proteins for the detection
of linear epitopes should minim ize the concerns of the epitope's "intra-protein"
environment. A nother concern that is of particular im portance in the case of
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the strategy of multicistronic RNAs, is that such exogenously introduced
epitopes m ust not contain AUG codons or other potential, non-AUG initiation
codons.
A second obstacle, that m ust be overcome in the determ ination of the
tricistronic nature of the 3.5-kb RNA in vivo, is the ability of the 3.5-kb RNA to
be spliced to one of the three small EIAV Tat expressing transcripts. Although I
have show n here that the pSV3.5kb vector produces prim arily the 3.5-kb
transcript, there are significant levels of other ELAV-specific RNAs that
presum ably arise from splicing. This problem could be overcome by sitespecific mutagenesis of the tw o splice donor sites in the 3.5-kb RNA. The first
of these sites lies between the Tat termination codon and the S2 initiation
codon. Thus, splicing events that utilize this splice donor site result in the
rem oval of the S2 and gpl35 initiation codons. The second splice sites lies in
the env cistron dow nstream of the S2 term ination codon. RNA analysis of the
m utants w ould have to be perform ed, so that one could assure that cryptic
splice sites w ould not be activated by m utating the natural sites. If no cryptic
sites are activated, then a vector similar to pSV3.5kb that lacks these splice
donor sites, should allow the expression of high levels of 3.5-kb RNA only.
Such constructs will be required for the definitive examination of the coding
capabilities of the 3.5-kb in vivo.
The third obstacle that m ust be overcome in determ ining the tricistronic
nature of the 3.5-kb RNA in vivo, is the inability to stably m aintain and
propagate plasm id vectors that contain EIAV env sequences in E. coli. Typical
high copy num ber cloning vectors the contain EIAV env sequences accumulate
m utations w hen grow n in bacterial cultures. In this dissertation, I have
described how I tried to minimize the frequency of these m utations by
propagating enu-containing plasm ids in standard LB media, rather than
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enriched m edia such as "super broth" or "terrific broth", and growing the
cultures at 30°C rather than the standard 37°C. While this approach is
sometimes successful, it cannot be relied upon. Recently, Cunningham et al.
(1993) have described the stable maintenance of EIAV env sequences in low
copy num ber plasmids. All future experiments that involve the expression and
detection of the EIAV envelope glycoproteins should em ploy these vectors. I
have already constructed low copy num ber vectors that are analogous to
pSP720 and pSV720 b u t contain the entire EIAV env gene. These vectors should
prove useful in future research.
In addition to the need for in vivo data on the EIAV 3.5-kb RNA, there
are a num ber of interesting experiments that should be perform ed in the in vitro
system. Perhaps the m ost interesting of these w ould be the further
investigation of the mechanism of translation of the three cistrons. The data
presented here that dem onstrates the cap-dependence of the three cistrons of
the 3.5-kb RNA is merely consistent with a leaky ribosome scanning
m echanism for translation and does not provide any direct evidence to support
this hypothesis. Site-specific m utagenesis of the Tat CUG initiation codon and
the S2 sub-optim al AUG codon to stronger initiation sequences, w ould be
expected to reduce translation of the downstream cistrons in vitro and possibly
completely prevent their expression in vivo. Such experiments w ould provide
strong direct evidence for the involvement of a leaky ribosome scanning
m echanism in the translation of the three cistrons of this RNA.
The putative post-translational modification of the in vivo synthesized S3
protein and the potential involvement of the EIAV-encoded proteins in
m ediating this modifications is certainly w orthy of further investigation.
Although other researchers have reported the detection of the EIAV Rev
protein in vivo (Saman et al., 1990; Stephens et al., 1990), they have not observed
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that the protein exists in two forms. It is possible that the combination of a
highly-specific monoclonal antibody and the sensitive chemiluminescent
detection techniques used here, m ay have allowed the detection of this low
abundance form of the protein. Based upon similarities of EIAV Rev w ith the
HIV-1 Rev protein, which is know n to be a phosphoprotein, it appears likely
that this modification could be phosphorylation. This hypothesis is readily
tested by perform ing in vivo labeling experiments of either EIAV-infected cells
or pSV3.5kb-transfected cells in the presence of [32P]. A similar experim ent was
perform ed during the course of m y work, but I used the pSVS3 vector
transfected into COS-7 cells. As presented here, the Rev protein produced from
this vector is very inefficiently modified. I was, however, able to detect a faint
[32P]-labeled band that co-migrated with an [^S]-labeled protein of 20-kd and
w as im m unoprecipitated w ith the mab86 monoclonal antibody. This result was
less than convincing and did not lend itself well to presentation, so I decided
not to include it in the text.
The question of w hether other EIAV proteins m ay be involved in the
putative modification of the Rev protein is a particularly intriguing one. This
hypothesis is based prim arily upon the observation that the pSVS3 vector that
produces only Rev cannot be efficiently modified, while the pSV3.5-kb vector
produces large am ounts of the modified protein. One w ay to test w hether the
other EIAV proteins are involved w ould be to co-transfect the pSVS3 vector
w ith the pSV3.5kbAS3 vector described in Chapter 3. The latter vector contains
a frame-shift m utation in the ORF S3 exon of the rev gene and does not produce
the Rev protein in vivo. If indeed, the pSV3.5kb plasm id encodes a factor that
facilitates Rev phosphorylation, then this factor may also be encoded by
pSV3.5kbAS3. If the latter plasm id vector is capable of directing the
modification of the Rev protein encoded by the pSVS3 vector, then this w ould
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provide strong evidence for this hypothesis. Deletion m utants of the
pSV3.5kbAS3 construct then could be generated to localize the sequences
required to m ediate this modification.
A nother topic of interest that requires further study is the role of the S2
protein in EIAV infection. One approach taken by researchers on HIV-1 and
other lentiviruses to investigate the roles of predicted proteins w ith unknow n
functions, is to m utate the region of the genome that encode the protein in an
infectious proviral clone and determ ine the effect of the m utation on viral
infection. Researchers that w ork on EIAV have not had the luxury of the
availability of infectious proviral clones until recently. The instability of clones
containing the viral envelope sequences has m ade the construction of proviral
clones very difficult. The use of low copy num ber plasm ids has recently
allowed the generation of infectious proviral clones. W e now have these clones
in-hand and could begin analysis of ORF S2 mutants. Since ORF S2 overlaps
w ith the env gene in an alternative reading frame, site-specific mutagenesis
w ould be required to specifically interrupt the S2 coding region.
The observation that the SI Tat protein synthesized in vitro is amino
terminally blocked also w arrants further study. Also the observation that the
S2 protein synthesized in vitro is apparently modified by sera from EIAVinfected animals is also w orthy of further study. Perhaps the first investigation
that should be performed, is to try and determ ine w hether these observations
apply to the in vivo produced proteins. Since we presently do not have a means
of detecting these proteins in vivo, these studies m ay need to aw ait the
developm ent of im proved detection techniques.
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Rodney Louis Schiltz w as born on March 30,1960 in Normal, Illinois to
Rodney M. Schiltz and Bonnie Joyce Lowe. Louis’ family m oved to Metairie,
Louisiana, a suburb of N ew Orleans, in 1965. It was here that Louis was raised
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Matas Elementary School and T. H. Harris M iddle School before entering East
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years, Louis enjoyed playing organized football for a local playground. This
experience taught Louis valuable lessons about winning, losing, competition
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his high school years Louis w as an active member of the St. M atthew's United
M ethodist Church youth group and youth choir. Louis also worked over thirty
hours per week in a local pizza restaurant and held a position as shift
supervisor from his sophom ore to his senior year in high school. Louis
graduated from East Jefferson High School in 1978 with honors, graduating
eighth in a class of over five-hundred students.
Louis received a scholarship to attend Louisiana State University in the
Fall of 1978. He had acquired a strong interest in m ath and science in high
school, and had a particular interest in biology. Although Louis initially
declared him self as a pre-m ed major, he later determ ined that he was more
interested in basic biological research and became a Biochemistry major. Louis
received his bachelor's degree in biochemistry from Louisiana State University
in the sum m er of 1984. In the sum m er of 1985 Louis entered the Ph.D. program
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in the departm ent biochemistry at LSU. Louis was particularly interested in
viruses, therefore he entered the laboratory of Dr. Ding Shih. Louis' thesis
research involved the study of mechanisms of gene expression of equine
infectious anem ia virus, a virus that is related to the AIDS-causing hum an
im munodeficiency virus.
In 1990 Louis m et and fell in love w ith Helen Fu, a graduate student in
the D epartm ent of Biochemistry. In 1992 Louis and Helen w ere m arried and
had a son, Stephen A ndrew Schiltz. In order to provide for his family, Louis
took a job as a research associate in the laboratory of Dr. Ezzat Younathan.
Louis’ research in Dr. Younathan's lab involved the cloning of a cDNA for the
rabbit liver phophofructokinase (PFK) gene using the polym erase chain
reaction (PCR) and analysis of the kinetic properties of site-directed and
deletion m utants of rabbit m uscle PFK. In the spring of 1994 Louis decided to
take leave of his job to complete the requirem ents for the doctoral degree. After
the successful defense of his dissertation research Louis returned to his job in
the laboratory of Dr. Younathan. Louis hopes to continue his research on
viruses in the future. H e w ould like to use his background in retrovirology to
become involved in gene therapy using retroviral vectors.
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